Development and evaluation of enzymatically-degradable hydrogel microparticles for pulmonary delivery of nanoparticles and biologics by Wanakule, Prinda 1985-
 
 
 
 
 
 
 
 
 
Copyright 
by 
Prinda Wanakule 
2012 
 
 
 
The Dissertation Committee for Prinda Wanakule Certifies that this is the approved 
version of the following dissertation: 
 
 
Development and Evaluation of Enzymatically-Degradable Hydrogel 
Microparticles for Pulmonary Delivery of Nanoparticles and Biologics 
 
 
 
 
 
Committee: 
 
Krishnendu Roy, Supervisor 
Laura J. Suggs 
Konstantin V. Sokolov 
Robert O. Williams, III 
Jason T. McConville 
 
 
Development and Evaluation of Enzymatically-Degradable Hydrogel 
Microparticles for Pulmonary Delivery of Nanoparticles and Biologics 
 
 
by 
Prinda Wanakule, B.S.; M.S.E. 
 
 
 
Dissertation 
Presented to the Faculty of the Graduate School of  
The University of Texas at Austin 
in Partial Fulfillment  
of the Requirements 
for the Degree of  
 
Doctor of Philosophy 
 
 
The University of Texas at Austin 
December 2012 
 Dedication 
 
This work is dedicated to my loving family for all of their support and encouragement 
throughout my education: 
My father, Dr. Nisai Wanakule, who received his Ph.D. in engineering from the 
University of Texas at Austin in the same year and month that I was born, and laid the 
early foundations that resulted in my pursuit of engineering and science. 
My mother, Paulla Wanakule, whom I take after in creativity and imagination, and who 
gave me the inspiration to understand and improve pulmonary disorders and treatment. 
My sister, Dr. Nisita Wanakule, also a Ph.D. engineer, who helped me with my 
homework when we were kids, got me started in research early on, and whom I have 
always looked up to as a mentor and role model. 
 
 
 v 
Acknowledgements 
 
I would first like to thank my advisor, Dr. Krishnendu Roy, for taking a chance on 
me and letting me join his lab, despite my vastly different research background and 
complete lack of experience in biomaterials. I am especially grateful that he believed in 
me and gave me the opportunity and challenge of creating my own project, and was there 
to motivate and guide me when I needed it. He has truly been a great mentor from the 
first day we met, and has always encouraged me to pursue my passions and other 
opportunities for personal and professional development. 
Next, I must give thanks to all of my committee members for their support and 
advice in all the different areas of my work. Dr. Williams and Dr. McConville were 
absolutely invaluable with their advice on pulmonary formulations and particle synthesis 
methods. I could not have achieved my end goal without their support, expertise, and 
generosity with their time and equipment. Dr. Sokolov also provided valuable guidance 
in various imaging methods, and was always happy to share equipment. Dr. Suggs 
provided helpful advice and insight for the chemistry and materials aspects of my project, 
and always served as a great role model. 
I would also like to thank several research staff members, both currently and 
formerly at the University of Texas at Austin. Dwight Romanowicz, Angela Bardo, and 
Julie Hayes of the Institute for Cellular and Molecular Biology Core Facility spent 
countless hours training and helping me to use the SEM, cryoSEM, and confocal 
microscopes. Klaus Linse, formerly in the Protein Core Facility, helped to demystify 
protein and peptide biochemistry. Greg Lyness and Jamye O'Neal in TherapUTex also 
spent countless hours in support of my research. The staff at the Animal Resources 
 vi 
Center were especially invaluable in the last year of my work: Kathryn Starr, Dr. 
Kathleen Roellich, Dr. Glen Otto, Jennifer Cassaday, Jocelyn Franklin, and Nachi Shukla 
and his facilities support team. 
Special thanks go out to all my friends and colleagues for their support throughout 
the years. First and most especially, I must recognize other members from the Roy Lab. I 
could not have made it to the end without the help of my undergrad Gary Liu, and 
labmate Asha Fleury, who helped me tremendously with many experiments. Mary 
Caldorera-Moore taught me the basics of peptide acrylation and made my first UV-
polymerized hydrogel with me. Bilal Ghosn introduced me into the lab, and taught me the 
basics of chitosan chemistry and mouse necropsy. Ankur Singh started me on the path to 
Michael addition chemistries, and helped me create my first Michael addition hydrogels. 
Nathalie Guimard further worked with me on chitosan chemistry, mentored me, and 
taught me so many other aspects of proper laboratory safety and practices. Myung Hee 
Michelle Kim patiently taught me how to do cell culture, and always helped me to 
troubleshoot various aspects of my project. Eileen Dawson was always willing to discuss 
issues, and helped bring out our best work with her high standards and scientific scrutiny. 
Krista Fridley and Rachit Agarwal taught me how to do flow cytometry, and Tracy Ooi 
helped me further along and demystified Flow Jo. I must also thank my former 
undergrads Amy Bergeron and James Chang for their hard work and dedication in the 
lab. Lonnissa Nguyen, Jian Lin, Jardin Leleux, Pallab Pradhan, Kathryn Erickson, and all 
other members of "Klub Krish," your support and camaraderie helped to get me through 
these years! I am so grateful to have you all both as friends and labmates. 
Many thanks go to my other colleagues from different labs that have impacted my 
work in various ways. Eric Spivey helped with optical trapping; Thiago, Yoen-Ju, and Ju 
from Pharmaceutics were always helpful in discussing a field that I was unfamiliar with. 
 vii 
Special thanks go to colleagues from Jeffrey Hubbell's and Melody Swartz's labs at 
EPFL: Evan, Jennifer, Sachiko, and Armando, all of whom I learned a remarkable 
amount from in just one summer. 
To my other BME-affiliated colleagues and friends, I am so grateful to have you 
in my lives: Thomas, Justina, Deanna, Navid, Arnold, Eric, Ashwin, Vaish, Mark, and 
Michelle. Most sincere heartfelt thanks must go out to the SWE@UT Graduate 
Committee founding and early members for being my graduate school cheerleaders: 
Anne, Richelle, Katie, and Ellison. Of course, I must also include my nationwide 
SWEsters for always encouraging me: Ruby, Pree, Cristina, Chelsea, and Tabitha. 
I must express my most heartfelt love and appreciation for my family, and my 
deepest gratitude for their encouragement, inspiration, and support all throughout my life. 
For their many personal sacrifices in always putting my education and happiness first, I 
am forever in their debt. My parents were both the motivation for me to pursue graduate 
study in engineering, and also the inspiration that led me to my field, and I try my best 
everyday to make them proud. My sister was also there to lend a supportive and 
understanding ear, and always gave me the best advice in both professional and personal 
matters. I know that I could not have gotten to where I am without her mentorship and 
guidance. I must also thank Shasta, who always kept me company, and made sure I 
stayed healthy and active. 
Finally, this research would not have been possible without the financial support 
from the National Science Foundation Division of Materials Research, as well as 
generous support from the National Science Foundation Graduate Research Fellowship 
Program, the University of Texas THRUST, Bruton, Heuer, and WEP Fellowship and 
Scholarship Programs, and the Society of Women Engineers Scholarship Program.  
 viii 
Development and Evaluation of Enzymatically-Degradable Hydrogel 
Microparticles for Pulmonary Delivery of Nanoparticles and Biologics 
 
Prinda Wanakule, Ph.D. 
The University of Texas at Austin, 2012 
 
Supervisor:  Krishnendu Roy 
 
The emerging class of biologic drugs, including proteins, peptides, and gene 
therapies, are widely administered by injection, despite potential systemic side effects. 
Rational design of targeted carriers that can be delivered non-invasively, with reduced 
side effects, is essential for the success of these therapies, as well as for the improvement 
of patient compliance and quality of life.  
One potential approach is to take advantage of specific physiological cues, such 
as enzymes, which would trigger drug release from a drug carrier. Enzymatic cleavage is 
highly specific and could be tailored for certain diseased tissues where specific enzymes 
are up regulated. Enzymatically-degradable hydrogels, which incorporate an enzyme-
cleavable peptide into the network structure, have been extensively reported for releasing 
drugs for tissue engineering applications. These studies showed that a rapid response and 
corresponding drug release occurs upon enzyme exposure, whereas minimal degradation 
occurs without enzyme. Recently, Michael addition reactions have been developed for 
the synthesis of such enzymatically-degradable hydrogels. Michael addition reactions 
occur under mild physiological conditions, making them ideally suited for polymerizing 
hydrogels with encapsulated biologic drugs without affecting its bioactivity, as in 
traditional polymerization and particle synthesis. The focus of my research was to create 
 ix 
enzymatically-degradable hydrogel microparticles, using Michael addition chemistry, to 
evaluate for use as an inhalable, disease-responsive delivery system for biologic drugs 
and nanoparticles.  
 In this dissertation, I utilize bioconjugation and Michael addition chemistries in 
the design and development of enzymatically-degradable hydrogels, which may be 
tailored to a multitude of disease applications. I then introduce a new method of hydrogel 
microparticle, or microgel, synthesis known as the Michael Addition During Emulsion 
(MADE) method. These microgel carriers were evaluated in vitro, and found to exhibit 
triggered release of encapsulated biologic drugs in response to enzyme, no significant 
cytotoxic effects, and the ability the avoid rapid clearance by macrophages. Lastly, in 
vivo studies in mice were conducted, and microgels were found to exhibit successful 
delivery to the deep lung, as well as prolonged pulmonary retention after intratracheal 
aerosol delivery. In conclusion, a new class of enzymatically-degradable microgels were 
successfully developed and characterized as a versatile and promising new system for 
pulmonary, disease-responsive delivery of biologic drugs. 
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Chapter 1:  Introduction, Specific Aims, and Overview 
 
1.1  INTRODUCTION 
In recent years, a series of highly sophisticated drugs, rationally designed to target 
various cellular pathways (e.g. signal transduction cascades, transcription factors, 
apoptosis etc.) have emerged [1-3]. They range from proteins and peptides designed to 
interfere with specific cell functions to DNA, siRNA, oligonucleotides, and aptamers that 
produce therapeutic proteins or block transcription/translation. Even though these drugs 
are very specific in their effect, most of them interfere with key cellular processes and 
therefore are highly cytotoxic. Moreover, the majority of these sophisticated drugs, 
especially those that target chronic and advanced diseases are primarily given via 
systemic administration and often through multiple, regular doses. Needless to say this 
severely interferes with the quality of life of these patients while leading to major 
systemic side effects. Rational design of targeted therapies that enhance patient 
compliance, improve quality of life while still being highly effective in treating the 
disease, is therefore essential [1-8].  
It is well appreciated that delivery of therapeutic agents through the pulmonary 
route could provide significant improvement in patient compliance and reduce systemic 
toxicity [9-13] for a variety of diseases. This is particularly relevant for chronic 
pulmonary disorders like airway allergy, asthma, and pulmonary fibrosis, as well as for 
lung cancers. Traditional drugs for inhalation suffer from low respirable fractions and 
high emitted (exhaled) fractions, clearance by alveolar macrophages, and target non-
specificity. Therefore, the design of effective pulmonary drug carriers must possess the 
following attributes: (i) optimal aerodynamic properties for respirable efficiency, (ii) 
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avoidance of alveolar macrophage clearance, (iii) site-specific delivery at diseased tissue 
to avoid local bystander and systemic side effects, and (iv) enhanced intra-cellular 
delivery of drugs.  
These criteria pose several unique engineering and biomaterial challenges. The 
established range for optimal aerodynamic particle diameter to achieve efficient deep 
lung deposition following inhalation ranges between 1-5 μm [9]. However, avoidance of 
phagocytosis and clearance by alveloar macrophages requires particle sizes that are 
significantly larger (larger than 10μm). Even then, drugs that are targeted to intracellular 
pathways and molecules, e.g. siRNA, DNA or intracellularly targeted proteins or 
peptides, require nanoscale carriers, on the order of 50-300 nm which can undergo 
efficient endocytosis or macropinocytosis by epithelial cells. This is a complex design 
space where the carrier should be (a) 1-3 μm during inhalation (b) >10 μm following lung 
deposition and (c) 50-300 nm to deliver the drug intracellularly. Moreover, it is also 
beneficial to incorporate disease-triggered release of the drug following lung deposition, 
in order to minimize non-specific side effects on normal cells.  
The body of research described in this treatise proposes an innovative solution to 
this problem through design and use of a nanoparticle-in-microparticle formulation, 
comprised of swellable, peptide-crosslinked microgel-carriers encapsulating therapeutic 
nanoparticles and/or free biologic drugs. Specifically, the focus of this work has been on 
the development of the platform hydrogel microparticle (microgel) carrier system that 
could be used for multiple applications. These inhalable microgel carriers were designed 
with the following criteria in mind:  
• patient-friendly method of administration by achieving efficient aerodynamic 
delivery to airway epithelial cells with uniform lung distribution, 
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• prolonged residence time in the lungs by avoiding alveolar macrophage 
uptake, due to in situ swelling (large geometric size) and stealth properties,  
• reduced side effects and toxicity by incorporating disease-triggered release of 
nanoparticles/drugs from microgels, specifically, degradation of the 
microcarriers by up regulated enzymes, only at the site of diseased tissue, 
• mild and easily scalable manufacturing process, suitable for use with biologic 
drugs, a relatively new class of pharmaceuticals, and 
• applicability to multiple disease indications, as well as the option to include 
enhanced intracellular drug delivery mechanisms using nanoparticles.  
Through the design and realization of such a system, several engineering and 
biomaterials topics were studied and incorporated. The overarching themes with more 
detail on the specific innovations are summarized in the following sub-sections, along 
with a table provided on page 5 (Table 1.1). The step-by-step specific aims are then laid 
out in the next section. 
 
1.1.1 Disease-triggered drug release 
A potential approach for site-specific or disease-specific therapy is to take 
advantage of specific physiological and pathological cues, such as enzymes, which could 
trigger drug release from the carrier. Enzymatic cleavage is highly specific and could be 
tailored for certain up regulated enzymes in diseased tissues. Enzymatically-degradable 
hydrogels, which incorporate an enzyme-cleavable peptide into the network structure, 
have been extensively reported for tissue engineering applications [14-18], along with 
limited work in drug delivery applications [19-22]. These studies showed that rapid 
degradation of the hydrogels occur upon enzyme exposure, whereas minimal degradation 
 4 
occurs without enzyme. Collectively, they demonstrate the possibility that similar 
peptide-based hydrogels could be used to control drug release from micro- and 
nanoparticle carriers. Previous students in the research advisor’s group have worked on 
the fabrication of nanoparticles, using top-down nanoimprinting techniques, that are 
degraded in the presence of enzymes [23]. However, such enzymatically degradable 
microparticulate carriers for pulmonary delivery drugs are yet to be reported.  
 
1.1.2 Enzyme-responsive microgels for improved pulmonary delivery 
Hydrogel microparticles (microgels) in the dry state are collapsed in comparison 
to their swollen or relaxed state. When hydrated, for example, upon contact with 
physiological fluids or in high humidity airways, the particles should begin to swell, 
increasing in diameter and density. The combination of the initial dry powder state and 
“in-transit” density change could provide optimal aerodynamic properties for pulmonary 
delivery leading to increased particle deposition within the lungs [9,10,12]. A hydrogel 
microparticle carrier system has recently been reported for sustained drug release by 
biodegradation, however, particle morphology was non-uniform and more mild 
fabrication conditions would be necessary for biological drugs [10]. To our knowledge, 
specific disease-responsive microgels designed for efficient pulmonary delivery of 
nanoparticles and biologic drugs are yet to be reported. 
 
1.1.3 Michael addition during emulsion (MADE) microgel synthesis method 
In this body of work, a new method of synthesizing fairly uniform, spherical, 
enzyme-responsive microgels was developed. The method involves using a simple 
Michael addition-type reaction within a water-in-oil emulsion, using low homogenization  
 5 
Table 1.1 Summary of engineered material and method innovations to address design 
criteria and challenges 
Design Criteria/Challenge Material and/or Method Innovation 
Optimal aerodynamic 
properties for efficient, 
non-invasive, patient-
compliant delivery by 
inhalation 
Aerosolized dry microgels of appropriate aerodynamic diameter undergo in-
transit swelling to increase both diameter and density, thus increasing 
particle impaction and minimizing exhaled fraction 
Enzyme-triggered drug release mechanism from microgels in response to 
enzymes secreted extracellularly at site of diseased tissue 
Normal Airway Epithelial Cells 
 
Diseased Epithelial Cells with 
Extracellular Enzyme Secretions 
 
Delivery of cellular-
pathway-interfering siRNA 
to the site of diseased tissue 
only in non-homogeneous 
pulmonary diseases 
 
Avoid rapid clearance of 
drug-containing particles 
by alveolar macrophages 
“Stealth” microgels that avoid uptake and clearance by alveolar 
macrophages – due to hydrophilicity, stealth, and swelling capacity of 
poly(ethylene glycol) 
Eventual clearance of 
particles over the long term 
Primarily, the mucociliary escalator will clear any un-triggered microgels 
after more than two days. Additionally, as microgels undergo hydrolysis 
over a 2-week time period, softening of the gel improves clearance with 
mucosal turnover. Microgels are designed with hydrolytic linkages as a 
“fail-safe” to prevent accumulation over the long term. 
Encapsulation of biologic 
drugs, avoiding degradative 
conditions (such as UV 
light, high temperatures, 
and organic solvents) 
Newly-developed method of Michael addition during emulsion at low shear 
homogenization and physiological conditions eliminates need for photo-
initiators or UV cross-linking, used in traditional hydrogel cross-linking. 
Encapsulation is achieved by simply incorporating the therapeutic with the 
aqueous pre-cursor polymer solution prior to emulsion. 
Applicable to multiple 
disease indications and 
ability to incorporate 
enhanced intracellular 
delivery mechanisms using 
nanoparticles 
Peptide cross-linker may be easily interchanged to tailor 
the system for multiple disease indications. 
The ability to encapsulate nanoparticles allows for a 
second delivery stage to improve intracellular delivery 
and endosomal escape for intracellularly-targeted drugs, 
such as siRNA. 
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energy input and mild aqueous conditions under physiological pH and temperature. This 
method is shown to produce particles within the desired particle size distribution for 
optimal aerodynamic diameter for delivery to the airways by inhalation. Overall, these 
microgel particles exhibit enzyme-triggered degradation and drug release, a mild 
manufacturing process, as well as stealth and swelling for avoidance of macrophage 
clearance. 
 
1.2 SPECIFIC AIMS 
The specific aims of this exploratory and development research treatise are as 
follows. 
 
1.2.1 Aim 1A: To rationally design and optimize Michael addition and 
bioconjugation chemistries to create enzyme-degradable hydrogels 
In this aim, enzyme-degradable hydrogels will be created by cross-linking 
enzyme-degradable peptides with multi-armed poly(ethylene glycol) acrylates (PEG-
acrylates) or multi-acrylated chitosan using a Michael addition-type reaction. This aim 
will include work in developing a library of optimal enzyme-specific peptide sequences 
for various disease applications, bioconjugation chemistry to add functional groups to the 
peptide, polymers, and polysaccharides to enable the Michael addition reaction, and 
optimizing the Michael addition reaction. I hypothesize that these hydrogels would 
exhibit triggered degradation and drug release in response to specific enzymes. 
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1.2.2 Aim 1B: To rationally design, develop, and optimize a method to produce 
enzyme-degradable hydrogel microparticles, using chemistries developed in Aim 
1A, that are suitable for pulmonary delivery via inhalation 
In this aim, the chemistries developed in Aim 1A will be incorporated into a 
method to produce hydrogel microparticles, or microgels, in a suitable size range for 
pulmonary delivery via inhalation. Work in this aim will include exploration of various 
particle manufacturing techniques, and determining feasibility for use with the chemistry 
developed and end goals. I hypothesize that these microgels will exhibit optimal 
aerodynamic properties for efficient pulmonary delivery, and retain the material 
properties, designed in Aim 1A, of exhibiting enzyme-triggered degradation. The final 
method will be easily scalable, use mild fabrication conditions, and be tailorable for 
multiple disease indications. 
 
1.2.3 Aim 2: To perform in vitro characterization and evaluation of the microgels in 
terms of drug release and cellular interactions 
In this aim, microgels developed in Aim 1 will be evaluated and characterized for 
their performance in vitro. This will include the study of drug and nanoparticle release 
from enzymatic degradation, hydrolytic degradation, and diffusion. The microgels will 
also be evaluated for cytotoxic effects on multiple cell lines, and the extent of phagocytic 
uptake by macrophages will be studied. I hypothesize that the microgels will exhibit 
rapidly triggered release of drug in response to enzyme, in stark contrast to drug release 
by diffusion and hydrolytic degradation. Furthermore, I hypothesize that the swelling 
capacity of the microgels, and in one formulation, the PEG composition, will contribute 
to the reduced uptake and clearance of the microgels by macrophages. 
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1.2.4 Aim 3: To evaluate the in vivo pulmonary distribution and clearance of 
microgels after delivery to murine lungs by an intratracheal aerosolizer 
The objective of this aim is to evaluate the pulmonary distribution and clearance 
of the microgels in mouse lungs over a two-week time period. Microgels will be 
simultaneously aerosolized and delivered intratracheally to mice using a Penn-Century 
microsprayer device. The distribution will be evaluated using fluorescent IVIS imaging 
and fluorescent quantification from lung homogenates over a two-week time course. I 
hypothesize that the microgels will exhibit uniform distribution throughout the lungs 
following delivery, and show improved retention (as compared to non-swellable polymer 
particles) over the course of the study. 
 
1.3 OVERVIEW 
The following chapter, Chapter 2, will discuss background material in the field 
of Drug Delivery and its applications, especially for delivery of proteins and other 
biologic drugs. Chapter 3 then focuses on the background and significance of the 
concept of Disease-Responsive Drug Delivery, providing greater context for this 
dissertation work within the greater field of Drug Delivery. Chapter 4 describes the 
bioconjugation and Michael addition chemistry used to create enzymatically-degradable 
hydrogel networks from different biopolymers, including the design and incorporation of 
peptide sequences to create the disease-specific trigger. Chapter 5 then details the 
numerous particle synthesis methods that were attempted before developing and 
optimizing the Michael Addition During Emulsion (MADE) method for synthesizing 
microgels. Chapter 6 describes the in vitro characterization of the microgels in terms of 
material properties, drug release, and interactions with cell. Chapter 7 then discusses the 
performance, distribution, and clearance patterns of microgels from the lungs after 
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simultaneous aerosolization and intratracheal delivery to mice, in vivo. Lastly, Chapter 8 
will discuss the implications of the research, as well as potential future studies and 
development. 
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Chapter 2: Drug Delivery Strategies for Eliciting Cellular Responses in 
Tissue Engineering and Drug Therapy 
 
[This chapter has been adapted, with permission*, from P. Wanakule & K. Roy† (2012). 
Chapter 17: Drug Delivery. In J. P. Fisher, et al, (Eds.), Tissue Engineering: Principles 
and Practices. CRC Press, Taylor & Francis Group.] 
 
2.1  INTRODUCTION 
Drug delivery has proven to be an integral part in manipulating cellular responses 
in various diseases, and directing the development and differentiation of cells into 
functional tissues, specifically, the controlled delivery of pharmacologically active or 
bioactive agents, such as cytokines, growth factors, and morphogens. By controlling the 
delivery of these drugs at different time points and concentrations, a direct effect is 
exerted on the cell proliferation, differentiation, or migration, with the potential for 
controlling the phenotype and functionality of cells and tissues [1-8]. 
The goals of drug delivery are manifold, and include (1) the targeting of drug to 
specific cells or sites in the body, (2) overcoming tissue barriers associated with delivery 
routes, including the epithelial layers of the skin, lungs, and intestine, (3) overcoming 
cellular barriers which control cellular uptake, and (4) controlled release. 
Controlled release concepts encompass the ability to control release of bioactive 
molecules at target sites, the effective concentration of drug in the body, as well as its 
                                                 
* Copyright 2012 From Tissue Engineering: Principles and Practices, Section 2: Enabling Technologies, 
Chapter 17: Drug Delivery by J.P. Fisher, A.G. Mikos, J.D. Bronzino, & D.R. Peterson (Editors). 
Reproduced by permission of Taylor and Francis Group, LLC, a division of Informa plc. 
† Statement of co-author contribution: This chapter was written by Prinda Wanakule, with editorial and 
content assistance by Krishnendu Roy (research supervisor). 
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duration of activity [9]. The use of controlled drug delivery, more so than the other goals 
of drug delivery, has come into greater use in recent years [1,3,8]. While it is possible to 
directly infuse drugs directly into culture flasks and plates (in vitro) or by injection (in 
vivo), this may be undesirable for several reasons. For example, many proteins and 
peptides have short half-lives in serum or media due to inactivation by proteases and 
enzymes, and thus, need continual replenishment to maintain a certain minimum effective 
concentration (see Figure 2.1). Additionally, unconstrained repeated doses may result in 
toxic effects. The controlled temporal and spatial release of these drugs may then reduce 
the amount of expensive drug and chemical signals required, as well as the potential toxic 
effects [1-3,6,8-10]. This temporal and spatial control has also given rise to new 
possibilities and advances in tissue engineering, for example, the use of three-
dimensional scaffolds to spatially differentiate cells into various “zones” consisting of 
different cell types [1-8,11]. 
 
 
Figure 2.1 In classical drug delivery, controlled release systems aim to achieve a 
constant minimum effective concentration of bioactive drug. 
 14 
This section will encompass the basics of drug delivery, an overview of controlled 
drug delivery technologies, as well as their applicability to and significance in eliciting 
cellular responses for tissue engineering and drug therapies. We first begin by providing a 
brief review on the modes of drug delivery, or drug release, from drug delivery systems. 
Next, we move on to discuss some biological drugs of interest in cell therapy 
applications, as well as their properties that affect the design of the delivery system. We 
then explore the methods used to control the release of drugs, with special emphasis on 
the release of drugs from scaffolds, matrices, and particulates.  
 
2.2 MECHANISMS OF DRUG DELIVERY 
There are myriad mechanisms from which we may choose to drive the release of 
drugs in a controlled manner. We can classify the drug delivery mechanisms of special 
interest in cellular therapies into three main categories: diffusion from non-degradable 
systems, bioerodible systems, and stimuli-responsive systems.  
 
2.2.1 Diffusion from Non-Degradable Systems 
Diffusion is one of the most kinetically well-defined concepts of transport 
phenomena, and is especially applicable in the diffusion of drug molecules from some of 
the early non-degradable drug delivery systems [9,12,13]. Thermodynamically driven, it 
is the result of the random walk of submicron particles, called Brownian motion. 
Although movement may seem random at the microscopic level, at the macroscopic 
level, movement of particles along a concentration gradient is observed. Fick’s second 
law of diffusion describes the temporal and spatial net movement of particles by 
diffusion: 
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Numerous solutions for this equation have been derived in order to describe the 
diffusion of drug molecules from several types of drug delivery devices under several 
conditions; for details, we refer the reader to an excellent text by Truskey, et al. 
[1,3,8,12]. However, the two main diffusive conditions of special interest in drug delivery 
for tissue engineering are the diffusion of drug from a polymer matrix and the diffusion 
of drug from a reservoir through a membrane (see Figure 2.2), both of which are 
predictably well-defined. The solutions to the problem are highly dependent on the initial 
drug concentration and the geometry of the device, and as such, the diffusion of drug out 
of the system may be changed by altering the device geometry, and prolonged by 
increasing the initial concentration [1-3,6,8-10,12,13].   
Along the same lines, however, the disadvantage of this system lies in its 
dependence on drug concentration to define the flux of drug out of the system. As the 
drug concentration decreases over time and there is less of a concentration gradient, the 
release rate also decreases over time. This is especially pronounced in the diffusion of 
drug from a polymer matrix. However, by using a highly saturated drug reservoir with 
diffusion of drug driven through a membrane, a constant release of drug may be achieved 
over an extended period of time – longer than may be typically achieved through use of a 
matrix alone[9,12,13]. 
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Figure 2.2 (A) Diffusion-driven release of drug from a matrix. (B) Diffusion-driven 
release of drug from a saturated reservoir through a membrane. 
 
2.2.1.2 Diffusion from Swellable Polymers 
Diffusion of drugs may also be controlled by the use of swellable polymers, 
including swellable cross-linked hydrogels. In this case, there is an increase in polymer 
chain mobility due to the uptake of a solvent, such as water, that decreases the glass 
transition of the polymer (Tg). Drugs that are entrapped and immobilized by the non-
swollen polymer matrix may then begin to diffuse out due to the increased flexibility, 
resulting in a heightened release rate. In order to achieve this, the pore size of the 
polymer matrix must be sufficiently small so as to restrict a drug of known hydrodynamic 
radius. Upon swelling, the pore size increases, thus allowing movement and diffusion of  
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Figure 2.3 Diffusion of drug from a swellable polymer matrix. In the pre-swollen state, 
drug molecules are entrapped within the network structure. Swelling of the 
polymer network results in increased polymer chain mobility or pore size, 
allowing diffusion of the drug out of the network. 
the drug out from the matrix (see Figure 2.3) [9,13,14]. The diffusion of drugs from 
swellable polymer matrices has been well studied for macroporous (pore size between 
0.1-1.0μm), microporous (100-1000Å), and nonporous (10-100Å) hydrogels by several 
groups, and tunable drug release profiles from swellable polymers have been achieved 
[9,15]. 
 
2.2.2 Bioerosion 
By definition, bioerosion refers to the erosion of a polymer into water-soluble 
products under physiological conditions, including both physical and chemical processes 
(according to the European Society for Biomaterials Consensus Conference in 1986) 
[16]. As a side note, biodegradation refers to the degradation by biological molecules, 
such as enzymes, which will be covered in the following section on stimuli-responsive  
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Figure 2.4 Surface erosion (left) and bulk erosion (right) of polymeric devices, 
resulting in differing release kinetics. 
systems. The most common mechanism of bioerosion is by hydrolysis of a 
polymer backbone by neutral water, however, accelerated hydrolysis may occur in the 
presence of ion catalysts and acidic pH. Erosion may proceed by either surface erosion or 
bulk erosion (see Figure 4). In surface erosion, the rate at which water is able to penetrate 
the device is slower than the erosion rate. On the other hand, bulk erosion occurs when 
the rate of water penetration into the device is greater than the rate of erosion [17-19]. 
Bioerodible drug delivery systems have been designed to both provide a 
mechanism of controlled drug release, as well as to eliminate the need for device 
extraction after the lifetime of the system. As the device erodes, drug that has been 
solubilized or suspended within the device are slowly released. In general, surface 
eroding systems (heterogeneous) have a release rate proportional to the surface erosion 
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rate, are driven primarily driven by erosion rather than diffusion, and can be varied 
according to device geometry. Bulk eroding systems (homogeneous) are driven by a 
combination of erosion and diffusion kinetics, with first order kinetics for the rate of 
erosion, as well as the permeability of the device. Several parameters affect the rate of 
hydrolysis, and thus, release rate, including lability of the polymer backbone, 
hydrophobicity or hydrophilicity of the polymer, morphology, and molecular weight [17-
21]. 
 
2.2.3 Stimuli-Responsive Systems 
In recent decades, a greater interest in the stimuli-responsive subfield in 
controlled drug delivery has been developing as a means to deliver drug only when or 
where it is needed. These stimuli-responsive types of systems often rely on 
physicochemical changes due to disease pathology or the cell microenvironment. 
Common stimuli include pH, temperature, ions, enzymes, light, and biomolecules, all of 
which have been designed it elicit a response in drug carriers to trigger drug release 
[3,10,22-26].  
 
2.2.3.1 pH-Responsive Systems 
Several hydrogel-based drug delivery systems with the ability to swell or shrink in 
response to pH changes have been developed as triggered-release delivery systems. The 
pH triggered swelling and shrinking mechanisms are primarily due to the properties of 
the side chain pendant group, which are cationic or anionic [10,27,28]. Anionic hydrogels 
are ionized at pHs above their pKa, and thus exhibit high swelling at these higher pHs 
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due to repulsion of the ionized groups [28]. In contrast, cationic hydrogels are ionized at 
pHs below their pKa, exhibiting high swelling below their pKa [27].  
Changes in pH exist throughout the body at the organ, tissue, and cellular level, 
and even due to various disease states. For example, pH triggered drug delivery systems 
have been developed that are capable of triggering drug release when moving from the 
acidic gastric cavity to the more neutral small intestine [29,30], where much drug 
absorption occurs, as well as from the neutral extracellular environment to the slightly 
more acidic early endosome (intracellular) [31,32]. Thus, pH-responsive systems offer a 
versatile way in which to trigger drug release in response to environmental cues. 
 
2.2.3.2 Enzyme-Responsive Systems 
A relatively new strategy in drug delivery is to incorporate enzyme sensitive 
components into the drug carriers, which are primarily hydrogel-based. Enzyme-
degradable hydrogels have been shown to exhibit minimal release without the presence of 
enzyme, and triggered release in the presence of enzyme [10,26,33-36]. This strategy has 
been used extensively in tissue engineering applications [37,38], however, it also 
provides an effective means of physiologically controlled release of drugs [36,39]. 
Enzyme-responsive systems are suitable for site-specific delivery because enzymatic 
cleavage is highly specific, and many enzymes are upregulated in several diseases, such 
various cancers and inflammatory diseases [10,22,25,36,39,40]. In most cases, enzyme-
cleavable proteins, peptides, or extracellular matrix (ECM) components are incorporated 
into the hydrogel cross-links [26,33,34,38]. In another set-up, enzyme-degradable 
components are used as covalent linkers to conjugate drugs as pendant groups off the 
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polymer backbone [10,41]. Upon encountering the enzyme, the cross-links are broken, 
releasing any encapsulated drug.  
 
2.2.4 Overall Release Profiles 
Oftentimes, the overall drug release mechanism may be due to a combination of 
the aforementioned modes. For example, diffusion plays a role in each of these 
mechanisms in that the drug must diffuse out of eroding scaffolds, or swollen matrices. 
Stimuli-responsive carriers may also release drug by stimuli-induced erosion or swelling. 
In choosing a release mechanism, the temporal requirements of drug in the system, as 
well as drug pharmacokinetics, must be considered.  
 
 
Figure 2.5 Release profiles of various delivery mechanisms.  See Figure 2.2 for 
diffusion-driven release profiles. 
 22 
There are several release profiles that may be achieved by the delivery systems 
described here (see Figure 2.5). Several classical drug delivery systems were designed 
with the aim of achieving a zero order, or linear, release rate, which results in a constant 
level of drug in the tissues. However, newer drug delivery systems are designed to release 
drug when and where it is needed, thereby reducing side effects [1,9,12,13]. Since spatial 
and temporal control over drug release is often required to guide the differentiation of 
cells into their appropriate niches, highly ordered systems with a combination of 
mechanisms may be required. 
 
2.3 BIOLOGICAL DRUGS OF INTEREST IN CELLULAR AND DRUG THERAPIES 
The primary drugs of interest for eliciting cellular responses and next generation 
drug therapies include biologic drugs, or biologics. These include nucleotides, proteins, 
and peptides, such as siRNA, DNA, cytokines, growth factors, and adhesion factors. 
Growth factors are cell signaling proteins or hormones that have an effect on cell 
differentiation, proliferation, and maturation through a process of ligand-receptor 
binding. Some examples of growth factors include bone morphogenetic proteins, vascular 
endothelial growth factors, and some cytokines. Adhesion factors are proteins and 
peptides that are typically bound to the extracellular matrix and relay mechanical stress 
feedback to the cell. Adhesion factors include vitronectin and fibronectin, as well as the 
fibronectin-derived peptide sequence, RGD. Some common biologics used in cell-based 
therapies, as well as the intended function or purpose, are summarized in Table 2.1 
[7,9,13,38,42]. 
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2.3.1  Drug Properties and Design Considerations 
Given that the majority of growth factors and adhesion factors are composed of 
bioactive proteins, or derivatives thereof, there are many considerations that must be 
made in order to design suitable systems for the delivery of these proteins in active forms. 
The most prominent consideration is the need to deliver the proteins in their native forms, 
that is, with their tertiary structure intact. Several methods of drug incorporation into 
delivery systems may cause proteins to denature from processing and encapsulation 
conditions, such as the application of heat, high shear forces, pH changes, UV, and 
exposure to organic solvents. Also considering that the majority of these proteins are 
hydrophilic, the choice of delivery materials is important in that exposure to hydrophobic 
materials may cause protein denaturation [43-45]. Lastly, the conditions that lead to drug 
release must also be evaluated to verify that they do not damage the protein. For example, 
in the case of hydrolytically degradable polyester drug carriers, a slightly acidic 
microenvironment is often created, which could affect protein activity [46]. The final 
conformation of the protein must be such that its bioactivity is not affected, and there are 
no forms present that may elicit ill effects or immunogenicity [9].  
Along the same lines, the biological environment that the protein drugs are 
exposed to, whether in vitro or in vivo, may affect the protein conformation and activity. 
Several components in serum, including enzymes and peptidases, cause protein 
degradation often within minutes, decreasing the half-life dramatically. Glomerular, or 
renal, filtration also plays a key role in decreasing the half-life of proteins. For example, 
in vivo, the half-lives of PDGF, bFGF, and VEGF are approximately 2, 3 and 50 minutes 
respectively. A common strategy to improve the circulating half-lives of these proteins is 
to encapsulate them within polymers, however, care must be taken to ensure that the 
encapsulating material does not cause protein agglomeration or activate clotting factors  
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Table 2.1 Common biologic drugs used in cell-based therapies 
Abbreviation Bioactive Agent Application 
BMP Bone morphogenetic protein Osteogenesis 
PTH Human parathyroid hormone Osteogeneisis 
TGF-β Transforming growth factor beta Differentiation, anti-
proliferation 
HGF Hepatocyte growth factor Proliferation  
G-CSF Granulocyte colony-stimulating factor Proliferation 
GM-CSF Granulocyte-macrophage colony-
stimulating factor 
Proliferation 
VEGF Vascular endothelial growth factor Angiogenesis 
FGF Fibroblast growth factor Angiogenesis 
EPO Erythropoietin Angiogenesis 
OPG Osteoprotegerin Angiogenesis 
Ang1 Angiopoietin-1 Angiogenesis, vessel 
maturation 
PDGF Platelet-derived growth factor Angiogenesis, vessel 
maturation 
NGF Nerve growth factor Nerve regeneration 
GDNF Glial-derived neurotrophic factor Nerve regeneration 
 Fibronectin Adhesion, cell substrate 
 Vitronectin Adhesion, cell substrate 
 Fibrinogen Adhesion, cell substrate 
 Laminin Adhesion, cell substrate 
RGD Arginine-Glycine-Asparagine Adhesion 
S1P Sphingosine 1-phosphate Chemoattractant 
MIP3α Macrophage inflammatory protein 3 
alpha 
Chemoattractant 
 
[43-45]. Another common strategy is the conjugation of poly(ethylene glycol), or PEG, 
referred to as PEGylation [47-50]. PEGylation of proteins has been shown to increase 
circulation time in vivo and decrease the rate of protein degradation by enzymes [51,52]. 
Aside from classical cell culture flasks and dishes, there has recently been an 
increased usage of ECM-mimicking gel matrices to serve both as a cell scaffold and a 
controlled drug delivery device [33,53]. These bio-inspired matrices may be either a 
hybrid of synthetic and biomaterial or biomaterial alone, offer improved compatibility 
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and stability with proteins, and have been designed to mimic the ways in which growth 
factors are released in the body [53-56]. In the body, growth factors are either stored 
within the extracellular matrix or secreted by cells for short-term signaling. The ECM 
serves as a responsive delivery system for these growth factors, which may be controlled 
dynamically by cell movement and secretion of enzymes that degrade the matrix [9,33]. 
Adhesion factors in the ECM also relay mechanical feedback to the cells, and help the 
cells migrate as controlled by cellular signals [23,57,58]. These ECM-mimicking systems 
offer several advantages over classical systems, as we will discuss in the following 
section. 
 
2.4 DRUG DELIVERY AT THE CELLULAR LEVEL 
Given the complex temporal and spatial control of drug delivery required at the 
local cellular level, several strategies have been developed to meet the needs of this 
growing field. The strategies may be roughly classified into four major categories: 
• Classical drug delivery systems for use in cell culture or in vivo at local sites 
• Drug delivery from tissue engineering scaffolds and matrices 
• Cells (genetically altered or otherwise) to produce drugs in the system 
• Biomimetic systems with conjugated drugs. 
The primary focus of this chapter will be to discuss in greater detail the first two 
strategies, the use of classical drug delivery systems, and especially the delivery of drugs 
from the cell scaffolds and matrices. The third strategy is beyond the scope of this work, 
and will not be discussed. The final strategy will be covered in the following chapter on 
disease-responsive drug delivery. 
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2.4.1 Classical Drug Delivery Systems 
Several classical drug delivery systems for tissue engineering are still in use for a 
wide variety of applications. The majority of these systems are employed to provide a 
means of long term, controlled release of drugs into the local environment, whether in 
vitro or in vivo. The required release profile may be chosen based on several factors, 
including the rate of drug clearance from the system, pharmacokinetics, and stability. 
Thereafter, a system will be designed or chosen based on these requirements, considering 
parameters such as material properties, degradation rate, and device geometry. Generally, 
the major types of classical systems used include monolithic or slab-type systems, 
particulate systems, and gel-like systems.  
 
2.4.1.1 Monolithic Systems 
Monolithic polymer systems have a long history in drug delivery in that they were 
the first types of systems to be used for the controlled release of bioactive proteins and 
peptides. Among the first systems reported for controlled release was the polymeric 
membrane system composed of poly(ethylene-co-vinyl acetate) or EVAc, as described by 
Folkman and Langer in 1976 [59]. Although these systems were not biodegradable, the 
excellent controlled release profiles set the stage for an entirely new strategy of 
controlled release. In the following decade, several new biodegradable or bioerodible 
materials were developed with the aim of achieving sustained release in vivo without the 
need for removal after transplantation. Some of the materials included polyanhydrides 
[21], poly(ortho esters) [20], and poly(α-hydroxyesters) [60], with several more 
described in the literature. However, with the advent of these erodible systems came new 
unforeseen challenges due to the new intricacies of the system, including pH changes and 
side reactions with encapsulated drug due to the degraded products [46,61,62]. 
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These early delivery systems were made in the form of monolithic devices 
because of their ease of manufacture by solvent casting, extrusion, and injection molding. 
These bulk devices were also able to carry a large payload of drug, and could be tailored 
for different release rates by changing material composition, drug loading, or including 
dispersants. As discussed in the previous section on the mechanisms of drug release, 
release from non-degradable systems is controlled primarily by diffusion. Erosion 
controlled release provided more control over the release rate, which could be changed by 
the degradation rate, or by choosing between surface or bulk erosion. Monolithic devices 
based on the poly(lactic-co-glycolic acid) copolymer, PLGA, were and still are 
commonly used in the erodible systems because erosion may be well-controlled by 
changing crystallinity, copolymer composition, and molecular weight [46,62-66]. Other 
monolithic devices have been based on cross-linked hydrogels, and will be discussed in 
more detail in following sections. 
 
2.4.1.2 Particulate Systems 
Following the progress made in monolithic and erodible devices, microparticulate 
systems began to surface in the field. Whereas monolithic systems required surgical 
implantation in vivo and are associated with a strong drug gradient, particulate systems 
offered the possibility of an injectable system and more even distribution in the tissue in 
vivo, or in cell culture. Microparticles also provided the flexibility for cell 
microencapsulation, or combinatorial delivery from microparticle distribution within 
monolithic systems or gels [12,13,67]. Aside from microparticles, nanoparticles, 
liposomes, and other similar particulate technologies have also been explored; however, 
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microparticles have been most widely applied to tissue engineering, and are the focus of 
this dissertation. 
Microparticulate systems have been widely used for the delivery of growth factors 
for directing cell differentiation and proliferation. One application that has been 
extensively studied is the use of both EVAc and PLGA microparticles to deliver nerve 
growth factor (NGF) for supporting cellular therapy in neurodegenerative diseases [68]. 
PLGA microparticles are also still in use for delivery of several other proteins, including 
BMP-2 [69] and interferon-α [65]. Poly(phosphoester) microspheres with encapsulated 
NGF loaded within silicone nerve conduits showed greater peripheral nerve regeneration 
as compared to conduits with free NGF loaded [70]. Pfister et al [71] has reviewed other 
similar systems of NGF loaded microspheres for nerve regeneration. Excellent reviews 
may be found in the contemporary literature on the important considerations with protein 
encapsulation within polymer systems [62,64]. 
Hydrogel microparticles have also been used extensively to encapsulate proteins 
for drug delivery in tissue engineering. Some of the earliest hydrogel microparticle, or 
microgel, systems were the alginate beads, easily formed by dropping or spraying into 
cationic solutions, such as calcium [54,72]. Alginate microbeads are still widely used for 
delivery of FGF and osteogenic proteins [73-75], as well as for microencapsulation of 
chondrocytes for co-culture with bone marrow stem cells for osteogenic differentiation 
[76]. Along with alginate, microgels based on collagen [77], gelatin  [78], and hyaluronan 
and its derivatives [79] are all used to deliver a variety of proteins. 
Aside from encapsulation of proteins, much work has been done on the surface 
functionalization of microparticles for cellular interaction and proliferative effects. 
Surface modification of PLGA microspheres with an amine-terminated dendrimer 
improved long-term proliferation of chondrocytes without observed changes in the cell 
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phenotype, as compared to monolayer culture systems [66]. Additionally, surface 
functionalization of polystyrene magnetic microbeads with the DLL4 notch ligand used 
in co-culture has been shown to efficiently generate T cells from mouse bone marrow 
hematopoietic stem cells [80]. 
 
2.4.1.3 Gel-Based and Gel-Like Systems 
Several gel-based and gel-like systems also offer the advantage of being 
injectable in vivo, taking on the shape of the tissue cavity. Additionally, the hydrophilic 
matrix structures of gels offer the advantage of high compatibility with the majority of 
proteins and peptides of interest in tissue engineering. Gelation occurs by several 
methods including thermally- or pH-induced cross-linking [38,81], sol-gel transitions, 
and physical gelation. Early injectable gel-like systems include those composed of 
alginate, gelatin, and collagen [54-56]. Although gel systems for protein delivery are a 
classical form of drug delivery, they have in recent decades gained much significance as 
a combinatorial tissue engineering substrate and drug delivery medium. As such, much 
attention will be directed towards these systems in the following section. 
 
2.4.2 Drug Delivery from Scaffolds and Matrices 
As the previous section focused on controlled delivery strategies separate from a 
cellular substrate, herein referred to as the substrate, much work has been done in using 
the substrate itself as a controlled release medium. The use of both scaffolds and matrices 
have been used to achieve desirable release strategies, where scaffolds refer to macro- or 
microporous substrates to provide structural support, and matrices refer to more or less 
continuous nanoporous substrates, such as gels. Several strategies may be used to achieve 
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the desired effect, including the admixing of drugs within matrices, entrapment of drugs 
within matrices, covalent binding of drugs to the matrix, affinity binding of drugs to the 
matrix, and microparticles embedded in matrices for delivery of drug.  
 
2.4.2.1 Drugs Admixed with Cell Substrate 
A common form of drug delivery from the cell substrate is by simply admixing 
the drug with the cell substrate. As previously discussed, various mechanisms may be 
used to control the release, with the desired effect usually being prolongation of the 
release. In the case of prolongation, even a small degree of affinity between the substrate 
materials may serve to slow the release rate. Additionally, poorly soluble drugs may 
dissolve over time and provide a sustained release profile. The cell substrate may also 
serve as a diffusion-limiting factor, providing drug release in a localized area of the 
scaffold, also known as zonal release.  
Several examples of drugs admixed within a cell substrate have already resulted 
in commercial products, especially the release of bone morphogenetic proteins from 
collagen sponges and matrices [82]. Aside from the collagen sponge, other substrates for 
BMP delivery have included calcium phosphate cement, both of which have shown 
excellent orthopedic tissue regeneration in vivo [82-85].  Gelatin, a form of denatured 
collagen, has also been used in both its native self-assembled gel form and as a cross-
linked gel to deliver growth factors. During fabrication, gelatin may be modified into 
either negatively or positively charged gels at physiological pH in order to create low-
affinity electrostatic interactions with a protein drug [56,86,87]. These low affinity 
electrostatic interactions of proteins with gelatin have been shown to prolong release rates 
as compared to non-electrostatic gelatin [86,88-90]. 
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2.4.2.2 Drugs Entrapped within Cell Substrate 
It is also possible to engineer hydrogel cell carriers with structures capable of 
physically trapping drug molecules within the cell carrier’s molecular structure, most 
commonly, with hydrogels. Hydrogels form somewhat of a 3-dimensional network 
structure, where the molecular weight and structure of the cross-linking molecule 
determines the pore size.  If the pore size of the hydrogel is sufficiently close to the size 
of the drug of interest, then the release of the drug from the matrix could then be inhibited 
by the network structure [14]. In this case, drug release would be driven either by 
polymer swelling or degradation of cross-links. Commonly, the drug is loaded with the 
polymer precursor solutions, and the hydrogel network is then reacted to form around the 
drug [23,91,92]. 
Common materials used for these systems include PEG, fibrin, collagen, and 
hyaluronic acid [23,53,91,93,94]. A study by van de Wettering et al. illustrated the ability 
to tune the release of human growth hormone (hGH) from various PEG-based hydrogels 
using different cross-linked network architectures. Tighter cross-linked networks were 
able to significantly prolong the release of hGH over loosely-formed networks [95]. In 
addition to single-component hydrogel networks, hybrid hydrogels of interpenetrated 
networks or semi-interpenetrated networks are similarly able to form diverse network 
structures of varying pore sizes and cross-linking densities [93].  
Due to the tight nanoporous properties of these hydrogels, which may prevent cell 
inter-growth, these systems are often employed as particulate systems within a scaffold. 
Scott et al. created PEG-based scaffolds using a modular assembly system of hydrogel 
microspheres with encapsulated sphingosine 1-phosphate (S1P), microspheres for 
 32 
structural support, and porogen particles. The resulting macro-porous scaffolds with 
incorporated S1P-loaded microspheres showed an approximate two-fold increase in rate 
of cell migration into the scaffold as compared to scaffolds without S1P-loaded 
microspheres [96]. Alternatively, cell ingrowth into such nanoporous hydrogels may be 
achieved by incorporating enzyme-cleavable moieties into the network structure, thus 
allowing a cell to easily infiltrate the hydrogel by secreting ECM-degrading enzymes. 
Examples of these ingrowth matrices with entrapped drug include fibrin-based matrices 
for controlled release of NGF [94] and PEG-based matrices with matrix 
metalloproteinase substrates as cross-linkers with entrapped rhBMP [53]. 
 
2.4.2.3 Covalent Binding of Drugs to Cell Substrate 
It is oftentimes advantageous, if not required, to covalently bind drugs to the cell 
substrate itself. For example, adhesion peptides must be bound to the substrate in order to 
elicit the correct response in the cell for migration. Although adhesion sites are already 
present in naturally derived materials, such as collagen and fibrin, cell substrates 
composed of synthetic components (such as PEG) must include adhesion peptides to 
effectively promote cell adhesion and signaling. Scaffolds of naturally derived materials 
may also benefit from adhesion peptide or growth factor incorporation to provide a 
higher degree of control over cell migration and differentiation. 
In a study by Hern and Hubbell, the cell adhesion peptide RGD (Arg-Gly-Asp) 
was covalently bound to PEG-based hydrogels either directly, or using a PEG spacer arm, 
and compared to a non-adhesive control peptide [97]. Due to the greater steric availability 
of the adhesion peptide bound to the PEG spacer arm, specific mediation of cell 
spreading was observed in contrast to non-specific cell spreading observed in direct 
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conjugation of the peptide to the scaffold. Wacker, et al. compared S1P-induced 
endothelial cell migration in PEG hydrogels with either linear or cyclic RGD peptide 
sequences for implications in implant endothelialization speed following implantation 
[57]. Although linear RGD produced greater adhesion strength and long-term adhesion 
on exposure to shear stress from fluid flow, cyclic RGD produced a faster rate of 
endothelial cell migration. These studies illustrate the complexity in the incorporation of 
adhesion peptides into scaffolds, from determining the optimal conformation for steric 
availability, and finding the balance between high adhesion strength and higher migration 
rates for tissue regeneration. 
In addition to covalent binding of adhesion peptides into cell substrates, drugs 
may also be covalently bound to the substrates in order to achieve directed 
differentiation, interaction, or promote migration of a specific cell phenotype. For 
example, vascularization of regenerated tissues is necessary for nutrient delivery in vivo, 
and requires high order cell and tissue arrangement controlled by growth factors. Leslie-
Barbick et al. were able to achieve endothelial cell tubulogenesis in 2D and 3D PEG-
based scaffolds by covalently attaching VEGF and an RGD adhesion peptide, in 
comparison to RGD-immobilized scaffolds alone [98]. Similarly, a study by Chiu and 
Radisic showed enhanced vascularization of endothelial cells in collagen scaffolds with 
immobilized VEGF and Angiopoietin-1 over collagen scaffolds alone and soluble factor 
in collagen scaffolds alone [99]. 
Furthermore, some drugs require binding to the substrate such that they are 
released only in response to cell-ingrowth, for example by enzymatic cleavage, providing 
on-demand delivery of the drug. In the case of bone regeneration, high concentrations of 
drug may result in overactivation of cells locally, and thus, abnormal tissue regeneration. 
By incorporating an enzyme-cleavable prodrug of a parathyroid hormone fragment into a 
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cell-ingrowth matrix, Arrighi et al. were able to circumvent osteoclast overactivation and 
show dose-dependent bone healing in vivo [100].  
 
2.4.2.4 Affinity Binding of Drugs to Cell Substrate 
Another strategy for binding drugs to a cell substrate involves the use of affinity 
binding molecules that have strong interactions with several growth factors and other 
proteins. A comprehensive review of the myriad molecules is outside the scope of this 
chapter, and we refer the reader to excellent reviews in the literature [8,101]. Instead, we 
will focus on two groups of common affinity binding molecules: heparin/heparan sulfate 
and fibrin/fibrinogen. Other molecules of interest include laminins, collagens, 
glycosaminoglycans, DNA, poly(amino acids), avidin-biotin [102-104], and other 
polysaccharides. 
Heparan sulfate and heparin are glycosaminoglycans (GAGs) that are present in a 
variety of tissues throughout the body, regulate many processes, and bind a variety of 
proteins or growth factors. There are several growth factors that bind to both heparan 
sulfate and heparin, and are known as heparin binding growth factors (HBGFs). 
Commonly noted HBGFs include members of the families of FGF, HGF, and VEGFs. 
Heparan sulfate has been used in micropatterned PEG-based scaffolds for spatiotemporal 
release of growth factors and multilineage differentiation [105], and widely in other 
applications [106-108]. However, due to lower costs, heparin is more widely used in cell 
substrates for HBGFs, and has been incorporated into gels for osteogenic differentiation 
[109,110], endothelialization [111,112], nerve regeneration [113,114], and a variety of 
other applications [8,115-117].  
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Fibrin and fibrinogen are proteins found in the blood that are critical in the 
clotting and wound sealing process; cleavage of fibrinogen by thrombin yields fibrin 
[8,118,119]. Fibrinogen is used primarily in fibrin glue systems, where a mixture of 
fibrinogen solution and calcium-rich thrombin solution are co-delivered for surgical use 
as a sealant or hemostatic agent [118,119], but has recently gained more interest as a cell 
substrate with protein immobilization capabilities [118]. Fibrin is widely used for its 
affinity binding characteristics with other proteins to slowly release growth factors, 
particularly VEGF and FGF, to loaded cells within the gel [120,121]. Work by the Swartz 
group used VEGF bound to fibrin-based matrices along with interstitial fluid flow in 
order to direct blood and lymphatic capillary morphogenesis, resulting in organized 
tubular structures [122,123]. Hybrid PEG and fibrin matrices have also been used to 
create cell substrates with the ability to entrap, covalently conjugate, and affinity bind 
growth factors, and have tunable mechanical properties for directed differentiation 
[124,125]. PEG-based materials that mimic the fibrin clotting cascade, known as fibrin 
analogs, have also been created for tissue engineering applications [126].  
 
2.4.2.5 Particulate Systems within Cell Substrate 
Microparticles, and to a lesser extent, nanoparticles, may often be incorporated 
into cell substrates to provide another mechanism of controlled drug release to the cells. 
The complexities in these systems are vast when considering the combinations of 
material properties, release profiles, release mechanisms, or substrate construct. In some 
cases, the particles may be hydrophobic and rely on hydrolysis to control the release of 
growth factors, as in the release of BMPs from PLGA microspheres in scaffolds and 
matrices [127-130]. In other cases, the particles provide a facile means in which to 
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provide controlled delivery of growth factors in vivo, for example, by injection 
[129,131,132] or intratracheally [133]. Particles may also serve as cell carriers 
themselves, or assemble into a cell substrate at a later stage [96]. 
 
2.5 PERSPECTIVE 
Drug delivery, and especially controlled drug delivery with engineered 
biomaterials, has proven to be an essential means for eliciting desired cellular responses 
in tissue engineering and drug therapy. The complexity of these biological systems, and 
the response to the concentration and pattern of drug introduced into the system, warrants 
further study to improve future therapies. The following chapter will further discuss the 
concept of disease-responsive drug delivery, previously introduced here as a part of the 
stimuli-responsive release modality.  
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Chapter 3: Disease-Responsive Drug Delivery 
[This chapter was adapted, with permission‡, from P. Wanakule, K. Roy§, Disease-
responsive drug delivery: the next generation of smart delivery devices, Curr Drug 
Metab. 13 (2012) 42–49.] 
 
3.1  INTRODUCTION 
As more effective and sophisticated drugs begin to emerge, greater emphasis must 
be placed on the specificity and accuracy by which they are delivered to diseased cells in 
the body. These new classes of drugs include biological molecules, such as proteins, 
peptides, DNA, and siRNA, which are designed to target specific cellular pathways (such 
as signal transduction cascades, transcription factors, and apoptosis). Although these 
drugs are very specific in their action, many of them interfere with key cellular processes, 
and are therefore highly cytotoxic. When delivered to physiologically normal cells or 
tissue, the side effects are potentially damaging and debilitating. Moreover, the majority 
of these sophisticated drugs, especially those for chronic and advanced diseases, are 
primarily given via systemic administration, often through multiple, regular doses. The 
continued endurance of these side effects interferes with the quality of life of these 
patients, and may further lead to the development of other acute and chronic diseases. 
Therefore, rational design of targeted therapies that enhance patient compliance and 
improve quality of life while maintaining efficacy of treatment is essential [1-3]. 
                                                 
‡ Copyright 2012 From Disease-responsive drug delivery: the next generation of smart delivery devices, by 
P. Wanakule & K. Roy (Authors). Reproduced by permission of Bentham Science Publishers. Bentham 
Science Publishers retain the rights for all text, figures, and tables reproduced here. 
§ Statement of co-author contribution: This chapter was written by Prinda Wanakule, with editorial and 
content assistance by Krishnendu Roy (research supervisor). 
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Research to improve the mechanisms of controlled drug delivery has seen much 
success in recent decades, achieving long-lasting zero-order drug release, and reducing 
issues such as toxic plasma concentrations, short half-lives, and the need for multiple 
administrations. However, as their underlying mechanisms are uncovered, many diseases 
are found to follow biological rhythms or aberrant regulatory feedback cycles. Hence, 
ideal drug delivery systems should be designed to respond and modulate their release 
profiles to synchronize with the changing physiologic and pathophysiologic condition, 
both temporally and spatially [1,3]. 
In response to this, a growing interest in controlled drug delivery has been 
developing as a means to deliver bioactive agents (drugs) only when or where it is 
needed, primarily in response to specific stimuli. These stimuli-responsive types of 
systems often rely on local physicochemical changes arising from disease pathology or 
the cell microenvironment as well as on external stimuli that could be provided by a 
device. Common stimuli include pH, temperature, ions, enzymes and other biomolecules 
as well as light and mechanical forces, all of which have been designed to illicit a 
response in drug carriers to trigger drug release [1,2,4-11]. Stimuli-responsive systems 
are also referred to as “smart,” “environment-sensitive,” and “intelligent” systems, 
among others.  
In this chapter, we focus on systems that respond to local, disease-specific stimuli 
– pH, ions, and biomolecules. The overwhelming majority of these delivery strategies are 
based on both natural and synthetic polymers, including biopolymers such as proteins, 
peptides, nucleic acids, and carbohydrates. We first begin with a detailed description of 
the disease-triggered drug release mechanisms, as well as advantages and disadvantages. 
We then move on to provide enabling applications and examples of these disease-specific 
delivery systems for various pathologies. Finally, we conclude the chapter with future 
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outlooks. External stimuli like light, magnetic field, ultrasound, electrical, and thermal 
triggers are not discussed extensively. Instead, we refer the reader to excellent reviews in 
the literature [2,5,8] that covers these aspects. It is also beyond the scope of this review to 
thoroughly discuss systems that respond to intracellular pH changes and reductive 
environments, although a few examples are provided. We again refer the reader to 
excellent articles in the literature [7,9,12-15] describing such systems. 
 
3.2 DISEASE-RESPONSIVE DRUG RELEASE MECHANISMS 
First, we will begin with a discussion of the various disease cues that may be used 
to create disease-responsive drug delivery systems.  These include pH responsiveness and 
biomolecule sensitivity, such as enzymes, antibodies, and metabolic products. An 
illustration of the many types of disease-responsive systems discussed here is shown in 
Figure 3.1 (page 55). A table is also provided at the end of the chapter, which gives an 
overview of the mechanisms discussed, a brief description of the mechanism, and a cross-
listing of general references and disease-specific references (Table 3.1, page 67). 
 
3.2.1 pH-Responsive 
Variations in pH exist throughout the body at the organ, tissue, and cellular level, 
as well as in the local microenvironment of disease-affected tissues. pH-triggered drug 
delivery systems have been especially used in oral drug delivery to protect drugs from the 
acidic gastric cavity, triggering release in the more neutral small intestine [16,17], where 
much drug absorption occurs. More recently, as gene delivery systems have been gaining 
increasing significance, pH-responsive carriers have been developed to take advantage of 
the pH gradient from the extracellular environment through the early and late endosomes  
 55 
 
Figure 3.1 Illustrations of select disease-responsive release mechanisms. 
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[18]. pH variations within the microenvironment of disease-affected tissues have also 
been observed, including tumors, infarctions [19], and several other conditions connected 
with acidosis and alkalosis. Thus, pH-responsive systems offer a versatile way in which 
to trigger drug release in response to physiological or pathological cues. 
Several hydrogel-based drug delivery systems with the ability to swell or shrink in 
response to pH changes have been developed as triggered-release delivery systems. The 
pH triggered swelling and shrinking mechanisms are primarily due to the properties of 
the side chain pendant group, which are cationic or anionic [2,6,20,21]. Anionic 
hydrogels are ionized at pHs above their pKa, and thus exhibit high swelling at these 
higher pHs due to repulsion of the ionized groups [20]. In contrast, cationic hydrogels are 
ionized at pHs below their pKa, exhibiting high swelling below their pKa [6]. pH-
triggered swelling systems have been developed to be sensitive to minor pH changes, as 
low as 0.2-0.6 pH [22].  
Other pH-responsive delivery systems have been designed to undergo hydrophilic 
to hydrophobic transitions, based on incorporated acid-degradable linkers, such as acetal 
[23,24], hydrazone [19], and pH-hydrolysable protecting groups [25]. Some materials 
with pH-dependent solubility also exhibit pH-dependant drug release, and have also been 
used [26]. Related to pH-responsive delivery, ionically driven drug release systems have 
also been developed [27,28].  
 
3.2.2 Biomolecularly-Responsive 
Systems that incorporate biomolecular recognition are some of the most relevant 
stimuli-responsive systems for disease-triggered drug release. Several different types of 
biomolecules could be used as drug release triggers, including high affinity binding of 
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proteins and peptides, enzyme-substrate recognition, and metabolically reactive systems. 
The incorporation of biomolecular recognition often involves the addition of 
complementary proteins, peptides, ligands, enzymes, substrates, antibodies, antigens, and 
metabolic products within a polymer system [1-5,8]. Polymer systems with incorporated 
biomolecules are often referred to as biopolymers or bio-inspired materials. These 
biomolecules could also be incorporated with non-polymeric delivery systems, for 
example, gold nanoparticles [29,30] or other theranostic systems [31-35]. 
Protein and ligand interactions have been used for years as a way to target drugs 
to certain cells. In the classical system, the drug is tethered to a protein, which binds to a 
receptor that is over expressed in the target cell type. Due to the higher accumulation of 
drug at these target cells and the process of receptor-mediated endocytosis, these systems 
are able to preferentially deliver drugs to the diseased tissue. These protein-ligand 
systems have also been incorporated into micro- and nanoparticles by conjugating 
proteins to the particle surfaces [36-39].  Common receptors targeted in cancer include 
CD44 [40-43], HER2 [37,44], transferrin [45,46], and folate [47,48].  
Aside from usage as targeting molecules, affinity binding has also been used to 
create reversibly swelling hydrogel systems based on antigen-antibody binding [49]. In 
this system, both antibody and antigen are grafted onto polymer chains, and in 
combination, the antibody-antigen binding induces hydrogel formation. When the 
hydrogel is then exposed to free antigen, competitive binding disrupts the hydrogel 
network, resulting in swelling. When free antigen is removed, the original binding 
between the grafted antibody-antigen are re-formed, demonstrating a memory-like 
property. This early system paved the way for extensive work on molecular imprinting in 
hydrogel systems, which continue to be explored for disease-responsive release [50,51], 
targeting, and biosensors [2,3,52,53]. 
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Another class of biomolecularly-responsive systems involves incorporation of 
enzyme-sensitive components into drug carriers, usually peptides, proteins, or 
polysaccharides. Several of these biomolecules have been integrated into enzyme-
degradable hydrogels, either as a cross-linker (short peptide sequences) or as the matrix 
material, e.g. polysaccharides (chitosan, hyaluronic acid) and protein-based gels 
(collagen, gelatin). These hydrogels have shown minimal release in the absence of the 
stimulating enzyme, and triggered release in the presence of the enzyme [2,3,54,55]. This 
strategy has been used extensively in tissue engineering applications [56,57], however, it 
could also provide an effective means of disease-responsive drug delivery [58-60]. 
Enzyme-responsive systems are suitable for site-specific and disease-specific delivery 
because of the high specificity of enzymatic cleavage, and the up regulation of enzymes 
in several diseases, such as various cancers and inflammatory diseases [46,55,58,59,61-
63]. Aside from enzyme-sensitive hydrogels, enzyme-degradable components are often 
used as covalent linkers to conjugate drugs as pendant groups off a polymer backbone. 
Upon encountering the enzyme, the pendant chains are broken, releasing the tethered 
drug [2,60,64]. Yet another set-up incorporates an enzyme-sensitive peptide-based 
coating on a porous particle. Drug molecules are loaded within the pores of a particle and 
encased with a peptide coating such that the coating prevents drug release until it is 
removed via enzymatic degradation [65]. 
Common metabolic products and pathways may also be used as stimuli for 
polymer systems, an exemplary example of which includes the glucose oxidase-
containing cationic hydrogels created by Podual and colleagues [66,67] (described in 
detail under the Diabetes section). Other examples include a carbon dioxide-responsive 
cationic hydrogel developed as a feedback-regulated drug delivery vehicle [68], as well 
as a metabolism-mimicking glutathione-triggered drug release system [69]. In normal 
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cells, glutathione neutralizes reactive oxygen species, preventing free-radical damage to 
nucleic acids. However, glutathione is elevated in tumor cells, and contributes to 
chemotherapy drug resistance [70]. 
With recent advances in computing and bioinformatics, a number of protein and 
enzyme databases with detailed binding and specificity information are available for 
researchers to carefully choose appropriate molecules for incorporation into their systems 
as the stimulus, or stimulus-responsive component. Just to name a few, these databases 
include the Protein Data Bank (PDB) [71], Braunschweig Enzyme Database (BRENDA) 
[72], Expert Protein Analysis System (ExPASy) [73], and Universal PBM Resource for 
Oligonucleotide Binding Evaluation (UniPROBE) [74]. 
 
3.2.3 Other Notable Stimuli 
Several other common stimuli within the field of stimuli-responsive drug delivery 
include temperature, light, magnetic field, and ultrasound [1,5,15,75]. Although these 
stimuli are not specifically disease-responsive, many of these have been incorporated into 
drug release systems as a means of externally controlling drug release, with the 
possibility of dosing according to a regimented schedule. These types of stimuli are 
especially applicable in the newly emerging area of theranostics, in which diagnostics 
and therapy are combined into one delivery system, and delivered to the patient in a 
single, combined dosage form. In this way, theranostics allows for simultaneous 
monitoring of disease progression or regression in response to a prescribed therapy. 
Combined with imaging-based diagnostics, the accumulation of the theranostic treatment 
could be monitored until significant levels are achieved at a known disease site, and then 
triggered for drug release in response to applied stimuli. Several opportunities exist, all of 
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which we invite the reader to explore in several exceptional reviews in the literature 
[34,35,76-81]. 
 
3.3 DISEASE APPLICATIONS 
3.3.1 Cancer 
Physiological differences found within the tumor microenvironment, or stroma, 
may be exploited by drug delivery systems in order to trigger drug release. Aside from 
the leaky vasculature that results in the enhanced permeation and retention (EPR) effect, 
the tumor-stroma exhibits a slightly acidic pH, around 6.5-7.2. This acidic environment 
stems from poor perfusion rates and increased glycolysis in tumor cells, which results in 
a local accumulation of acidic waste products [46,82,83].  Although this low pH slows 
the uptake of weakly basic drugs like doxorubicin (DOX), several strategies have been 
employed to improve the uptake and efficacy of DOX [84]. For example, pH-sensitive 
micelles composed of poly(L-histidine)-poly(ethylene glycol) block copolymers were 
developed by Bae and coworkers [85,86] that destabilize at the slightly acidic tumor 
microenvironment. When loaded with DOX and subjected to decreasing pH, a marked 
increase in release of DOX and corresponding decrease in A2780 cell viability was 
observed between pH 7.4 and 6.8. Further in vivo studies also demonstrated increased 
tumor suppression using the pH-sensitive micellar formulation versus free DOX. Similar 
results were obtained with another acidic pH-destabilizing micelle formulation of methyl 
ether poly(ethylene glycol)-poly(β-amino ester), developed by Kwon and colleagues 
[87]. Whereas both of these micellar systems utilized the acidic microenvironment to 
increase the tumor-localized concentration of DOX for increased uptake and efficacy, 
another system devised by Stayton et al. improved overall DOX efficacy by using pH 
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responsive polymers to co-deliver siRNA [88]. In this system, pH-responsive 
poly(styrene-alt-maleic-anhydride) was complexed with siRNA to improve endosomal 
escape within the tumor cell, and packaged inside a micelle to be co-delivered with DOX. 
The siRNA used was shown to sensitize multidrug resistant tumor cells to DOX by 
silencing the gene polo-like kinase 1, demonstrating a potent combinatorial treatment 
system. Aside from buffering-induced endosomal disruption, pH triggered expansion of 
hydrogel nanoparticles within the endosome, and thus a bursting of the endosome, has 
also been conceived as means of cytosolic anti-cancer drug delivery [25]. 
Enzyme-triggered release is an especially noteworthy method of achieving 
disease-responsive delivery for tumors and cancer cells. Several enzymes are up 
regulated in various cancers, both intracellularly and extracellularly, including secretory 
phospholipase A2 (sPLA2) [89], cathepsins [4,59], Src family kinases [90], and MMPs 
[60,63,91]. sPLA2 is an extracellularly up regulated lipid hydrolyzing enzyme, and is 
primarily used as a trigger for liposome-based delivery systems [89]. Several variations 
of these sPLA2-sensitive liposomal formulations are possible, such as incorporating the 
enzyme-sensitivity to activate a phospholipid prodrug, or triggering release of anti-cancer 
drugs encapsulated within a liposome. Kaasgaard and co-workers demonstrated 
promising cytotoxicity of a novel methotrexate analogue encapsulated within sPLA2-
degradable liposomes in KATO III and HT-29 cancer cell lines. However, the 
cytotoxicity was independent of the enzyme degradation, indicating leakage of the anti-
cancer drug from the system, and illustrating the difficulty in ensuring anchoring stability 
of such drugs in liposomal formulations [92]. Pederson and colleagues demonstrated the 
sPLA2-mediated cytotoxicity of several retinoid phospholipid prodrugs toward HT-29 
and Colo205 colon cancer cells (no significant cell death observed in the absence of 
enzyme). Furthermore, the phospholipid prodrugs were able to form ~100nm particles 
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suitable for intravenous administration, demonstrating a marked improvement over 
previous liposomal formulation strategies that often result in leakage of the drug from the 
carrier [93].  
Our group has recently demonstrated the incorporation of an enzyme-triggered 
release mechanism within size- and shape-specific hydrogel nanoparticles for cancer 
treatment [4,59]. Specifically, disease-responsive release is mediated by cathepsin B 
activity on a di-acrylated peptide sequence, GFLGK, which is incorporated into a PEG 
hydrogel via UV cross-linking of acrylate groups. The nanoparticles are fabricated using 
step and flash imprint lithography (S-FIL), allowing precise control over size (down to 
50nm), shape, composition, and ease of harvest and recovery. Specific enzyme triggered 
release from these nanostructures was demonstrated with plasmid DNA and IgG 
antibodies, with minimal release of both model drugs in the absence of enzyme.  
The family of matrix metalloproteinases has perhaps received the most attention 
of all the up-regulated enzymes in cancer. This is largely due to early interest in the 
therapeutic potential of down-regulating MMP activity. However, significant work by 
Gemeinhart and colleagues established MMPs as an effective target for disease-specific 
triggered drug release [55,60,63,91].  In these systems [60,63,91], cisplatin is used as a 
model chemotherapeutic drug, and is incorporated within a PEG hydrogel via MMP-
sensitive peptide tether. Collectively, the work demonstrates the enzyme-dependant 
release of drugs from the system, with a PEG chain length of 4000 kDa being sufficient 
to allow MMP activity within and throughout the hydrogel, and a PEG chain length of 
574 Da being insufficient. Cytotoxicity studies of the cisplatin-loaded system using U-87 
malignant glioma cells and the 4000 kDa PEG chain showed 0% cell survival in the 
presence of MMP versus ~50% cell survival in the absence of MMP. This early work has 
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paved the way for the development of other MMP-responsive systems for localized 
treatment of cancer and other diseases [64,94-97].  
 
3.3.2 Diabetes 
Feedback-regulated control of insulin release, required to maintain optimal blood-
glucose levels is of utmost importance in controlling diabetes, preventing diabetic coma, 
and reducing the risk of developing more serious pathologies as a result of glucose 
imbalance [98]. Peppas and colleagues developed one of the most significant insulin 
delivery systems capable of achieving this feedback-regulated control [66,67]. In this 
system, glucose oxidase and catalase was incorporated into cationic hydrogel 
microparticles, employing hybrid disease-responsive triggers: biomolecule-sensitivity 
and pH-responsive swelling. As glucose interacts with glucose oxidase in the hydrogel, it 
is enzymatically digested into gluconic acid, thereby shifting towards a slightly acidic pH 
in the hydrogel microenvironment. The cationic hydrogel then swells in response to the 
acidic pH, releasing insulin, and reversibly shrinks once glucose is removed and local pH 
returns to the neutral physiological norm.  
 
3.3.3 Inflammatory Diseases 
Prolonged inflammation after acute injury or in chronic diseases, such as asthma 
and arthritis, can severely debilitate a patient and lead to development of more serious 
conditions, including fibrosis and cancer [23,58,99,100]. Since inflammation is an 
essential part of the normal immune response, it is undesirable to non-specifically deliver 
anti-inflammatory or immune-suppressive drugs over the long term. Disease-responsive 
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drug delivery is therefore needed to treat only the tissue affected with prolonged 
inflammation.  
One strategy to achieve such inflammation-responsive drug delivery involves an 
enzyme-degradable PEG hydrogel, sensitive to human neutrophil elastase, an enzyme 
secreted during inflammation [58]. The authors were able to demonstrate enzyme-
dependent release of a model protein from the system, and effective retention of the 
protein without enzyme, by creating hydrogels with sufficiently restrictive mesh size so 
as to drive the mechanism towards enzyme-mediated surface erosion. 
In another system, an intracellular protein kinase that is constantly activated in 
inflammatory cells was used as a cell-specific stimulus to cleave a transcription-
inhibiting polymer complexed with plasmid DNA [99]. This system was able to 
effectively demonstrate gene activation only in cells exposed to an inflammatory stimulus 
(lipopolysaccharide), as compared to normal cells, showing potential in targeting only the 
inflammatory cell types.  
 
3.3.4 Infection 
There are many benefits for applying disease-responsive drug delivery to 
infections, including bacterial, fungal, or viral. In the case of bacterial infection, the rise 
of antibiotic resistant bacterial strains has created a tangible need to limit and control the 
improper and/or prophylactic usage of antibiotics. Although antibiotic-treated bandages 
have been available for years, in vitro studies have shown that most antibiotics exert 
somewhat cytotoxic effects on human fibroblasts. To address these issues, an antibiotic 
delivery system based on PVA with peptide tethered-gentamicin was created to release 
the antibiotic only in the presence of infection by Pseudomonas aeruginosa. Gentamicin 
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release was clearly observed from infected samples as compared to negligible release of 
gentamicin from non-infected control samples [101]. Another system for enzyme-
mediated gentamicin release was designed using poly(trimethylene carbonate) for the 
treatment of osteomyelitis, via lipase degradation [102]. 
Enzymatic activity due to viral infection has also been used to target and treat 
only those cells that are infected with the virus. For example, an anti-HIV transgene was 
coupled with an intelligent gene delivery carrier using enzyme specificity to achieve 
HIV-infected cell specificity. The authors fabricated an HIV-1 protease sensitive polymer 
known as CPCHIVtat (cationic polymer possessing a cleavage site for HIV-1 protease), 
which formed a polyplex with the transgene, suppressing transcription. The presence of 
the HIV-1 protease caused the cleavage of the CPCHIVtat polymer, releasing the 
transgene to be expressed in activated HIV-infected cells, whereas other uninfected cells 
remained intact [103]. 
 
3.4 CONCLUSIONS AND FUTURE PERSPECTIVES 
Drug release from nano to macroscale delivery systems in response to 
physiological or disease-specific signals holds significant promise in reducing side effects 
and increasing efficacy of a variety of therapeutic agents. New particle and device 
fabrication methods have enabled incorporation of a variety of stimuli-responsiveness 
within delivery systems.  The field is expanding rapidly with more and more new systems 
being reported. However, a few areas need to be studied more carefully before such 
systems can find clinical usage. For example, most of the systems developed so far must 
rely on a threshold level of stimuli signal to “trigger” the drug release. This is critical for 
distinguishing disease-specific signals from normal physiological levels of the stimulus. 
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However, inter patient variability and variability between different phenotypes of the 
disease could significantly complicate the design of such systems. As in the case of pH or 
enzyme-responsive devices, the threshold of pH or enzyme concentration would dictate 
drug release, both in terms of when drug is released and at what rate. Variability in 
enzyme levels or pH levels from tumor to tumor or patient to patient could provide 
significant differences in those variables. Another critical issue is that of scale up and 
cost. Drug carriers involving biological molecules (peptides, proteins, nucleic acids) in 
addition to the drug itself could drive up cost significantly. Therefore, it is necessary to 
study cost-benefit issues when developing such systems for clinical use. Nevertheless, the 
recent developments in this area are exciting, and open up new directions in treating 
complex diseases with reduced side effects and improved efficacy. 
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Table 3.1 Summary of disease-responsive release mechanisms, with cited references 
(in-chapter reference list). 
Mechanism Description References 
pH-Responsive 
Materials 
Includes hydrogels with the ability to swell or shrink in 
response to minor changes in pH, and micelles that 
destabilize according to pH, triggering release of 
encapsulated drug. 
[2,6,20-22] 
Cancer: [85-88] 
Diabetes: [66,67] 
pH-Dependent 
Hydrophilic to 
Hydrophobic 
Conversions 
Systems release drug after undergoing conversion, using 
acid-degradable linkages, hydrolysable protecting groups, 
or pH-dependent solubility. 
[19,23,24,26]  
Cancer: [25] 
Ionically-Driven 
Drug Release 
Systems 
Changes in ion concentration trigger release of drug. [27,28] 
Protein-Ligand 
Interactions 
Addition of a specific protein that binds with an over 
expressed receptor increases drug accumulation at 
diseased tissue. 
[36-39] 
Cancer: [37,40-48]  
Hydrogels based on 
Antigen-Antibody 
Binding 
A hydrogel network is formed by affinity binding 
between conjugated antigens and antibody. Introduction 
of free antigen disrupts the network, causing release of 
drug. 
[50] 
Enzyme Responsive 
Hydrogels 
Hydrogel networks are formed with a cross-linker that is 
sensitive to an enzyme. The enzyme is either up-
regulated in diseased tissue, or may be location-specific. 
Exposure to the enzyme causes network degradation and 
release of drug. 
[2,3,46,54,55,59-
63,96]  
Cancer: [4,59] 
Inflammatory 
Diseases: [58,99] 
Enzyme Responsive 
Linkages 
Enzyme sensitive linkages are used to tether drug to a 
polymer backbone or to a particle. The enzyme is either 
up-regulated in diseased tissue, or may be location-
specific. Exposure to the enzyme causes release of the 
tethered drug. 
[2,60,64,97] 
Infection: [99,101-
103] 
Enzyme Responsive 
Coatings or 
Membrane Structures 
An enzyme sensitive coating is used to cover the surface 
of a porous particle with embedded drug, or solid drug 
particle. Upon enzyme exposure, the coating is degraded, 
triggering drug release. Also realized in micellar and 
liposomal formulations. 
[65,94] 
Cancer: 
[55,60,63,89,91-
93,95,104] 
Systems Responding 
to Metabolic Products 
Systems are designed to respond to metabolic products, 
usually via chemical reactions, including glucose, carbon 
dioxide, and glutathione. 
[68] 
Diabetes: [66,67] 
Cancer: [69,70] 
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3.5 LIST OF ABBREVIATIONS 
BRENDA = Braunschweig Enzyme Database 
CPCHIVtat = cationic polymer possessing a cleavage site for HIV-1 protease 
DDS = drug delivery system 
DOX = doxorubicin 
ECM = extracellular matrix 
EPR = enhanced permeation and retention 
ExPASy = Expert Protein Analysis System 
MMP = matrix metalloproteinase 
PDB = Protein Data Bank 
PEG = poly(ethylene glycol) 
S-FIL = step and flash imprint lithography 
sPLA2 = secretory phospholipase A2 
UniPROBE = Universal PBM Resource for Oligonucleotide Binding Evaluation 
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Chapter 4: Development of Enzyme-Responsive Hydrogel Networks 
using Michael Addition Reactions 
 
4.1  INTRODUCTION 
This chapter focuses on the development of enzyme-responsive hydrogel 
networks that have been formed using Michael addition reactions (Specific Aim 1A). 
Hydrogel compositions were designed to consist of a combination of multi-armed or 
multi-branched polymer cross-linked with an enzyme-specific peptide sequence, as 
popularized by the Hubbell group [1-6]. For this specific Michael addition chemistry, the 
reactive groups were chosen to be acrylates and sulfhydryls [7]. Polymers explored were 
poly(ethylene glycol), or PEG, and chitosan. Peptides were designed to be sensitive to 
trypsin for cost-efficient proof-of-concept studies. The approach to the design of 
components and the feasibility studies carried out are laid out in Figure 4.1. 
 
4.1.1 Stimuli-Responsive Hydrogel Networks 
4.1.1.1 Currently available stimuli-responsive networks 
Stimuli sensitive hydrogels have been developed as ‘smart’ drug delivery systems 
and biomimetic tissue engineering scaffolds to sense environmental changes and induce a 
structural change or degradation [2,8-17]. Temperature and pH sensitive hydrogels can be 
used for site-specific delivery. Biomolecule-sensitive hydrogels have been used to deliver 
drugs when in contact with glucose or specific antigens [11,13]. There are also hydrogels 
that are sensitive to light, magnetic field, and ultrasound [12,13]. However, 
physiologically site-specific responsive gels have not been incorporated for pulmonary 
drug delivery.  
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Figure 4.1 Approach to component design and feasibility studies in development of 
enzyme-responsive hydrogel networks 
 
4.1.1.2 Enzyme-responsive networks 
For a bolus dose at a target location, an enzymatically degradable polymer carrier 
could be advantageous. This is because enzymatic cleavage is highly specific and could 
be tailored for certain diseased tissues where specific enzymes are up regulated. A series 
of enzymatically degradable hydrogels, specifically designed to mimic the extracellular 
matrix (ECM) in tissue engineering applications, have been extensively reported 
[9,10,14]. These designs contain a peptide linkage either in the backbone of the polymer 
or as a cross-linking agent that is degraded by the presence of tissue-specific enzymes 
(e.g. collagenase, elastase or MMPs). A key relevant finding in these studies, reported by 
Hubbell and colleagues [1] was the highly specific enzyme-controlled release of 
recombinant human bone morphogenetic protein (rhBMP). West and co-workers [10] 
showed the differential degradation kinetics of these gels in the presence of various 
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concentrations of the peptide-specific enzymes (collagenase or elastase). Their results 
indicated that the hydrogels do not degrade in the absence of enzymes, while rapid 
degradation can be achieved by optimizing the enzyme concentrations. These studies 
demonstrate the possibility that similar peptide-based hydrogels could be used to control 
drug release from micro- and nanoparticle carriers.  
 
4.1.2 Michael addition reactions 
Polymeric delivery systems have exhibited the potential for controlled release and 
protection of protein therapeutics; however, ideal polymer systems for broad use with a 
wide variety of proteins are yet to be developed. Although the classic poly(lactide-co-
glycolide) (PLGA) or polyanhydride-based systems have demonstrated suitable delivery 
characteristics, these systems may often cause protein denaturation due to the fabrication 
conditions, degradation characteristics or hydrophobicity [18-20]. A number of hydrogel 
materials have also been characterized as hydrophilic delivery systems, which greatly 
decreases the foreign body response as compared to hydrophobic materials. Typically, 
the protein and polymer are in the same solution, allowing the polymer network to form 
around the proteins. However, many of the proposed hydrogel networks are formed in a 
way such that the polymer reacts with the protein, or network formation requires 
initiation by radiation, UV light, or high temperatures that may also denature the protein 
[1-6,19,21].  
Michael addition reactions for the formation of hydrogel networks with 
encapsulated proteins have been recently developed using reactions between acrylate and 
thiol groups on a number of different synthetic and natural polymers, including PEG, 
PVA, dextrans, hyaluronic acid, and chitosan [7,22]. This allows rapid initiation of 
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polymerization or cross-linking at physiological temperature and pH, and under aqueous 
conditions.  Reactions between acrylate and thiol groups on the polymers occur much 
more quickly than with the chemical groups found on proteins, thus eliminating possible 
covalent modification of protein, which may hinder its release rate or bioactivity.  
Hydrogel swelling and degradation typically drive the release of protein, with variations 
in cross-linking density and molecular weights between cross-links offering tailor-ability 
in protein release rates [2,8-17,19-24]. 
As previously mentioned, the Michael addition reaction proceeds under mild 
conditions; it occurs in aqueous conditions at physiological temperature and pH, although 
a slightly basic pH will accelerate the reaction. Reactions are between a Michael donor, 
the nucleophile, and a Michael acceptor, the electrophile. Some other common Michael 
reactions occur with amines, vinyl-sulfones, and maleimides [7,11,13,21,25]. 
The Michael reaction used in this work is between a sulfhydryl and acrylate 
group. The slightly basic buffer creates a thiolate anion, which then reacts with the 
acrylate. For example, using a multi-armed polymer acrylate and a di-sulfhydryl peptide, 
this reaction yields a cross-linked network structure, or hydrogel network. In this case, 
the sulfhydryl group acts as the Michael donor, and the acrylate group is the Michael 
acceptor. The specific reaction scheme, as well as an illustration of the hydrogel cross-
linking reaction, is shown in Figure 4.2.  
 
4.1.3 Choice of Biocompatible Polymers 
Two different polymers were chosen to evaluate in feasibility studies to form 
these enzyme-degradable hydrogel networks: chitosan and poly(ethylene glycol). 
Chitosan is a polysaccharide, and functional groups would need to be added as side  
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Figure 4.2 Michael addition reaction scheme and illustration of hydrogel network 
cross-linking 
 
functional groups to the monomer units (“multi-branched” or “multi-functionalized”). 
Poly(ethylene glycol), or PEG, is commercially available in multi-armed, dendrimer-like 
configurations. The terminal groups of these multi-armed PEGs can be functionalized 
with a variety of reactive moieties. Figure 4.3 shows an illustrated schematic of the 
Michael addition cross-linking for the different types of polymers (multi-branched or 
multi-armed) used. 
 
4.1.3.2 Chitosan 
Chitosan is a biodegradable and biocompatible polysaccharide that is inexpensive and 
readily available. It is currently FDA approved for use as a haemostatic bandage due to 
rapid blood clotting capabilities. Chitosan has also been widely studied as a drug and 
gene delivery vehicle due to its mucoadhesive and cationic properties. It is comprised of 
β 1-4 linked units of glucosamine and N-acetyl glucosamine and has been shown to have  
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Figure 4.3 Schematic representing Michael addition based crosslinking of polymers 
and enzymatic degradation of the peptide 
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minimal cytotoxicity. Chitosan has been crosslinked into a number of hybrid hydrogels 
for encapsulation of various macromolecular drugs for oral, intranasal, and intravenous 
delivery. For the purposes of mucosal delivery, mucoadhesive and enhanced paracellular 
permeability properties of chitosan have been well established that could increase 
bioavailability of various drugs, while maintaining low cytotoxicity [12,13,22,26-37].  
 
4.1.3.3 Poly(ethylene glycol) 
Poly(ethylene glycol) has long been a staple biomaterial in drug delivery 
applications, both as a covalently-attached molecule, and as a hydrogel-based protective 
drug carrier. PEG is non-toxic, non-immunogenic, non-antigenic, hydrophilic, and FDA-
approved [9,10,14,38,39]. Due to its widespread use in a number of biomaterial 
applications, it is widely available in a variety of molecular weights and a number of 
functionalized forms, including multi-armed PEGs, and acrylate or thiol-containing 
groups. PEG has been used in numerous hydrogels, especially with hybrid components, 
for applications in drug and contrast agent delivery and tissue engineering scaffolds 
[1,19,21,38,39]. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
Four-armed poly(ethylene glycol) acrylate with a molecular weight of 
approximately 10,000 kDa or 20,000 kDa was purchased from Laysan Bio (Arab, AL). 
Protasan (chitosan salt) was purchased from Novamatrix (Sandvika, Norway). Chitosan 
oligosaccharide lactate, trypsin from bovine pancreas (USP grade, >2500 USP units per 
mg), 2-carboxyethyl acrylate, acrylic acid, glycidyl methacrylate, and triethylamine were 
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purchased from Sigma-Aldrich (St. Louis, MO). EDC, Sulfo-NHS, and snakeskin 
dialysis tubing were purchased from Pierce/Thermo Fisher Scientific (Rockford, IL). 
Float-a-Lyzer dialysis tubes were purchased from Spectrum Labs (Rancho Dominguez, 
CA). 
 
4.2.2 Design of enzyme-responsive peptide cross-linker 
For this body of work, as a proof-of-concept, peptides that are sensitive to the 
enzyme trypsin were used for cost-efficiency. Trypsin cleaves non-specifically at the 
terminal carbon of the amino acids lysine and arginine, either of which may be 
incorporated into the peptide sequence in to provide specificity for degradation and 
release in response to trypsin. Varying sequence lengths may be used to vary the pore 
size of the resulting hydrogel, thus giving the option to tailor for different molecular 
weight peptide and protein drugs. In general, however, sequences were kept below 10 
amino acids. 
Two approaches were taken for the design of these peptide cross-linkers: (1) 
naturally-inspired peptide sequences, or (2) rationally-designed synthetic sequences. 
Naturally-inspired peptide sequences may offer improved biocompatibility, whereas 
rationally-designed sequences may be intelligently designed using the wealth of 
knowledge in enzyme/substrate bioinformatics databases.  
 
4.2.2.1 Design of naturally-derived peptide sequences 
For naturally-inspired peptide sequences, the human protein hemoglobin A (HbA) 
was used as the peptide design base. The protein was plotted on a Kyte-Doolittle/Hopp-
Woods scale to determine regions of hydrophobicity and hydrophilicity. All hydrophobic 
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regions were removed from consideration, as hydrophobic sequences would be unlikely 
to easily incorporate into a hydrophilic hydrogel. Sequences were then run through a 
model protein cutter for trypsin [10,40], and those with the least specificity removed from 
consideration. Top candidates with a size range of 5-7 amino acids were then run through 
careful NCBI BLAST (National Center for Biotechnology Information Basic Local 
Alignment Search Tool) sequence analysis for exclusion of those bearing similarity to 
toxic and/or apoptotic peptide sequences. Remaining sequences were evaluated for 
primary amines (arginine, glutamine, lysine, and asparagine) for further bioconjugation 
of acrylate groups, or cysteine residues, which contain a sulfhydryl group. 
 
4.2.2.2 Design of rationally-designed synthetic peptides 
For rationally designed sequences, data was collected on trypsin activity and 
preferential cleavage sites using the BRaunshweig ENzyme Database (BRENDA) [18-
20,41]. As previously mentioned, trypsin cleaves terminal to either arginine or lysine 
residues in a peptide/protein sequence. Glycine was used as spacer amino acids, due to its 
minimal steric hindrance, surrounding the trypsin cleavage site. Cysteine residues were 
added at the alpha and terminal residue sites to provide sulfhydryl reactive groups for the 
Michael addition cross-linking. Sequences were checked for hydrophilicity, using the 
Hopp-Woods and Kyte-Doolittle scales. Other optimization considerations could include 
(1) the use of arginine over lysine, because arginine is more effective at lowering the pKa 
of sulfhydryl groups, accelerating the cross-linking reaction, and (2) use of glutamic acid, 
which inhibits disulfide bond formation, maintaining stoichiometric ratios required for 
the reaction [7]. 
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4.2.3 Synthesis of the peptide cross-linker 
Peptide synthesis was performed at The University of Texas at Austin Institute for 
Cellular and Molecular Biology in the Protein Microanalysis Facility (Austin, TX) by 
custom peptide order. Following initial studies, custom peptide orders (up to one gram) 
were then obtained from CHI Scientific (Maynard, MA) at 95% purity, verified by mass 
spectrometry. 
 
4.2.4 Confirmation of peptide cross-linker degradability 
Trypsin digestion of the designed peptide sequences was confirmed by liquid 
chromatography-mass spectrometry (LC-MS) using an in-solution trypsin digestion 
protocol. Briefly, a 50 μl sample of 50 picomole/μl peptide in 100 mM ammonium 
bicarbonate at pH 8.5 was prepared for digestion. 0.1 μl of trypsin was dissolved in 1 mM 
HCl to a concentration of 1 mg/ml and added to the peptide solution. The mixture was 
then placed in an incubator on a rotator at 37°C, and samples were collected for HPLC 
and MALDI analysis at 2, 4, 6, and 12 hours to quantify digested fragments. A control 
group (without trypsin) was also analyzed for comparison.   
 
4.2.5 Modification of peptide cross-linker with acrylate groups 
Peptides for crosslinking with thiol polymers were QVRAHGK and KGHGKK.  
The di-acrylation of these peptides at the α-amine and terminal lysine amine was 
accomplished using EDC/Sulfo-NHS (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride; N-hydroxysulfosuccinimide) chemistry. First, 25mg of peptide was 
dissolved into 2mL de-ionized water. A four to eight molar excess of acrylic acid, EDC, 
and Sulfo-NHS was reacted to create an amine reactive NHS-ester-acrylate. The reaction  
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Figure 4.4 Reaction scheme for acrylation of amine-containing peptide (QVRAHGK) 
using EDC/NHS chemistry (top half of image courtesy of Mary Caldorera-
Moore) 
 
was run for 2 hrs at room temperature while stirring, then titrated up to the pKa of the 
target amine, added to the peptide solution, and reacted for 2 hrs at room temperature 
while stirring.  The solution was subsequently dialyzed for 48 hours in de-ionized water 
using a 500 MW cutoff Float-a-Lyzer dialysis tube, followed by snap freezing, 
lyophilization, and 1H NMR analysis to evaluate degree of acrylation.  
 
4.2.6 Modification of chitosan with acrylate groups by EDC/NHS chemistry 
The grafting of acrylate groups to chitosan was carried out using EDC and Sulfo-
NHS (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride; N-
hydroxysulfosuccinimide) chemistry with acrylic acid and/or 2-carboxyethyl acrylate. 
Acrylic Acid Amine-reactive NHS-ester Sulfo-NHS Reactive O-acylisourea ester EDC 
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Both acrylic acid and 2-carboxyethyl acrylate contain carboxyl groups, which may be 
grafted onto the primary amine groups of chitosan (de-acetylated). Briefly, chitosan was 
dissolved in 80-100 ml deionized water and pH adjusted to 4.75. Acrylic acid or 
Carboxyethyl acrylate (1.5 mL) was added to EDC and Sulfo-NHS to create an amine 
reactive NHS-ester with an acrylate group. Reaction components were mixed at varying 
molar ratios. The reaction was run for 2 hours at room temperature while stirring, added 
to the chitosan, and allowed to react for 4-8 hours at room temperature (in the dark) while 
stirring. Finally, dialysis was performed using snakeskin dialysis tubing for 24 hours with 
the following cycles: 3 times for 2 hours against 5 mM HCl buffer, followed by 3 cycles 
of 6 hours in length against de-ionized water. Dialyzed product was lyophilized to 
remove water. Acrylate substitution was confirmed and percent degree of substitution 
(DS) was determined using NMR [22].  
 
4.2.7 Modification of chitosan with acrylate groups using glycidyl methacrylate 
Chitosan was modified with methacrylate groups by reaction with glycidyl 
methacrylate and triethylamine, in which the hydroxyl group on the chitosan monomer 
units are reacted (both acetylated and de-acetylated monomer). Figure 4.5 shows the 
reaction scheme and procedure. Briefly, chitosan was dissolved into a solution of up to 
40% acetone at a concentration of 10 mg/mL by high-speed vortexing, and allowed to stir 
for an additional hour. A 20 M excess of triethylamine was then added to the solution and 
allowed to react for two hours while stirring, followed by addition of 20 M excess of 
glycidyl methacylate, which was reacted for 24 hours with stirring. The resulting solution 
was then placed on dialysis (snakeskin dialysis tubing) over 48 hours against three 
washes of 5mM HCl and three washes of de-ionized water. The sample was then snap 
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frozen in liquid nitrogen, lyophilized for 48 hours, and then analyzed by 1H NMR to 
confirm the degree of substitution.  
 
 
Figure 4.5 Reaction scheme for conjugation of methacrylate groups to chitosan by 
reaction with triethylamine and glycidyl methacrylate 
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4.2.8 Michael addition cross-linking of polymer with enzymatically-responsive 
peptides 
In order to crosslink the polymer with the enzymatically-responsive peptide, a 
Michael’s addition reaction between acrylate and sulfhydryl groups was employed.  
Multi-armed polymers with acrylate groups and peptides with sulfhydryl groups were 
dissolved separately in 0.3 molar triethanolamine (TEA) buffers, or 1X phosphate 
buffered saline (PBS), ranging from pH 7.4 to 8.15. Solutions were then combined in a 
1:1 acrylate to sulfhydryl ratio in varying concentrations and incubated at 37°C to react. 
Varying concentrations of polymer and peptide were explored, and expressed as a total 
combined percent weight by volume: 
 
€ 
Hydrogel % wv =
weight of polymer, grams( ) + weight of peptide, grams( )
milliliter of solution ×100%  
 
4.3 RESULTS AND DISCUSSION 
4.3.1 Design of enzyme-responsive peptide cross-linker 
4.3.1.1 Design of naturally-derived peptides 
Peptide sequences derived from human hemoglobin subunits were analyzed for 
trypsin responsiveness, hydrophillicity, and functional groups on terminal amino acids.  
The sequences were then subjected to BLAST analysis for detrimental physiological 
impacts. The sequences found to suit all these requirements were QVRAHGK 
(glutamine-valine-arginine-alanine-histidine-glycine-lysine) and KGHGKK (lysine-
glycine-histidine-glycine-lysine-lysine). These peptides have amine terminal groups that 
may be modified with acrylate groups, as described earlier, such that they may be used to 
cross-link sulfhydryl-containing polymers into hydrogels.  
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Figure 4.6 Chemical structure of CGRGGC peptide 
 
4.3.1.2 Design of rationally-designed synthetic peptides 
A second set of peptide sequences, containing terminal cysteine residues (for 
sulfhydryl groups) for Michael-addition cross-linking, were also designed for trypsin 
responsiveness, least steric hindrance surrounding the trypsin cleavage site, 
hydrophillicity, functional groups on terminal amino acids, and BLAST analysis. The 
sequences that met all the conditions were CGRGGC (cysteine-glycine-arginine-glycine-
glycine-cysteine, Figure 4.6) and CGKGGC (cysteine-glycine-lysine-glycine-glycine-
cysteine). 
 
4.3.2 Confirmation of peptide cross-linker degradability 
Results for the digestion of the QVRAHGK sequence after 12 hours are shown in 
Figure 4.7. Analysis of the control group shows the peak fractions are primarily 
composed of the un-digested peptide (795 Da and 398 x 2 = 796 Da for doubly-charged 
peptide). The trypsin-digested group exhibits peak fractions primarily composed of 
QVRA, QVR, and K fragments (429 Da, 355 Da, and 149 Da, respectively), confirming 
predicted degradation. 
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Figure 4.7 Digestion of QVRAHGK peptide by trypsin confirmed by HPLC. 
 
4.3.3 Modification of peptide cross-linkers with acrylate groups 
Di-acrylation of both peptides was achieved, as indicated by the 1H NMR spectra 
shown in Figure 4.8. However, despite pH-based optimization (towards pKa of targeted 
amines) and varying molar ratios, the highest di-acrylation achieved was a degree of 
substitution (average) up to 1.75. This indicates that a significant portion of peptide had 
only one acrylate substitution, which would affect hydrogel cross-linking. Another 
possible reaction scheme would involve the side chain primary amines on the center 
arginine/lysine (trypsin cleavage site) being modified with acrylate groups. This is 
problematic in that it may prevent full cleavage of the hydrogel by trypsin. 
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 With these results, it became apparent that the most feasible pathway to continue 
was to use cysteine-containing peptides (with sulfhydryl groups) to react with acrylated 
polymers. Thus, successful peptide synthesis would result in two readily available 
sulfhydryl groups per peptide, without the need for further modification (as well as 
peptide loss through modification and purification). 
 
 
Figure 4.8 NMR spectra for di-acrylated QVRAHGK peptide (acrylate groups 
magnified within the inset figure) 
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4.3.4 Modification of chitosan with acrylate groups by EDC/NHS chemistry 
Addition of acrylate groups to chitosan, carried out using EDC/NHS chemistry, 
was successful, as verified by a sample 1H NMR shown in Figure 4.9. However, the 
presence of several other unexplained peaks, despite careful dialysis and methodically 
varying molar ratios in the reaction, indicated the presence of other side reactions and 
polymerizations. This method was therefore not continued, and other methods (namely, 
glycidyl methacrylation of chitosan) were explored. 
 
Figure 4.9 1H NMR spectra for chitosan modified with acrylate groups by EDC/NHS 
chemistry (magnified spectra shown in inset window) 
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Figure 4.10 1H NMR spectra for chitosan modified with methacrylate groups by reaction 
with triethylamine and glycidyl methacrylate 
 
4.3.5 Modification of chitosan with glycidyl methacrylate 
As discussed above, another method for modification of chitosan with acrylate 
groups, to produce cleaner products, was desired. A new modification scheme for the 
methacrylation of chitosan, using triethylamine and glycidyl methacrylate, was developed 
based on methacrylation schmes for hyaluronic acid [42]. With this reaction, the 
methacrylate group is added onto the hydroxyl group, rather than amine groups. This 
Unmodified  
Chitosan 
Methacrylated  
Chitosan 
Acrylate 
Peaks 
New Methyl 
Peak 
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allows for the possibility of greater degrees of substitution, as every chitosan monomer 
subunit contains a hydroxyl group. In contrast, the presence of primary amines on 
chitosan (for EDC/NHS reaction) depends on the degree of deacetylation of the chitosan 
(from chitin). 
Using this protocol, degrees of substitution up to 21% were achieved, as was 
confirmed by 1H NMR. Figure 4.10 displays the NMR spectra of unmodified chitosan in 
contrast with the methacrylated chitosan spectra below. Methacrylate peaks are clearly 
visible in the 5.5-6.5 ppm range. 
 
4.3.6 Michael addition cross-linking of polymer with enzymatically-responsive 
peptides 
Gel formation between CGRGGC and 4-arm-PEG-acrylate was observed within 
15 minutes in all samples in TEA buffer. TEA buffered samples in the range of pH 7.6 
and higher began forming gels at room temperature, prior to putting into the incubator. 
However, the samples remained incubated overnight to ensure complete reaction. 
Samples in PBS primarily formed loose or inconsistent gels, and were not used. Figure 
4.11 shows a sample of these hydrogels formed in 0.3M TEA buffer at pH 8.15. Little to 
no gel was formed in 2-8% w/v, loose gels formed in 10-12% w/v, and stiffer gels formed 
at 14-20% w/v. 
Gel formation between CGRGGC and methacrylated chitosan was wholly 
unsuccessful, with only loose and inconsistent gels being formed. In large part, the issue 
was that the methacrylated chitosan proved difficult to dissolve into solution. Chitosan is 
already quite viscous and difficult to work with, and the addition of methyl groups likely 
resulted in even greater hydrophobicity. The chitosan portion of this project was therefore 
not continued. 
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Preliminary characterization studies of 20, 40, 60, and 80% (w/v) gels composed 
of PEG-4-Acr (MW 20kDa) and CGRGGC peptide showed that the gels did not 
completely hydrolytically degrade until days 5, 9, 9, and 11, respectively, when left in 
PBS pH 7.4 at 37°C (Figure 4.12). 
Higher percent composition gels displayed the greatest structural integrity, longest 
time before hydrolytic degradation, and tightest theoretical network (to maintain drug 
encapsulation), while still displaying high swelling behavior. Gels of 80% composition, 
though possible to make, had practical issues in handling and synthesis, due to the high 
viscosity of precursor solutions. Therefore, moving forward, 60% w/v composition 
hydrogels were chosen to move forward into the particle synthesis phase of Aim 1.  
 
 
Figure 4.11 Bulk enzymatically-degradable microgels formed by Michael addition 
between PEG-4-Acr and CGRGGC peptide of various percent weight by 
volume composition 
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Figure 4.12 Swelling and degradation behavior of PEG-4-Acr and CGRGGC peptide 
hydrogels formed via Michael addition 
 
4.4 CONCLUSIONS 
Through the series of experiments shown here, it was concluded that the 
optimized hydrogel composition moving forward into Aim 1B would consist of the 
following: 
• 4-arm Poly(ethylene glycol) acrylate 
• CGRGGC peptide 
• 60% w/v gel composition 
• 0.3M triethanolamine buffer at pH 7.6 or higher 
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Chapter 5: Development of the Michael Addition During Emulsion 
(MADE) Method for Fabricating Enzyme-Responsive Microgels 
 
5.1  INTRODUCTION 
As described in the preceding chapters, enzymatically-degradable hydrogels offer 
several engineered material advantages over other types of polymers used in drug 
delivery today. Furthermore, the ability to perform polymerization cross-linking of these 
types of hydrogels under mild conditions, using a Michael addition cross-linking 
reaction, makes these materials ideal candidates for next generation drug vehicles. The 
ability to scale this hydrogel synthesis method down to create microgels would be a 
significant step forward in the development of disease-responsive carriers for biologic 
drugs delivered via non-invasive routes. 
This chapter consists of a collection of preliminary data from feasibility and 
optimization studies on several particle synthesis methods, from cryomilling to molding, 
before arriving at the optimized Michael Addition During Emulsion (MADE) synthesis 
method. In-depth characterization of the microgels is discussed in the following chapter. 
 
5.1.1 Design Criteria 
Taking several of the same criteria from the previous chapter, the design criteria 
for the microgel synthesis method included: 
• optimum Michael addition reaction conditions (physiological pH and 
temperature) 
• maintain bioactivity of biologic drugs using mild manufacturing techniques. 
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However, several new criteria were also considered in order to create the ideal 
particle synthesis method: 
• size range of approximately 1-5 μm 
• efficient recovery after synthesis 
• low residual volume or material loss during synthesis 
• stability and shelf life 
• high-throughput 
• high encapsulation efficiency 
• low cost for start-up and continuous operation. 
 
5.1.2  Context and Perspective 
When work on this portion of the project began, it was not clear that the ultimate 
use of these particles would be for pulmonary drug delivery. It was first determined that 
feasibility studies should be done to see if hydrogel microparticles could be formed using 
Michael addition chemistry, and in what size range. Other primary uses considered, 
besides pulmonary delivery, included oral delivery of proteins and responsive release of 
growth factors in tissue engineering systems. Therefore, many of the methods for forming 
particles discussed throughout this chapter were not ideal methods to fabricate particles in 
the 1-5 micron range (optimal aerodynamic range). Additionally, many of these methods 
were developed and tested concurrently, until one clear “winner” began to emerge. At 
that point, all time and resources were diverted to development in that area. 
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5.2 MATERIALS AND METHODS 
5.2.1 Materials 
Peptide sequence QVRAHGK was custom synthesized by the University of Texas 
at Austin, Institute for Cellular and Molecular Biology, Protein Microanalysis Facility 
(Austin, TX). Peptide sequence CGRGGC was custom synthesized by CHI Scientific 
(Maynard, MA). All 4-arm PEG products were purchased from Laysan Bio (Arab, AL). 
Trypsin from bovine pancreas and paraffin oil was purchased from Sigma Aldrich (St. 
Louis, MO). All other reagents were of at least USP or biological grade, and were 
purchased from either Sigma Aldrich (St. Louis, MO) or Thermo Fisher Scientific 
(Waltham, MA). 
 
5.2.2 Trial and Error: Other Particle Synthesis Methods 
5.2.2.1 Micron Mesh Molding 
Hydrogel pre-cursor solution consisting of 20% total w/v of 4-arm poly(ethylene 
glycol) sulfhydryl (PEG-4-SH, 20kDa molecular weight) and di-acrylated QVRAHGK 
(or PEG di-acrylate, 3400 Da molecular weight) peptide was spread onto a glass slide 
into a thin layer. A nylon mesh screen with a 64 μm pore size was then pressed onto the 
thin polymer solution. The set-up was placed inside a humidity chamber at 37°C for 4 
hours or overnight. The resulting patterned hydrogel particles, affixed to the slide, were 
then viewed under the microscope. Particles were removed from the slide by scraping, 
and any leftover residual layer was broken up to release the particles by stirring in de-
ionized water for several hours. 
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5.2.2.2 Mortar and Pestle Grinding Under Liquid Nitrogen 
Hydrogels were made by combining 4-arm poly(ethylene glycol) acrylate (PEG-
4-Acr, 20 kDa molecular weight) with CGRGGC peptide in 0.3M TEA buffer at pH 8.15 
at a 20% w/v composition. The mixture was incubated at 37°C for four hours. The 
resulting hydrogel was then removed from the reaction vessel, placed in a mortar, and 
submerged in liquid nitrogen until frozen through (about 1 minute). A pestle was used to 
crush the hydrogel for approximately 3 minutes, replenishing liquid nitrogen about once 
per minute. The resulting crushed hydrogel particles were recovered from the mortar 
using 3ml of 1% poly(vinyl alcohol), or PVA, in de-ionized water. The use of liquid 
nitrogen was required make the hydrogel brittle enough to break apart. 
 
5.2.2.3 Cryogenic Milling 
Hydrogels (500 mg each) were pre-prepared as above in section 5.2.2.2 . The 
resulting gels were cut into ¼ inch pieces, snap frozen in liquid nitrogen, and lyophilized 
for 48 hours. Using a SPEX Sample Prep (Metuchen, NJ) 6870 Freezer/Mill, the 
following cycles were programmed and run: 
• 10 minute pre-cooling in liquid nitrogen 
• 2 minute milling at a rate of 10 cycles per second (20 impacts per second) 
• 2 minute re-cooling 
• Repeated for 8 cycles 
The chamber and impactor were then placed in a 37°C water bath for 1 hour to 
equilibrate in temperature, avoiding condensation when opening the chamber. Resulting 
particles were then collected from the milling chamber. One additional optional step was 
to place the sample on an orbital shaker for 48 hours to break up clumps. 
 
 112 
5.2.2.4 Reactive Spray Drying 
Peptide-crosslinked microparticles will be obtained by spraying the macromer 
precursor solutions through the nozzle (0.7 mm diameter) of a spray dryer (co-current 
flow type) model Mini Spray Dryer Büchi B-191 (Büchi Labortechnik AG, Flawil, 
Switzerland) as mentioned elsewhere62,63. In spray drying, the inlet air temperature with 
the polymer spray is usually around 100°C, which is intended to quickly evaporate off all 
water in the particles.  However, we want to ensure protection of the peptide and model 
drug IFN-β from high temperature denaturation; thus a cooler injection temperature of 
60°C is proposed and will be optimized. The conditions of the spray-drying process will 
involve following parameters: inlet air temperature 60°C; outlet air temperature 60°C; 
pump ratio 13%; aspirator ratio 73%; flow control 400/600 l/h and spray rate of feed 
about 8 ml/min. Following parameters will be extensively optimized in the process: 
crosslinking density (% w/v), effect of solution pH (7-8.5), air flow speed, and 
temperature. We hypothesize that Spray dryer temperature at 60°C should allow for quick 
formation of microparticles and also quickly dry them to prevent any aggregation in the 
collection chamber. The dried (or semi-dried) microparticles will be harvested from the 
apparatus collector and kept under vacuum for 24-48 hours at room temperature for 
complete drying.  
 
5.2.2.5 Handheld Nebulization 
As a proof-of-concept, microparticle fabrication, using the 4 arm PEG-SH and the 
acrylated peptide was performed using a Valois handheld nasal-spray type nebulizer.  
Briefly, 200μl of polymer and peptide in 0.3M TEA buffer at pH 8.15 was fed into the 
nebulizer inlet. The solution was sprayed onto a clean hydrophobic surface at 37°C, or a 
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shallow bath of warm paraffin oil, allowed to react for 3 hours, vacuum-dried overnight, 
and harvested using a scraper.   
 
5.2.3 Michael Addition During Emulsion (MADE) Method for Microgel Synthesis 
5.2.3.1 Choice of Surfactants 
Several surfactants were tested out in the course of this study to determine which 
worked best with different types of emulsions. Surfactants included poly(vinyl alcohol) 
and several in the Brij, Tween, and Span family.  
Several surfactant combination recipes were also used. For the water-in-paraffin 
oil emulsion, a hydrophilic-lipophilic balance (HLB) ranging from four to six was desired 
[1,2]. To determine concentrations of each component surfactant, the following equation 
was solved for each combination: 
 
HLB of surfactant mixture = Σχs × HLBs 
 
where χs is the weight fraction of each surfactant, and HLBs is its corresponding HLB. 
Apart from varying the HLB and surfactant combinations, different percent compositions 
of surfactant in the emulsion were also considered, ranging from 0.01% to 3%. 
Surfactant mixtures were eliminated using a method adopted by Fisher and 
Peppas [3]. Briefly, the stability of test emulsions, consisting of 0.3M TEA buffer and 
paraffin oil, were observed under light microscopy (40x). Following homogenization, a 
sample of the emulsion was placed on a glass slide with a coverslip and observed. If a 
high incidence of droplet coalescence was observed within 1 minute, the emulsion was 
considered unstable. 
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5.2.3.2 Choice of Emulsion Oil 
Two types of “oil,” or organic, solvents were considered for the emulsion process: 
(1) evaporative, or (2) viscous, non-evaporative. Namely, dichloromethane (DCM) was 
chosen as an evaporative “oil” to facilitate the removal of the oil phase after the 
emulsion. On the other hand, evaporative organic solvents tend to have low viscosities, 
and it was postulated that a viscous oil could contribute towards stabilizing the emulsion. 
Therefore, paraffin oil was chosen as the viscous, non-evaporative oil. A ratio of 15 mL 
oil to 100 μL water/aqeous phase was set and maintained for all experiments (15 mL is 
the minimum operating volume for a 50 mL Corning® centrifuge tube with the particular 
homogenizer used).  
 
5.2.3.3 Other Optimization Parameters 
Aside from varying the surfactant composition and emulsion oil, other parameters 
for optimization included the pH of reaction buffer (0.3M TEA), homogenization speed, 
and washing steps. 
 
5.2.3.4 MADE Basic Protocol 
Equimolar amounts (sulfhydryl:acrylate) of peptide and PEG-4-acr were 
dissolved separately into 0.3 M triethanolamine buffer to a total combined concentration 
of 60% (w/v), in a total volume of 100 μL. The two solutions were combined, mixed, and 
added to 15 mL of paraffin oil with varying surfactant combinations and concentrations. 
The entire mixture was then immersed in a hot water bath at 40–45 °C and homogenized 
for 3 min at 3000-5000 rpm using a Polytron PT 3100 homogenizer. The resulting 
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surfactant-stabilized water-in-oil emulsion was incubated for at least 2 hours at 37 °C to 
allow the cross-linking reaction to complete, forming solid, cross-linked, micro-sized 
hydrogels (microgels). Thus, as the reaction proceeds, the mixture becomes a suspension 
of solid microgels in oil, rather than an emulsion. These microgels were removed from 
oil, residual surfactant, and un-reacted material by a series of centrifugal washes with 
fresh oil and water. Briefly, microgels were centrifuged at 10,000×g for 20 min, 
supernatant discarded, re-suspended in de-ionized water, and vortexed. The process was 
repeated three times, with the final re-suspension in either de-ionized water, phosphate 
buffered saline, or 100 mM ammonium bicarbonate (depending on the buffer required for 
various assays). 
 
5.2.4 Microgel Degradation 
Hydrogel microparticles were allowed to re-hydrate in 40mM ammonium 
bicarbonate in a 37°C incubator for one hour (if previously dried). 100 μL of 1 mg/mL 
Trypsin (in 1mM hydrochloric acid) was added to hydrogel particles in 900 μL 
ammonium bicarbonate for a final solution of 90% 40mM ammonium bicarbonate and 
10% hydrochloric acid (final concentration of 0.1 mg/mL Trypsin), and placed in a 37°C 
incubator with shaking. Control samples without enzyme contained the same ratio of 
ammonium bicarbonate/hydrocholoric acid solution. Samples were observed at various 
time points for particle degradation.  
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5.3 RESULTS AND DISCUSSION 
5.3.1 Trial and Error: Other Methods 
5.3.1.1 Micron Mesh Molding 
Hydrogels were successfully molded into micron-scale features, as shown in 
Figure 5.1. Figure 5.2 displays the trypsin-mediated degradation of these microparticle 
features on the slides after only two hours. Particles remain affixed to the slide surface in 
these images. Using this method, the particles would often remain interconnected due to a  
 
 
Figure 5.1 PEG hydrogel microparticles formed by the micron mesh patterning press 
method 
 117 
 
Figure 5.2 Trypsin-mediated degradation of PEG-QVRAHGK hydrogel microparticles 
formed by the micron mesh patterning press method 
 
residual polymer layer, which could be somewhat broken up through high-speed 
vortexing or stirring, though not entirely. 
 
5.3.1.2 Mortar and Pestle Grinding Under Liquid Nitrogen 
Particles were observed via light microscropy of the recovered samples, as shown 
in Figure 5.3. The method, however, proved to be quite variable, difficult to work with, 
and posed a significant safety hazard (even with cryo gloves). Moreover, when the 
particles collected were subject to trypsin degradation, there was no observable change 
after 24 hours exposure. This method was, therefore, not pursued any further. 
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Figure 5.3 Particles formed by mortar and pestle grinding of frozen PEG-CGRGGC 
hydrogel 
 
5.3.1.3 Cryogenic Milling 
As was mentioned in section 5.2.2.2 , shattering of the hydrogel required low 
temperatures, as the hydrogel material was quite soft and pliable at room temperature 
(low Tg). Therefore, cryogenic milling (cryomilling) was explored rather than other 
traditional milling methods. The cryomilling technique was able to produce a fine, free 
flowing powder, as can be seen in Figure 5.4. These particles, however, faced the same 
difficulty observed with the mortar and pestle grinding; the particles were not observed to 
degrade by trypsin within 24 hours. This method was, therefore, not explored further. 
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Figure 5.4 Scanning electron microscope images of cryomilled PEG-CGRGGC 
hydrogel particles 
 
5.3.1.4 Handheld Nebulization 
The particles sprayed onto a hydrophobic surface were on the scale of 500-1000 
μm, were flat and discoidal in shape, and had air-pocket features. Visual observation of 
particles in solution by optical microscope revealed complete particle degradation by 40 
minutes.  Figure 5.5 shows particle degradation at 0 and 30 minutes. 
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Figure 5.5 Trypsin-driven degradation of enzymatically-responsive hydrogel particles 
formed by nebulization.  Control group remains intact, whereas Trypsin 
group is degraded after 30 minutes. 
 
5.3.1.5 Other Methods 
Other ideas and set-ups explored for feasibility included set-up of a microfluidic 
syringe pump system and preliminary studies into reactive spray drying [4]. The 
microfluidic syringe pump system consisted of a double-barreled syringe, individually 
loaded with precursor polymer solution, which would mix together in the mixing tip. 
Another line was introduced into the system to maintain a flow of paraffin oil. The 
 121 
syringe pump would slowly pump micro-droplets of polymer solution into the oil, which 
would collect in a heated vessel with paraffin oil. Ultimately, the system proved to be too 
slow and low-throughput to continue developing in comparison to other methods. 
An attempt at “reactive spray drying” [4] was carried out using PEG-4-Acr and 
PEG-DA, suspended in 70% ethanol/30% 0.3M TEA pH 8.15. Using a Mini Spray Dryer 
Büchi B-191 (Büchi Labortechnik AG, Flawil, Switzerland), the following conditions 
were attempted in order to achieve an outlet temperature near the optimum reaction 
temperature: 
• Rate 2 mL/min, Inlet 70°C, Outlet 40°C 
• Rate 2 mL/min, Inlet 100°C, Outlet 55°C 
• Rate 5 mL/min, Inlet 100°C, Outlet 50°C 
All of these runs resulted in a sprayed coating of PEG film in the collection 
chamber, which may have been a reacted PEG hydrogel film, or simply a PEG film, as 
the melting point of PEG is approximately between 45-50°C (depending on molecular 
weight). No further runs were attempted. 
 
5.3.2 Michael Addition During Emulsion (MADE) Method for Microgel Synthesis 
Microgels were successfully formed using a variety of conditions, as described in 
section 5.2.3 . A sampling of microgel images formed using various emulsion oils and 
surfactants is shown in Figure 5.6. When using DCM as the emulsion oil, it was observed 
that the microgels did not seem to be fully formed, and there was an abundance of 
leftover unreacted monomer. This likely was due to the evaporative cooling of DCM after 
the emulsion process. Emulsions carried out using viscous, non-evaporative paraffin oil 
were all well-formed, discrete particles. Furthermore, these microgels (PEG-CGRGGC 
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microgels with 0.01% Brij 30 with paraffin oil) were verified to undergo trypsin-
mediated degradation, depicted in Figure 5.7. This preliminary work indicated that the 
Michael Addition During Emulsion (MADE) method for microgel synthesis could be 
further optimized and fine-tuned to produce enzymatically-degradable microgels within 
the desired range of 1-5 μm. 
 
 
Figure 5.6 Light microscrope images of microgels formed under varying conditions by 
the MADE method 
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Figure 5.7 Trypsin-mediated degradation of PEG-CGRGGC microgels synthesized 
using the MADE method 
 
5.3.2.2 Emulsion Optimization to Tune Microgel Size 
Parameters to optimize microgel size included homogenization speed, time, and 
surfactant concentration. Homogenization time beyond three minutes was not observed to 
affect microgel size. Immersion of the vessel in a 40-45°C hot water bath, rather than at 
room temperature, during the emulsion process was visually observed under light 
microscopy to minimize microgel agglomerates (microgels that cross-linked together), 
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although this point was not further studied beyond visual observation. Homogenization 
speeds up to 5000 RPM did not appear to significantly affect microgel size as compared 
to 3000 RPM (Figure 5.8).   
The surfactant cocktail was found to be the most critical parameter in changing 
microgel size.  Several surfactants and combinations were evaluated to identify those that 
provided the longest droplet stability time, as previously described [3]. Out of the many 
surfactant combinations adopted here, an HLB value of five using a combination of Span 
80 and Tween 80 was deemed the most stable and uniform. Although other combinations 
in the HLB range from five to six were also fairly stable, those with an HLB value of five 
were the most uniform. Furthermore, although use of Brij 30 also was successful in 
creating stabilized emulsions, groups of agglomerated droplets were observed in Brij 30 
samples, which were not observed in others. Varying the percent concentration of 
surfactant in emulsion did produce the expected shift in particle size distribution, as seen 
in Figure 5.8. However, microgel batches with 3% surfactant required more extensive 
washing than those of lower percentages. The final optimized surfactant cocktail was 
found to be a combination of Span 80 and Tween 80, in a mixture ratio to achieve an 
HLB of five, at a concentration of 1% volume by volume of surfactant in paraffin oil. The 
final optimized homogenization conditions were a three minute homogenization time at 
3000 RPM while immersed in a 40-45°C hot water bath. 
Parameters to optimize Michael addition cross-linking included buffer, pH, and 
reaction temperature. PEG-4-acr and peptide were combined in equimolar concentrations, 
adjusted for PEG-4-acr degree of acrylate substitution and the percent purity of PEG and 
peptide. The chosen buffer was 0.3M triethanolamine, as previously reported in the 
literature [5-7], although a pH of 7.8 was used, rather than a pH of 8.0. Gelation is 
observed to occur within seconds, even at room temperature, and a more basic pH 
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increases the reaction rate [8]. Using a slightly less basic pH 7.8 buffer allowed for more 
time to uniformly mix the combined polymer/peptide solution, using pipette aspiration, 
and transfer to the emulsion vessel before gelation prohibited pipetting of the solution. 
PBS from pH 7.0 to 8.4 was also evaluated for suitability, but it was observed that the 
triethanolamine buffer yielded an overall faster reaction time. The incubation temperature 
after emulsion was kept at 37°C in order to minimize any temperature-related denaturing 
of encapsulated biologics. Lastly, in order to minimize disulfide bond formation, the 
reaction buffer was not added to the peptide until immediately before mixing with the 
PEG-4-acr solution. 
 
 
Figure 5.8 The effect of surfactant concentration and homogenization speed on MADE-
fabricated microgel particle sizes 
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5.3.2.3 Final Adopted Protocol for MADE Method 
An illustration depicting the basic steps in the MADE method is shown in Figure 
5.9. Adapted from P. Wanakule, et. al. [9]: Equimolar amounts (sulfhydryl:acrylate) of 
di-sulfhydryl peptide and PEG-4-acr (10 kDa) were dissolved separately into 0.3 M 
triethanolamine buffer at pH 7.8 to a total combined concentration of 60% (w/v), in a 
total volume of 100 μL. The two solutions were combined, mixed, and added to 15 mL of 
paraffin oil with 1% (v/v) surfactant (Span 80/Tween 80 combination to achieve an 
HLB=5). The entire mixture was then immersed in a hot water bath at 40–45 °C and 
homogenized for 3 min at 3000 rpm using a Polytron PT 3100 homogenizer. The 
resulting surfactant-stabilized water-in-oil emulsion was incubated for at least 2 h at 37 
°C to allow the cross-linking reaction to complete, forming solid, cross-linked, micro-
sized hydrogels (microgels). Thus, as the reaction proceeds, the mixture becomes a 
suspension of solid microgels in oil, rather than an emulsion. These microgels were 
removed from oil, residual surfactant, and un-reacted material by a series of centrifugal 
washes with fresh oil and water. Briefly, microgels were centrifuged at 10,000×g for 20 
min, supernatant discarded, re-suspended in de-ionized water, and vortexed. The process 
was repeated three times, with the final re-suspension in either deionized water, 
phosphate buffered saline, or 100 mM ammonium bicarbonate (depending on the buffer 
required for various assays). 
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Figure 5.9 Illustration depicting basic steps in the MADE method 
 
5.4 CONCLUSIONS 
In this chapter, a variety of particle synthesis methods, using Michael addition 
cross-linked hydrogels, were explored in order to develop the most high-throughput and 
cost-effective fabrication method, while maintaining mild fabrication conditions. Out of 
all methods explored, the MADE synthesis method emerged as the clear choice for 
continued study and use. Preliminary data demonstrated that the microgels could be 
formed in the desired size range of 1-5 μm, and also maintain enzyme-responsiveness. 
Further characterization of these microgels is discussed in the following chapters. 
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Chapter 6: In Vitro Characterization of Microgels Fabricated using the 
MADE Method 
 
[This chapter was adapted, with permission**, from P. Wanakule, G.W. Liu, A.T. Fleury, 
K. Roy††, Nano-inside-micro: Disease-responsive microgels with encapsulated 
nanoparticles for intracellular drug delivery to the deep lung, J Control Release. 162 
(2012) 429–437.] 
 
6.1 INTRODUCTION 
In recent years, there has been increasing interest in developing systems for the 
controlled delivery of therapeutic molecules to the lungs, especially to intracellular 
targets in the deep lung.  Pulmonary drug delivery has great potential for both local and 
systemic treatments, especially with newly emerging biologic drugs, such as proteins, 
peptides and nucleic acids. Aside from its attractiveness as a non-invasive route of 
administration, delivery via pulmonary inhalation offers several advantages, including a 
large surface area with high vascularization for drug absorption, thin epithelial layer, low 
enzymatic activity, and avoidance of first-pass metabolism [1-3].   
Despite the many advantages, there exists several design challenges to achieve 
efficient and effective delivery of biologic drugs inside cells of the deep lung.  The 
                                                 
** Copyright 2012 From Nano-inside-micro: Disesase-responsive microgels with encapsulated 
nanoparticles for intracellular drug delivery to the deep lung, by P. Wanakule et al. Reproduced by 
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content assistance by Krishnendu Roy (research supervisor). All results, methods, and ideas described in 
this chapter are original works by Prinda Wanakule, with assistance in the laboratory by undergraduate 
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established range for optimal aerodynamic particle diameter to achieve efficient deep 
lung deposition (following inhalation) is between 0.5-5μm [1,2,4].  Significant fractions 
of particles with aerodynamic diameters (da) <0.5μm may fail to deposit, and are exhaled, 
whereas particles >5μm tend to deposit in the mouth and throat [1,2,4].  However, the 
rate of particle clearance by alveolar macrophages is especially high in this optimum 
aerodynamic diameter range [5-7].  To avoid this rapid clearance, particles must typically 
have a geometric diameter (dg) >6μm [4,6], and have hydrophilic, rather than 
hydrophobic, surface chemistry [5,7].  In addition, drugs that are targeted to intracellular 
pathways and molecules, such as siRNA, DNA or intracellularly-targeted proteins or 
peptides, often require nanoscale carriers <0.2μm to improve mucus penetration [8] and 
cellular uptake in airway epithelial cells [9,10].  These conflicting requirements make for 
a complex design space where the ideal carrier should be 0.5<da<5μm during inhalation, 
have a dg >6μm following lung deposition, and dg<0.2μm to penetrate the mucus and 
deliver drugs intracellularly.  Additionally, due to the non-uniform distribution and 
presentation of pathologies in the lungs, it should also be beneficial for pulmonary drug 
carriers to incorporate pathophysiologically-triggered drug release mechanisms to 
minimize non-specific side effects on normal cells [11,12].  
To address these challenges, we have developed an innovative nanoparticle-in-
microgel delivery system comprised of swellable, peptide-cross-linked microgel-carriers 
encapsulating therapeutic drugs and nanoparticles.  These carriers were fabricated using a 
novel method of Michael addition during (water-in-oil) emulsion (MADE).  This new 
method avoids exposure to UV, high temperatures, or organic solvents, all of which could 
potentially denature biologic drugs [13].  Here we report the potential of this 
nanoparticle-in-microgel system as inhalable carriers with (a) optimal aerodynamic 
diameter, (b) ability to avoid rapid clearance by alveolar macrophages (c) high 
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drug/nanoparticle loading efficiency and (d) efficient triggered release in response to 
disease-specific enzymes.  In this study, we use trypsin as a convenient model enzyme to 
trigger the drug release, although the system could be tailored in the future for various 
disease-specific enzymes, including matrix metalloproteinases, cathepsins, etc. [11].  
The Amiji group has previously reported a gelatin-poly(caprolactone)-based 
nanoparticle-in-microparticle system for oral delivery of plasmid DNA [14].  Edwards 
and colleagues have reported porous, micron-sized structures assembled from 
nanoparticles for pulmonary delivery [15].  Bawendi, Fukumura and co-workers have 
also reported a 10nm-QD-in-100nm-gelatin particle construct for efficient penetration 
into tumor tissue, which releases the QDs (quantum dots) upon exposure to matrix 
metalloproteinases [16].  In addition, a swellable hydrogel particle for pulmonary 
delivery has been recently described [4], and peptide-containing hydrogels have long 
been used for extracellular matrix mimicking scaffolds [17,18], with few reports on their 
application in drug delivery [19,20].  However, a swellable, multi-tiered two-stage 
system that incorporates all the design barriers for intracellular deep lung delivery for 
biologic drugs has not been introduced.  The nanoparticle-in-microgel system described 
here could have a significant impact in pulmonary delivery of biologics by increasing 
deep lung deposition, avoiding clearance by alveolar macrophages and delivering 
therapeutics intracellularly in response to disease-specific stimuli. 
 
6.2 MATERIALS AND METHODS 
6.2.1 Materials 
Four-arm-poly(ethylene glycol)-acrylate-10kDa (PEG-4-acr) was obtained from 
Laysan Bio (Arab, AL).  The peptide sequence, CGRGGC (cysteine-glycine-arginine-
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glycine-glycine-cysteine), was specifically designed in lab to have high specificity for 
trypsin [21,22], then custom synthesized by CHI Scientific (Maynard, MA).  All other 
chemicals and reagents were purchased from Sigma Aldrich (St. Louis, MO) unless 
otherwise specified.  Cell lines used in this study were purchased from ATCC® 
(Manassas, VA), and included A549 human lung epithelial cells (CCL-185™), HEK 293 
human embryonic kidney cells (CRL-1573™), and RAW 264.7 mouse 
monocytes/macrophages (TIB-71™).  Cells were cultured according to recommendations 
by ATCC® for each cell line. 
 
6.2.2 Synthesis of enzymatically-degradable microgels 
Enzymatically-degradable microgels were synthesized using a newly developed 
method of Michael addition cross-linking during water-in-oil emulsion (MADE), wherein 
the cross-linking occurs through a Michael-addition reaction within surfactant stabilized 
aqueous droplets to form microgels.  Equimolar amounts (sulfhydryl:acrylate) of the 
trypsin sensitive di-sulfhydryl peptide (CGRGGC) and PEG-4-acr were dissolved 
separately into 0.3M triethanolamine buffer at pH 7.8 to a total combined concentration 
of 60% (w/v), in a total volume of 100μl.  The two solutions were combined, mixed, and 
added to 15mL of paraffin oil with 1% (v/v) surfactant (Span 80/Tween 80 combination 
to achieve an HLB=5).  The entire mixture was then immersed in a hot water bath at 40-
45°C and homogenized for three minutes at 3000 RPM using a Polytron PT 3100 
homogenizer.  The resulting surfactant-stabilized water-in-oil emulsion was incubated for 
at least two hours at 37°C to allow the cross-linking reaction to complete, forming solid, 
cross-linked, micro-sized hydrogels (microgels).  Thus, as the reaction proceeds, the 
mixture becomes a suspension of solid microgels in oil, rather than an emulsion.  The 
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microgels were removed from oil, residual surfactant, and un-reacted material by a series 
of centrifugal washes with fresh oil and water.  Briefly, microgels were centrifuged at 
10,000xg for 20 minutes, supernatant discarded, re-suspended in deionized water, and 
vortexed.  The process was repeated three times, with the final re-suspension in either 
deionized water, phosphate buffered saline or 100mM ammonium bicarbonate 
(depending on the buffer required for various assays).   
 
6.2.3 Encapsulation of nanoparticles and biologics within microgels 
Nanoparticles and biologics were simply mixed into the PEG-4-acr in 0.3M 
triethanolamine buffer solution to achieve encapsulation within microgels.  All other 
steps were as described in the previous section.  Encapsulated nanoparticles included 
20nm and 40nm FluoSpheres (Invitrogen, Carlsbad, CA), and 200nm PEI-modified 
PLGA nanoparticles (produced in lab [23-27]).  Encapsulated biologics included Alexa 
Fluor® 594 labeled IgG and Lambda DNA (Invitrogen, Carlsbad, CA). 
 
6.2.4 Microgel sizing and characterization 
6.2.4.1 Size and morphology  
Microgels were sized using a Malvern Zen1600 Zetasizer (Malvern Instruments 
Ltd., Worcestershire, United Kingdom) in water (swollen state) or paraffin oil (relaxed 
state).  Particle size and distribution were obtained from the accompanying instrument 
software. 
To observe morphology, the microgels were dried at low vacuum for 48 hours, or 
lyophilized for 24 hours, and analyzed via SEM.  They were also imaged under light 
microscopy during the hydrolytic degradation studies (detailed in section 6.3.2 ) and 
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analyzed using the ImageJ particle analysis toolkit (public domain image processing and 
analysis software from the National Institutes of Health) for sizing.   
Cryo SEM was used to analyze the internal porous structure of the microgels.  A 
drop of microgel suspension in water was added onto the sample holder, flash frozen in 
liquid nitrogen, and fractured open to reveal cross-section using a scalpel.  The sample 
was transferred (EM VCT-100 vacuum cryo transfer system, Leica Microsystems, 
Weitzlar, Germany), sputter coated (Bal-Tec/Leica Med 20), and imaged (Zeiss Supra 40 
VP Scanning Electron Microscope with cryo stage) at low temperature and high vacuum.  
Three batches of microgels were prepared and analyzed. 
 
6.2.4.2 Density and aerodynamic diameter 
Microgel density was determined by centrifugation into discrete sucrose gradients 
of known density, based on the premise that the microgels will come to rest in a solution 
of matching density after adequate centrifugation time.  40%, 30%, 20%, and 10% (w/v) 
sucrose solutions were prepared, and 2mL of each solution was carefully layered (highest 
to lowest density) in a centrifuge tube in order to maintain a discrete interface between 
each.  2mL of microgel suspension in water was then carefully added to the top of the 
gradient, and the set-up was centrifuged at 10,000xg for 20 minutes.  Each gradient layer 
was then collected from the base of the tube using 2mL serological pipets, and sized 
using a Malvern Zen1600 Zetasizer.  Refractive indices were adjusted accordingly for 
each sucrose layer.  The microgel density and z-average size was then used to calculate 
the aerodynamic diameter of the microgels as detailed in the results section. 
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6.2.4.3 Swelling properties 
The extent of particle crosslinking (which determines degradation and release rate 
of encapsulated drugs or nanoparticles) was assessed through swelling studies in PBS 
(pH 7.4).  Specifically, 100mg of microgels were allowed to swell for 24 hours in 15 ml 
PBS with continuous rocking in a 37°C incubator. After 24 hours, swollen microgels 
were collected on filter paper (0.47μm pore) to remove surface water and placed in a pre-
weighed vial (Wv). The weight of the swollen microgels and vial were recorded (Ws,v). 
Microgels were then lyophilized for 24 hours and dry weight was recorded (Wd,v). 
Accordingly, the fold swelling ratio (S) was calculated as:  
 
€ 
S = Ws,v −Wd ,vWd ,v −Wv
 
 
6.2.5 Verification of enzyme-triggered degradation 
CGRGGC-peptide-crosslinked, trypsin-sensitive microgels were studied in the 
presence or absence of trypsin using time-lapse video from a Zeiss Axiovert microscope 
fitted with a Ti:S laser optical trap. A dilute microgel suspension was prepared in trypsin 
digestion buffer (10% 1mM HCl, 90% 100mM NH4HCO3) and a single microgel was 
optically trapped and held stationary in the focal plane for the duration of the study. 
Trypsin (325 U/mL; high concentration to reduce required trapping time) was added and 
the sample was observed for 10 minutes while comparing to control particles without 
enzyme.  
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6.2.6 Enzyme-triggered release of nanoparticles and biologics 
Microgels with encapsulated nanoparticles or biologics were allowed to swell for 
24 hours in trypsin digestion buffer and exposed to physiologically relevant levels of 
enzyme (10-16.5 USP U/mL; no enzyme in control samples) [28].  At each time point, 
the samples were centrifuged at 10,000xg for 20 minutes, and the supernatant was 
collected for analysis in a BioTek Synergy SIAFRTD plate reader (BioTek Instruments, 
Inc., Winooski, VT).  New samples, which were all aliquotted at the beginning of the 
study, were used for each time point.  One aliquot was quickly degraded by trypsin at 0.1 
mg/mL and read in a plate reader to determine encapsulation level, which was set as the 
100% release value to compare with experimental samples. All experiments were 
conducted using commercially available fluorescently labeled molecules or nanoparticles, 
with the exception of lambda DNA, which was fluorescently labeled post-release using 
the Quant-iTTM PicoGreen dsDNA Assay Kit (Invitrogen, Carlsbad, CA), following 
manufacturer protocols.   
 
6.2.7 Hydrolysis-mediated release of nanoparticles 
Microgels with encapsulated 40nm Dark Red (ex/em 660/680) FluoSpheres® or 
Alexa Fluor® 594 labeled IgG were loaded into hanging cell culture inserts with a 0.4μm 
filter size (EMD Millipore Millicell, Billerica, MA), then placed into 24-well ultra low 
attachment cell culture plates (Corning® Costar®, Corning, NY).  Approximately 3mg of 
microgels were loaded per well in a total volume of 1.5mL PBS (inside and outside of 
insert).  The entire set-up was wrapped in parafilm and plastic wrap, and placed on a 
rocker in a 37°C incubator for 20 days, or until readings reached a plateau, after which 
the experiment was terminated.  Using this setup, intact microgels remain inside of the 
cell culture inserts, whereas released nanoparticles are free to diffuse out of the insert, 
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and into the well plate.  At various time points, fluid from the well (outside of the insert) 
was sampled for fluorescence measurements using a BioTek plate reader, to measure 
cumulative release of nanoparticles from microgels.  Wells were replenished to maintain 
a volume of 1.5mL PBS. 
 
6.2.8 Cytotoxicity 
Using the MTS Assay (Promega, Fitchburg, WI), cytotoxicity of intact microgels, 
trypsin-degraded microgels, and un-reacted PEG-4-acr and CGRGGC peptide were tested 
on A549 human lung epithelial cells and HEK 293 human embryonic kidney cells.  High 
polymer doses of 0.5 mg/mL or 1.0 mg/mL were used for these studies (approximately 
4350 and 8700 microgels per cell, respectively). The un-reacted condition contained 
PEG-4-acr and peptide in equivalent amounts that would be used to synthesize microgels 
to a total weight of 0.5 and 1.0 mg/mL. 8000 cells were seeded into a 96 well plate with 
100μL of media and incubated at 37°C for 24 hours prior to the addition of the microgels 
and various component conditions.  After 6, 24, and 48 hours exposure, media was 
discarded, 100μL of fresh media and 20μL of MTS reagent was added to each well, 
incubated for 25 minutes, and the absorbance was read at 490nm using a BioTek plate 
reader.  
 
6.2.9 In vitro microgel uptake studies 
The potential for clearance by alveolar macrophages was evaluated though 
macrophage uptake studies both qualitatively by confocal microscopy, and quantitatively 
using flow cytometry analysis.  20nm-sized Dark Red (ex/em 660/680) FluoSpheres® 
were encapsulated within the microgels for use as a fluorescent tracer.  Uptake of 
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microgels was compared relative to uptake of 1μm-sized Orange (ex/em 540/560) 
FluoSpheres (Invitrogen, Carlsbad, CA) as a positive control.  
For confocal microscopy, 2 x 106 RAW 264.7 mouse monocytes/macrophages 
were seeded into a 6-well plate with a poly-L-lysine coated microscope coverslip at the 
base.  At various time points after particle incubation (15, 30 minutes, 1, 2, 12, and 24 
hours), the cells were fixed and stained according to the manufacturer instructions using 
DAPI nucleic acid stain and Texas Red-X labeled phalloidin (Invitrogen, Carlsbad, CA).  
The coverslips were then mounted onto glass slides and imaged on a Leica SP2 AOBS 
Confocal Microscope (Leica Microsystems). 
For flow cytometry analysis, 5 x 104 macrophages were seeded per well in a 24-
well plate.  Along with an untreated control sample, cells were treated with 1μm Orange 
FluoSpheres, 20nm Dark Red encapsulated FluoSpheres encapsulated inside microgels, 
and 20nm Dark Red FluoSpheres alone (for a signal comparison).  After 2 hours, cells 
were washed and agitated six times with PBS to remove free particles, gently removed 
using a cell scraper, and re-suspended in PBS.  Analysis was carried out on an Accuri C6 
flow cytometer (Becton, Dickinson and Company, Franklin Lakes, NJ) using FL2 for 
1μm Orange FluoSpheres and FL4 for both 20nm Dark Red FluoSpheres encapsulated in 
microgels and naked 20nm Dark Red FluoSpheres.  An untreated control was used to 
establish baseline autofluorescence. 
 
6.3 RESULTS AND DISCUSSION 
6.3.1 PEG-peptide microgels can be efficiently synthesized using the MADE method 
Microgels were formed by the newly developed Michael addition during (water-
in-oil) emulsion (MADE) process, which offers the advantages of large batch size and 
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simple manufacturing under mild conditions.  Typical batches studied here consisted of 
60mg combined total weight of PEG-4-acr and CGRGGC peptide in 100µl of reaction 
buffer, giving a final 60% weight by volume percent hydrogel (w/v).  Weight percentages 
higher than 60% were difficult to solubilize, and thus, were not explored further.  Lower 
polymer weight percentages were also achieved using the MADE method, but were not 
explored in this study.  After washing, typical microgel recovery was ~75% of the initial 
polymer weight. 
Parameters to optimize microgel size included homogenization speed, time, and 
surfactant concentration.  Homogenization time beyond three minutes was not observed 
to affect microgel size.  Immersion of the vessel in a 40-45°C hot water bath, rather than 
at room temperature, during the emulsion process was observed (under light microscopy) 
to minimize microgel aggregation.  Homogenization speeds up to 5000 RPM did not 
affect microgel size as compared to 3000 RPM (data not shown).  The surfactant cocktail 
was found to be the most critical parameter in changing microgel size.  Several 
surfactants and combinations were evaluated to identify those that provided the longest 
droplet stability time, as previously described [29].  The final optimized surfactant 
cocktail was found to be a combination of Span 80 and Tween 80, in a mixture ratio to 
achieve a hydrophile lipophile balance (HLB) of 5, at a concentration of 1% v/v of 
surfactant in paraffin oil.  The final optimized condition for synthesis involved a three 
minute homogenization time at 3000 RPM while immersed in a 40-45°C water bath. 
Parameters to optimize Michael addition cross-linking included buffer, pH, and 
reaction temperature.  PEG-4-acr and peptide were combined in equimolar 
concentrations, adjusted for degree of acrylate substitution and the percent purity of PEG 
and peptide.  The chosen buffer was 0.3M triethanolamine, as previously reported in the 
literature [27,30,31], although a pH of 7.8 was used, rather than a pH of 8.0.  Gelation 
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was observed to occur within seconds, even at room temperature, and a more basic pH 
increased the reaction rate [32].  Using a slightly less basic pH of 7.8 allowed for more 
time to uniformly mix the combined polymer/peptide solution, using pipette aspiration, 
and transfer to the emulsion vessel before gelation prohibited pipetting of the solution.  
PBS from pH 7.0 to 8.4 was also evaluated for suitability, but it was observed that the 
triethanolamine buffer yielded an overall faster reaction time.  The incubation 
temperature after emulsion was kept at 37°C in order to minimize any temperature-
related denaturing of encapsulated biologics.  Lastly, in order to minimize inter-peptide 
disulfide bond formation, the reaction buffer was not added to the peptide until 
immediately before mixing with the PEG-4-acr solution. 
Microgel morphologies in different hydration states were observed under SEM 
(dry), cryo SEM (wet, frozen) and light microscopy (wet), as shown in Figure 6.1 (page 
142).  In contrast to the smooth and spherical morphology observed under wet conditions, 
lyophilized microgels (Figure 6.1A), although mostly spherical, had a wrinkled surface.  
This was likely due to the high vacuum collapsing the internal porous structure, 
consistent with hydrogel microstructure.  When drying the samples under low pressure 
with a bench top Nalgene vacuum chamber, microgels retained their smooth spherical 
surface (Figure 6.1B).  Cryo SEM was performed on a swollen suspension of microgels 
in water to observe the surface architecture, internal morphology, as well as size in the 
wet, swollen state.  As shown in Figure 6.1C, cryo SEM revealed a porous internal 
network structure, indicating successful Michael addition-type cross-linking to form 
hydrogel microparticles within an emulsion droplet.  This is further evidenced by the 
swelling and hydrolytic degradation behavior observed over time.  The fold swelling ratio 
of the microgels across three separate batches was found to be 17.683±4.8394 (average ± 
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standard deviation), indicating the microgels are able to absorb approximately 18 times 
their dry weight in water. 
 
6.3.2 Microgel sizes are within the optimum range for deep lung delivery by 
inhalation 
In order to achieve effective delivery via pulmonary inhalation, the aerodynamic 
diameter of a particle should be in the range of 0.5-5µm [1,2,4]. The aerodynamic 
diameter (da) is dependent on the physical diameter, shape, and density of the particle.  
For a spherical particle, this is given by the equation 
 
€ 
da = ρ0.5dg  
where ρ is the density and dg is the geometric diameter [1].  Previous groups have shown 
success in pulmonary delivery using large porous particles, with larger geometric 
diameters, but low densities [15,33,34].  Given the highly porous nature of hydrogels, we 
theorized that microgels would have a low density while maintaining a larger geometric 
diameter, capable of carrying a higher drug payload.   
Due to the dynamic changes in microgel sizes based on states of hydration, 
microgels were sized while still in oil (relaxed state), immediately after washing into 
water, and at various time points afterwards to observe swelling and degradation 
behavior.  Microgels had an average geometric diameter of 1.660±1.362µm in the relaxed 
state (in oil, Malvern Zetasizer).  Immediately after washing into water, the average 
geometric diameter was 1.893±2.729µm (in water, Malvern Zetasizer).   
Michael addition reactions between PEG-4-acrylate and sulfhydryl groups result 
in the formation of a hydrolytically degradable ester bond [13,32].  Slow hydrolytic  
 142 
 
Figure 6.1 Microscopy of microgels in different states of hydration, swelling, and 
degradation.   
(A) SEM image of microgels after 24 hours lyophilization, scale bar = 
10µm.   
(B) SEM image of microgels after 48 hours in a low-pressure vacuum 
chamber, scale bar = 20µm.   
(C) Cryo SEM image of a single microgel frozen in water and fractured 
open under liquid nitrogen to reveal porous cross-section, scale bar = 5µm.   
(D) Light microscope images of microgels in water, showing swelling and 
degradation changes over 19 days in PBS at 37°C, scale bars = 30µm. 
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degradation of the particles was desired to provide an eventual clearance mechanism 
(further discussed in section 6.3.5 ).   
To determine rates of hydrolytic degradation, microgels were kept in PBS in a 
37°C incubator on a rotator.  During the hydrolytic degradation process, microgels 
exhibited increasing transparency, and thus, changes in refractive index (RI).  RI is a key 
parameter in dynamic light scattering (DLS) methods [35] and thus DLS could not be 
used to monitor particle size over time. Instead geometric measurements were taken 
using microscopy images and analyzed using the ImageJ particle analysis software.  The 
gels were sampled and observed out to day 19 (Figure 6.1D), however, geometric 
diameters were measured only to day 13.  Past this time point, microgels became too 
transparent to apply an accurate contrast threshold for the analysis function.  From day 15 
through experiment termination at day 19 only debris (<0.1µm) could be found in the 
samples.  The geometric diameters are summarized in Table 6.1 (page 144), and were 
taken as an average across three separate batches of microgels ± standard error.  For each 
time point, 30 images were analyzed (10 per batch), resulting in average of 
approximately 2250 particles analyzed per time point. 
Our data indicates that after the washing step, the microgels begin to swell and 
have slightly increased size.  By 24 hours after washing, the microgels have increased in 
size to >6µm, the size targeted to avoid macrophage uptake.  The time required to swell 
to >6µm may prove problematic in avoiding alveolar macrophage uptake.  Thus, to 
determine if this had an effect on uptake, we evaluated macrophage uptake at shorter time 
points (section 6.3.5 ). 
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Table 6.1  Microgel Characterization: Size, Swelling, and Degradation 
 Geometric Diameter  
(mean ± standard error) 
Suspension 
Medium 
Measurement 
Method 
Relaxed 1.660±1.362 µm  Paraffin oil DLS 
Washed 1.893±2.729 µm  D.I. water DLS  
Day 1 6.269±0.9148 µm PBS ImageJ 
Day 2 7.321±0.4725µm PBS ImageJ 
Day 3 8.179±2.872 µm PBS ImageJ 
Day 4 7.350±2.162 µm PBS ImageJ 
Day 5 7.816±1.883 µm PBS ImageJ 
Day 7 7.433±1.035 µm PBS ImageJ 
Day 9 10.76±3.165 µm PBS ImageJ 
Day 11 9.922±1.385 µm PBS ImageJ 
Day 13 9.604±3.139 µm PBS ImageJ 
 
In order to determine microgel densities in the hydrated state, microgels were 
centrifuged into discrete sucrose gradients [36].  Interestingly, the average geometric 
diameters of microgels varied across sucrose layers, although the majority of particles 
were visually observed to settle into the 0, 10, and 20% layers.  Theoretical aerodynamic 
diameters were calculated for each fraction, and ranged from 0.3146-5.824µm.  
Fractionated geometric diameters, densities, and aerodynamic diameters are summarized 
in Table 6.2 (page 145), taken as an average across three separate batches.   
The 10% sucrose fraction accumulated the majority of larger-sized microgels, 
resulting in an aerodynamic diameter of 5.824µm.  However, the microgels in the  
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Table 6.2 Microgel Characterization: Density and Theoretical Aerodynamic Diameter 
Sucrose 
Fraction 
Geometric 
Diameter 
Density Theoretical Aerodynamic 
Diameter 
40% 0.2901 µm 1.1764 g/cc 0.3146 µm 
30% 1.338 µm 1.1270 g/cc 1.420 µm 
20% 3.527 µm 1.0810 g/cc 3.667 µm 
10% 5.717 µm 1.0381 g/cc 5.824 µm 
0% 1.890 µm 0.9982 g/cc 1.889 µm 
Overall* 4.694 µm 1.0497 g/cc 4.809 µm 
*Corresponds to overall average normalized by the concentration of microgels in each 
fraction. 
 
remaining fractions had aerodynamic diameters well within the desired range, conferring 
their suitability for use as a pulmonary drug carrier system.  The overall values across the 
entire distribution were determined by normalizing to the concentration of microgels in 
each fraction.  This normalized theoretical aerodynamic diameter, 4.809µm over the 
entire population, is sufficiently within the desirable range for efficient deep lung 
delivery. 
Microgel aerodynamic diameters were not characterized using the Next 
Generation Impactor or Anderson Cascade Impactor systems, as the primary purpose of 
this study was to show the development and characterization of this disease-responsive 
microgel system.  Future work will include formulation development of these microgels 
for use in existing pulmonary delivery devices, such as dry powder inhalers (DPIs), 
nebulizers, and pressurized metered dose inhalers (pMDIs).  Due to the potential of 
hydrolytic degradation of the microgels during wet storage and administration, we 
speculate that dry powder formulations would be most suitable for stability and shelf life.  
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The actual aerodynamic diameter will depend on the device and formulation, and will 
thus be the subject of future study.  
 
6.3.3 Microgels are a versatile therapeutic carrier system, capable of encapsulating 
various biologics and nanoparticles 
We were able to successfully encapsulate a wide variety of nanoparticles and 
biologics, including proteins and nucleotides, within the microgels (Figure 6.2, page 
147).  Encapsulation was achieved by simply adding the nanoparticle or biologic to the 
pre-cursor PEG-4-acr in 0.3M triethanolamine buffer solution, mixing uniformly using 
pipette aspiration, and combining with the peptide solution just prior to emulsion.  Up to 
20μg of IgG and 859μg of nanoparticles were encapsulated per mg of PEG/peptide.  An 
important consideration is the solubility of the biologic or dispersability of the 
nanoparticle in the polymer solution, including whether or not it is lipophilic, and thus, 
more likely to associate with the paraffin oil phase during the emulsion process. 
 
6.3.4 Microgels rapidly degrade and release biologics and nanoparticles in response 
to varying levels of enzyme while efficiently retaining encapsulants in the absence of 
the enzyme 
The use of optical trapping techniques [37] provided a means to capture, view, 
and track the same microgel as it is being exposed to enzyme over time.  Microgels that 
had settled onto the surface of a slide were captured and optically pulled up into 
suspension, such that the reaction would be isotropic, and unhindered by the surface of 
the slide.  Reviewing the time-lapse images, select time points of which are shown in 
Figure 6.3A (page 151), we were able to observe the various stages of enzyme-mediated 
degradation.  The entire time-lapse sequence is provided in the online version of the  
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Figure 6.2 Bright field and fluorescence images of microgels with various fluorescent 
compounds encapsulated, including IgG-labeled with Alexa Fluor® 594, 
200nm PLGA nanoparticles with surface loaded Cy3-labeled siRNA, 20nm 
and 40nm fluorescent polystyrene nanoparticles (FluoSpheres®). Top row 
to bottom row consecutively, scale bars = 10µm, 10µm, 20µm, 30µm.  Up to 
20µg of IgG and 859µg of nanoparticles were encapsulated per mg of 
PEG/peptide. 
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published article [38].  As the enzyme cleaves the peptide cross-links, the particle 
initially begins to swell, which is consistent with increased swelling capacity seen in 
similar hydrogels of lower cross-linking density [18].  At this point, we postulate that the 
enzyme is able to further penetrate into the microgel, resulting in rapid bulk-type erosion.  
Degradation is accelerated due to the nature of the network structure, and remaining 
fragmented components freely dissolve into solution.  
Enzyme-mediated release studies were demonstrated with the encapsulation and 
enzyme-triggered release of fluorescently labeled IgG antibody, lambda DNA, and 20nm 
fluorescent polystyrene nanoparticles (Dark Red FluoSpheres®) in separate experiments.  
Figure 6.3B (page 151) provides a visual confirmation of the release of encapsulated 
fluorescent IgG, correlating to microgel degradation, over time.   
Figure 6.4A (page 152) quantitatively shows the cumulative release of 20nm 
polystyrene nanoparticles, lambda DNA, and IgG over time in response to enzyme after 
an 18-24 hour swelling period at 37°C.  The time at which trypsin was added is denoted 
in the figure.  A trypsin concentration of 10-16.25 USP U/mL was used, a level well 
below normal physiological ranges [28].  A burst release for all encapsulated compounds 
was observed within 30 minutes of enzyme addition, demonstrating the ability to exhibit 
a rapid response to low levels of enzyme.  Anomalous decreases seen in cumulative 
release may be attributed to the experimental method, in which each of the time points 
collected are from different samples, although originating from the same batch.  In order 
to avoid a misleading multi-phase release in response to supplemented enzyme, the 
trypsin was not refreshed or supplemented for the duration of the experiment.  Thus, the 
study was terminated after eight hours, before the IgG sample could reach 100% release.  
The overall trend, however, is clear.  
 149 
It appears that the nanoparticles are released at a higher rate than both the IgG and 
DNA in the trypsin-mediated release study.  This is likely an artifact of the assay method, 
in which the particles must be centrifuged in order to sample the supernatant.  The 
centrifugation process may deform soft materials, such as hydrogels, resulting in a force-
mediated release.  To test this, we also performed long-term diffusion/hydrolysis-
mediated release studies using cell culture insert filters, without the use of enzyme or 
centrifugation, as described in section 6.2.7 .  Figure 6.4B (page 152) shows the 
diffusion/hydrolysis-mediated release of nanoparticles and IgG over a period of 17-20 
days.  It is apparent that the IgG is released to a greater extent during this period, likely 
due to a combination of diffusion and hydrolysis.  It is also interesting to note that there is 
a spike in the release of both IgG and nanoparticles around day 12, which corresponds to 
the rapid change in hydrolytic degradation at this same time point, presented in Figure 
6.1D (page 142).   
Given that the hydrodynamic radius of the 20-40nm particles lies between the 
hydrodynamic radii of IgG (~5nm) [39] and lambda DNA (130-300nm, depending on 
conformation) [40,41], hydrodynamic size is not the only predictor of release.  It is 
possible that large macromolecules, such as DNA and IgG, can potentially entangle with 
the hydrogel network structure, which allows them to more easily be retained during 
centrifugation, but results in a diffusion-driven release during the first ten days.  
Nanoparticles, on the other hand, may be entrapped within the pores seen in Figure 6.1C 
(page 142).  When exposed to high centrifugal force (10,000xg), the microgel may be 
deformed such that the nanoparticles are released from these “pockets.”  Without any 
applied force, the nanoparticles are effectively retained by the microgels. 
The rate of diffusion-mediated release, of IgG for example, may be easily tuned 
by changing the cross-linking density, wherein a tighter cross-linking density (with a 
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higher % polymer weight by volume composition) will result in slower diffusion.  The 
four-armed PEG used in this study had a molecular weight of 10kDa per arm.  Increasing 
the number of branches on the polymer, using a 6- or 8-arm PEG for instance, and/or 
using a lower molecular weight polymer could also reduce the rate of diffusion. 
We do not expect there to be significant effects on bioactivity of the drug due to 
the mild fabrication conditions, as similar systems have been used to encapsulate cells 
and growth factors within bulk hydrogels for tissue engineering [42-44].  However, one 
important consideration that warrants discussion is the ability of the trigger enzyme to 
degrade not only the microgel, but also any encapsulated proteins or peptides.  For this 
study, we used trypsin as a cost-efficient model enzyme in these proof-of-concept studies.  
Trypsin is able to cleave amino acid sequences terminal to arginine and lysine residues 
[21], meaning that it may not be a viable trigger for delivery of many protein or peptide 
drugs.  However, there are a host of other enzymes that are up-regulated in diseases that 
require much more sequence specificity, including matrix metalloproteinases and 
cathepsins [11].  It may then be unlikely that the trigger enzyme could degrade an 
encapsulated protein.  This could be further improved by optimizing the cross-linker 
peptide sequence to have greater specificity and quicker degradation by the enzyme of 
interest (kcat) [42].  In moving towards a disease-specific system, the enzymatic activity of 
the trigger enzyme on any encapsulated protein or peptide must be considered, and a 
cross-linker peptide should be designed accordingly.  This does not pose a significant 
challenge, especially with the increasing prevalence and sophistication of bioinformatics 
tools and databases to predict enzyme-substrate activities [21,22].  Moreover, as we are 
specifically using protease triggers (enzymes that digest proteins), this is of less concern 
for other biologics (DNA, RNA) and nanoparticles. 
 
 151 
 
Figure 6.3 Microgel degradation and release of encapsulated compounds in response to 
enzyme exposure by microscopy.   
(A) Light microscopy of a single microgel captured by optical trapping 
techniques, exposed to trypsin enzyme over time to view isotropic enzyme-
responsive degradation in comparison to a control sample; 325 U/mL 
trypsin. All scale bars = 10µm. A video of the time-lapse degradation is 
provided in the web version of [38].  
(B) Fluorescent microscopy of IgG releasing from microgels at 325 U/mL 
trypsin. All scale bars = 50µm.  
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Figure 6.4 Microgel degradation and release of encapsulated compounds in response to 
or absence of enzyme, by quantitative fluorometric assays.   
(A) Cumulative release of encapsulated 20nm Dark Red FluoSpheres®, 
lambda DNA, and Alexa Fluor® 594 IgG from microgels in response to 
enzyme exposure. Rapid release of all encapsulated compounds is observed 
at physiologically relevant concentrations of 10-16.25 U/mL trypsin. 
Trypsin was added after an 18-24 hour equilibrium swelling period.  All 
error bars are plotted, but may be obscured by data markers.   
(B) Cumulative release of encapsulated 40nm Dark Red FluoSpheres® and 
Alexa Fluor® 594 IgG from microgels due to hydrolysis and/or diffusion. 
Nanoparticles are more effectively retained within the microgels than IgG, 
which may be related to hydrodynamic radius and/or hydrogel network 
entanglement. An increase in release of both IgG and nanoparticles is seen 
around day 12, which correlates to the rapid hydrolytic degradation seen 
during the same time frame in Figure 6.1D. 
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6.3.5 Microgels exhibit minimal cytotoxicity and evade clearance by macrophages 
Microgel toxicity was tested on two epithelial cell lines, A549 human lung 
epithelial cells and HEK 293 human embryonic kidney epithelial cells, using the MTS 
assay.  Microgels, trypsin-degraded microgels, and un-reacted PEG-4-acr and CGRGGC 
peptide (equivalent levels to microgel condition) at doses of 0.5 and 1.0 mg/mL were 
tested at 6, 24, and 48 hours.  The doses correspond to approximately 4350 and 8700 
microgels per cell, respectively, which are high enough doses to completely blanket the 
cells.  Significant cytotoxicity was determined by an F-test for equal or unequal variances 
(p<0.05), followed by a two-tailed t-test (equal or unequal variances depending on F-test 
result, p<0.01).  There was no significant difference in A549 or HEK 293 cell viability at 
high doses of 0.5 and 1.0 mg/mL of microgels over all time points, as compared to 
untreated control samples.  At 48 hours and a dose of 0.5 mg/mL, there was a significant 
difference (p=0.005) between the untreated control and the degraded microgel condition.  
This may be attributed to the extended presence of trypsin in the culture, which was 
required to degrade the microgels.  This significance was not observed in the higher dose 
of 1.0 mg/mL of degraded microgels at any time point, nor was it observed in conditions 
with un-reacted PEG-4-acr and CGRGGC peptide at any time point.  Overall, the data 
indicates that the microgels, and their components, are not significantly cytotoxic at 
extremely high doses over several time points.  The complete data set is shown in Figure 
6.5 (page 154).  
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Figure 6.5 In vitro cytotoxicity of microgels on multiple cell lines. 
Percent viability of (A) A549 human lung epithelial and (B) HEK 293 
human embryonic kidney cells following exposure to microgels and 
microgel components for 6, 24, and 48 hours. Cell numbers are normalized 
to untreated control samples for each time point, with a dotted line denoting 
100% viability. *The only significant difference found in cell viability 
across all conditions and time points was for trypsin-degraded microgels 
after 48 hours exposure in A549 cells, denoted in (A), where p=0.005. 
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A potential issue with long-term controlled release particulate systems for 
pulmonary delivery is the rapid clearance of particles by alveolar macrophages.  
Macrophages begin taking up inhaled micron-sized particulates in a span of minutes, thus 
negating the effects of slow or controlled drug release particle formulations [4-7]. We 
theorized that the swelling behavior and hydrophilicity of the microgels, coupled with the 
stealth characteristics of PEG, would result in a decreased amount of microgel clearance 
as compared to 1µm fluorescent polystyrene microparticles (1µm-MP Positive Control), 
used as a positive control.  In order to fluorescently trace microgels, 20nm fluorescent 
polystyrene nanoparticles were encapsulated within the microgels (Microgel-with-20nm-
NP).  Due to the particle size differences between the 1µm-MP Positive Control and 
microgels, dosages were matched by weight (28µg per well, 50,000 cells per well).  Free 
fluorescent polystyrene nanoparticles were also delivered as a comparative control (Free-
20nm-NP), and were matched to microgels by number of nanoparticles-encapsulated-in-
microgels and number of nanoparticles per cell (2.12x105 nanoparticles per cell).  The 
amount of Free-20nm-NP and Microgels-with-20nm-NP were experimentally matched 
using standard curves of fluorescence versus concentration.  Flow cytometry data for 
1µm-MP Positive Control (ex/em 540/560) were collected in the FL2 channel, and data 
for Microgel-with-20nm-NP and Free-20nm-NP (ex/em 660/680) were collected in the 
FL4 channel.  Using the fluorescence intensity of the untreated cells, a very tight gate 
was applied (depicted as a vertical dotted line in Figure 6.6, page 157) as a threshold on 
fluorescence intensity for positive uptake of particles. 
As can be seen in Figure 6.6 (page 157) and Figure 6.7B (page 158), 94.1% of the 
cell population has already taken up the hydrophobic polystyrene 1µm-MP Positive 
Control sample after only 2 hours, and 99.7% after 24 hours.  In comparison, Microgel-
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with-20nm-NP uptake was quantified as only 12.1% after two hours, and 11.8% after 24 
hours.  This was also visually confirmed by confocal microscopy, shown in Figure 6.7 
(page 158).  Effectively, this data supports the conclusion that the hydrophilic and 
swellable microgels may offer improved retention over hydrophobic polymer particles for 
long-term controlled drug release in the lungs by avoiding macrophage uptake in the 
short- and long-term.  As shown in section 6.3.2 , microgels required up to 24 hours to 
reach the theoretical size to avoid macrophage uptake (>6μm).  Freshly synthesized, pre-
swollen microgels were used for this study, indicating that other factors than size, 
perhaps the hydrophilic and/or PEG “stealth” characteristic, are involved.  Whether the 
hydrophilicity, swelling, or PEG composition plays a greater role in this macrophage 
avoidance must be further studied to draw final conclusions, and will be used to improve 
future microgel design.   
With regards to long-term treatment with an un-clearable particle, it may be 
dangerous to receive repeat chronic dosages, thereby increasing particle accumulation in 
the lungs over time.  This proposed microgel system, however, contains a hydrolytically 
degradable ester bond in the cross-link, which was shown to degrade over a time period 
of approximately two weeks (section 6.3.2 ).   
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Figure 6.6 Microgels exhibit reduced uptake and clearance by macrophages in 
comparison to polystyrene particles, by flow cytometry. Flow cytometry 
histograms comparing fluorescence intensity of untreated cells to those that 
have taken up 1µm fluorescent polystyrene microparticles as a positive 
control (1µm-MP Positive Control), free 20nm fluorescent polystyrene 
nanoparticles (Free-20nm-NP), and 20nm fluorescent polystyrene 
nanoparticles encapsulated in microgels (Microgel-with-20nm-NP). Free-
20nm-NP and Microgel-with-20nm-NP have the same nanoparticle dosage 
by number of nanoparticles. The 1µm-MP Positive Control and Microgel-
with-20nm-NP groups have the same dosage by weight.  Typical results are 
shown representing three experimental repeats, and are taken from a gated 
population of at least 10,000 RAW 264.7 macrophages.   
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Figure 6.7 Microgels exhibit reduced uptake and clearance by macrophages in 
comparison to polystyrene particles, by microscopy and flow cytometry.  
(A) Confocal microscopy of RAW 264.7 macrophages after one hour of 
incubation with 1µm-MP Positive Control at left, and Microgel-with-20nm-
NP at right. Cell nuclei are stained with DAPI in blue, and actin cytoskeletal 
protein is stained with phalloidin in red; 1µm-MP Positive Control particles 
are shown in orange; Microgel-with-20nm-NP are shown in green at inset. 
No uptake of microgels was observed. Scale bars = 20µm.   
(B) Percentage of RAW 264.7 macrophage cell population positive for 
particle uptake after two and 24 hours, by flow cytometry analysis of at least 
10,000 cells representing three repeats. Cells were considered positive for 
uptake if their fluorescence intensity was increased and shifted past an 
applied gated threshold on the untreated population, depicted by a vertical 
dashed line in (A).  
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6.4 CONCLUSIONS 
Here, we have discussed the many challenges to achieving effective delivery of 
biologic drugs inside cells to the deep lung, and the design of a new platform drug 
delivery system to overcome them.  In considering these challenges, the following criteria 
were considered: 
a. Reduced exposure to fabrication conditions that may denature biologic drugs 
b. Aerodynamic diameter between 0.5 and 5μm to achieve deep lung deposition 
c. Geometric diameter greater than 6μm and hydrophilic surface chemistry to 
avoid rapid clearance by alveolar macrophages 
d. Nanoscale sizes, less than 0.2μm, for mucus penetration and intracellular 
delivery 
e. Disease-responsive drug release mechanism to improve targeting to diseased 
tissue for non-uniform lung diseases, thereby reducing side effects. 
Regarding (a), we have introduced a new MADE fabrication method, which 
produces aqueous microgels by employing a Michael addition cross-linking during water-
in-oil emulsion at physiological temperature and pH, without exposure to organic 
solvents.  The microgels were shown to have geometric and theoretical aerodynamic 
diameters within the required range to achieve deep lung deposition, 0.5-5μm (b).  As the 
microgels are inherently micro-sized hydrogels, they exhibit hydrogel swelling behavior.  
After 24 hours of swelling in PBS, the microgels swelled to a geometric diameter greater 
than 6μm.  It was noted, however, that the required swelling time was longer than 
expected, leaving a question of whether or not they could avoid macrophage clearance in 
the short term (c).  Nonetheless, macrophage uptake studies with freshly synthesized 
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microgels (pre-swelling) were able to effectively avoid macrophage uptake at both two 
and 24 hours, indicating greater potential for retention of this controlled release system in 
the lungs. 
Concerning (d), we demonstrated the versatility to encapsulate various types of 
biologics (DNA, siRNA, and proteins) and nanoparticles (20nm to 200nm).  In future 
work, encapsulated nanoparticles could be further engineered to have improved mucosal 
penetration, uptake, and endosomal escape, if desired.  Lastly, we successfully 
incorporated a disease-triggered release mechanism into the microgels, in the form of 
enzyme-specific peptide cross-linkers.  The microgels exhibited rapid release of biologics 
and nanoparticles in response to enzyme and the ability to retain drug in the absence of 
enzyme.  In future iterations of this microgel system, the peptide cross-linker may be 
easily interchanged for one customized to a highly specific, disease up-regulated 
protease, thus providing the disease-responsive drug release mechanism (e). 
Overall, the microgel delivery system has successfully met all design criteria laid 
out in (a-e), showing great potential as a versatile disease-responsive system for 
pulmonary delivery of biologic drugs.  Future work will involve formulation optimization 
for existing, non-invasive, pulmonary delivery devices, such as DPIs, pMDIs, or 
nebulizers.  Other future studies will include in vivo biodistribution, efficacy, and 
significance of disease-responsive drug release triggers in reducing side effects. 
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Chapter 7: In Vivo Pulmonary Distribution and Clearance of Microgels 
 
7.1  INTRODUCTION 
As discussed in the previous chapter (Chapter 6), in the development of controlled 
release systems for pulmonary delivery, an important design consideration is the ability 
of the system to avoid the rapid clearance by alveolar macrophages [1,2]. In other words, 
a controlled release particle must reside in the pulmonary space sufficiently long enough 
to allow for its controlled release mechanism to take place, whether it is sustained and 
long-term release of drug, or until an environmental trigger causes the release of drug; 
both of these release mechanisms are applicable to the work presented in this dissertation. 
The majority of polymer particles are cleared from the rodent pulmonary space within 1-
3 days [3-5]. The goal of the study presented here was to determine if the in vitro data  
 
 
Figure 7.1 In Vivo Pulmonary Distribution and Clearance of Microgels: Study Groups 
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Figure 7.2 In Vivo Pulmonary Distribution and Clearance of Microgels: Timeline and 
Sample Assays 
 
from Chapter 6, which indicated that the PEG-CGRGGC microgels are better able to 
avoid macrophage clearance than polystyrene particles, was significant enough to 
prolong the residence time of microgels in the murine lung in vivo. 
For the purposes of this study, microgels were directly introduced into mouse 
lungs using a Penn-Century MicroSprayer device, commonly used to deliver test 
formulations to rodents in vivo [3,6-9]. Polystyrene microparticles were also used as a 
positive control for comparison. The amount of particles remaining in the lungs at days 1, 
3, 6, 10, and 14 were determined using IVIS (In Vivo Imaging System) imaging, as well 
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fluorescence measurements from lung homogenates. The IVIS images also provided a 
means to view the distribution of particles in the lungs.  The study groups, timeline and 
assays performed are illustrated in Figure 7.1 and Figure 7.2, respectively. 
 
7.2  MATERIALS AND METHODS 
7.2.1 Materials 
Alexa Fluor ® 633 Carboxylic Acid Succinimidyl Ester (AF633-SE) and 1 μm 
Crimson (excitation/emission 625/645) FluoSpheres® were purchased from Life 
Technologies (Carlsbad, CA). Float-a-Lyzer dialysis tubes were purchased from 
Spectrum Labs (Rancho Dominguez, CA). The microsprayer assembly, including the 
FMJ-250 High Pressure Syringe and Model IA-1C (1.25 inch, for mouse) 
MicroSprayer® tip, was purchased from Penn-Century, Inc. (Wyndmoor, PA). The 
Model LS-2 Small Animal Laryngoscope and Mouse Intubation Platform were also 
purchased from Penn-Century, Inc. Nylon suture thread and 20 gauge x 1 inch 
intravenous catheters were purchased from Thermo Fisher Scientific (Hampton, New 
Hampshire). Paraformaldehyde (dry powder) was purchased from Sigma-Aldrich (St. 
Louis, MO).  
 
7.2.2 Conjugation of Fluorescent Probe to Microgels 
The direct and covalent incorporation of fluorescent probes on microgels was 
carried out by bioconjugation of AF633-SE, which contains a carboxylic acid group, onto 
the peptide sequence CGRGGC, which contains primary amines. The reaction was 
carried out according to manufacturer instructions at a pH favorable for conjugation at 
the alpha amine, rather than the side chain amines. Following the reaction, the product 
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was dialyzed to remove side products and un-reacted materials for at least three dialysis 
changes in one liter of de-ionized water for four to six hours each. The product was snap 
frozen in liquid nitrogen and lyophilized for 48-72 hours, then stored under nitrogen gas 
at -20°C until used. Fluorescently labeled microgels were synthesized using the MADE 
method (as described in Chapter 5), substituting in a ratio of one fluorescently tagged 
peptide per five un-tagged peptides. 
 
7.2.3 Animal Strains, Care, and Use 
All experiments were approved by the University of Texas at Austin Institutional 
Animal Care and Usage Committee (IACUC), and all new procedures were developed 
with careful consultation with clinical veterinarians. All mice used in this study were 8-
10 week old female BALB/c mice from Jackson Laboratories (Bar Harbor, ME), 
weighing approximately 20 grams each. Prior to study assays, all animals were kept on a 
modified alfalfa-free diet for at least seven days to reduce tissue and food 
autofluorescence (Teklad Global Rodent Diet 2014, Harlan Laboratories, Indianapolis, 
IN) in IVIS images. 
 
7.2.4 Mouse Endotracheal Intubation and Intrapulmonary Aerosol Delivery of 
Particles using a Penn-Century MicroSprayer Device 
Both control fluorescent polystyrene particles and microgels were delivered using 
a Penn-Century MicroSprayer device designed for use in mice. This procedure has been 
significantly modified from the method given by Bivas-Benita, et. al. [8], through several 
practice administrations in mice post-mortem to reduce incidence of tracheal perforation 
and mortality. Primary deviations include the orientation of the mouse to improve 
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operator’s ergonomic posture, as well as introduction of a flexible intubation tube (20 
gauge catheter) to serve as a “guide” to insert the MicroSprayer needle tip, minimizing 
incidence of trauma. As such, a detailed protocol, including images, for this procedure is 
given in Appendix A. A procedure record and monitoring worksheet to facilitate 
recordkeeping for monitoring and recovery is also provided in Appendix B. Prior to 
loading into the MicroSprayer, all particle suspensions were filtered through a 36 μm 
mesh, to prevent the sprayer tip from clogging.  
Mice were anesthetized using an intraperitoneal (IP) injection of Ketamine (800-
100mg/kg) and Xylazine (10-20mg/kg). Anesthetized mice were kept on heating pads 
until recovery, except during intubation and dose delivery. The intubation platform was 
placed at a 20-degree angle, at eye level with the operator (seated). After approximately 
5-10 minutes, the depth of anesthesia was determined using a toe pinch to the back foot. 
When the mouse was no longer responsive to toe-pinch, it was placed on the intubation 
platform in the prone position (ventral side down), with the upper incisors hooked over 
the wire. The entire body of the mouse was then aligned and straightened. 
The mouth was gently opened using blunt forceps, held open with a lighted 
laryngoscope, and the tongue was pulled to the side. The epiglottis is opened to reveal the 
vocal cords, and the tapered end of a 20 gauge x 1 inch catheter is inserted into the 
trachea to intubate the mouse. The catheter should be initially angled downwards, then 
parallel to the intubation platform. With proper alignment, little to no resistance should 
be felt. To facilitate use with the Penn-Century MicroSprayer needle, accommodating the 
bend in the needle, a slit along the female Luer hub of the catheter must be cleanly cut 
prior to use (using a cut-off wheel of a Dremmel, or other similar device); see Appendix 
A for details and an image.  
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At this point, the laryngoscope can be removed and both hands may be dedicated 
to operation of the MicroSprayer. The needle tip of the MicroSprayer is then inserted into 
the catheter, until the bend of the needle reaches the opening of the mouth. The aerosol is 
then quickly delivered, and both catheter and MicroSprayer are quickly removed. Correct 
intubation and delivery will be signified by rapid breaths, which should return to baseline 
within 1-2 minutes. The mouse is allowed to recover to baseline normal breathing on the 
intubation platform before it is moved into a cage, on a heating pad, for recovery from 
anesthesia. 
 
7.2.5 IVIS Imaging of Mouse Lungs and Image Analysis 
Mice were euthanized at days 1, 3, 6, 10, and 14 after particle delivery with an 
intraperitoneal injection of sodium pentobarbital (200 mg/kg Euthasol), followed by 
cervical dislocation. Trachea, lungs, heart, and thymus were excised en block. The heart 
and thymus, along with any other remaining connective tissue, were then carefully 
removed from the lungs. The lungs and trachea were rinsed with PBS and then placed in 
a 12-well plate with 1 mL of PBS on ice. 
Lungs were placed on the flat underside of a black polypropylene 96-well plate 
(intended for fluorescence measurements) to facilitate later removal. It was found that 
lungs placed directly on black imaging paper tend to stick and are difficult to remove. 
The lungs were carefully arranged such that each lobe was layed out and visible. 
Fluorescent images of the lungs were then acquired using an IVIS Spectrum (Caliper Life 
Sciences, PerkinElmer, Waltham, MA) using the settings in Table 7.1.  
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Table 7.1 IVIS Imaging Settings 
Parameters Setting 
Pixel Width 1 
Pixel Height 1 
Binning Factor 4 (small) 
Image Units Counts 
f Number 2 
Field of View 13.2 (C) 
Excitation Filter 605 
Constant 
Emission Filter 660 
0.01 seconds 
0.05 seconds 
0.10 seconds 
0.25 seconds 
0.50 seconds 
0.75 seconds 
1.00 seconds 
1.50 seconds 
Varied (sequence) Exposure 
2.00 seconds 
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Quantitative data was collected using the IVIS Living Image software using the 
following steps: 
1. Set units to radiance (photons) 
2. Draw regions of interest (ROIs) around each lung 
3. Measure ROIs in radiance (photons) 
4. Export data into Microsoft Excel 
5. Data with saturated pixels cannot be used. 
The quantitative data was then analyzed and graphed in Microsoft Excel to 
determine if any trends or significant changes in clearance rates between particle groups 
could be established. The background fluorescence was determined from untreated lungs, 
and subtracted from the data set. 
 
7.2.6 Tissue Homogenization and Fluorescence Quantification 
7.2.6.1 FluoSpheres Fluorescent Polystyrene Particles 
Following IVIS imaging, the lungs were carefully trimmed to remove the trachea 
and any other remaining connective tissue, and then minced into small pieces (< 0.5 
centimeters) using dissection scissors. They were then suspended in 3 milliliters of tissue 
lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% Triton-X 100) and homogenized for 
one minute, or until completely homogenized. To dissolve and extract fluorescence from 
the 1 μm Crimson FluoSpheres® polystyrene microparticles, three milliliters of xylene 
was added. The sample was then capped, parafilmed, and allowed to rotate at room 
temperature for three days (time point determined from preliminary studies for assay 
validation). After removing from the rotator, the sample was centrifuged at RCF 3220 at 
4°C for five minutes to allow separation of the xylene and aqueous phases. Sample 
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aliquots of 100 μl were taken from the (top) xylene phase and read in a fluorescence plate 
reader at an excitation/emission of 645/680. Readings were quantified by comparison 
with standard curves. 
 
7.2.6.2 AF633-Conjugated Microgels 
The same protocol as above (section 7.2.6.1 ) was used to homogenize mouse 
lungs. However, to dissolve and extract fluorescence from the AF633-conjugated 
microgels, the (trypsin-degradable) microgels were digested in trypsin solution for 72 
hours at 37°C. After removing from the rotator, 1 mL aliquots were removed into 1.7 mL 
centrifuge tubes, and cell lysate was centrifuged out at 21,100xg. Sample aliquots of 100 
μl were taken and read in a fluorescence plate reader at an excitation/emission of 
645/680. Readings were quantified by comparison with standard curves. 
 
7.3 RESULTS AND DISCUSSION 
7.3.1 IVIS Imaging 
7.3.1.1 Troubleshooting 
The primary advantage to using an IVIS imaging system to track and quantify 
particle clearance and distribution was in the ability to perform live imaging on the 
experimental subjects, such that the same set of dosed mice could be followed throughout 
the time course of the study. In addition to being able to view the fluorescence 
distribution of particles, the IVIS Living Image software also contains analysis functions 
in which fluorescence intensity could be quantified.  
In practice, however, this system proved to be unrealistic for deep tissue 
fluorescence quantification (of the lung). Several preliminary studies were conducted in 
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an attempt to develop an experimental protocol that would follow the same set of dosed 
mice throughout the time course (live imaging). All recommended best practices from the 
manufacturer were followed, including: 
• Modification to an alfalfa-free diet, for at least seven days, to reduce gut and 
tissue autofluorescence 
• Use of near-infrared fluorescent probes 
• Removal of fur using a depilatory to reduce scattering 
• Imaging in various orientations 
• Trial with both epifluorescence (surface) and transillumination (deep) imaging 
settings. 
The variation of all these parameters produced no reliable fluorescent signal from 
the lungs under epifluorescence. Although transillumination would perhaps be more 
applicable, the in-practice imaging time was approximately one hour per mouse, which 
prevented its further use. One other option would have been to make use of specialized 
fluorescent probes for IVIS, but such probes were cost-prohibitive at the time of study. 
Therefore, different sets of mice were used for each time point, and the dosing and 
delivery was divided across multiple days for practicality and time limitations. 
 
7.3.1.2 Fluorescence Quantification from IVIS Images 
Raw data was originally collected in radiance, or photons, and the total flux 
(photons per second) from each region of interest was calculated and averaged as a total 
flux per lung. Background fluorescence was subtracted using the average from untreated 
control lungs. This data was then normalized as a percentage to the total flux at Day 1 in 
order to display the total remaining as a percentage of Day 1. Although IVIS imaging 
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settings were kept constant from day-to-day measurements (see Table 7.1), quantified 
data had anomalous changes in signal intensities. The data, from an exposure time of 0.5 
seconds, is plotted in Figure 7.3. Data cannot be quantified from images with saturated 
pixels, which was the case for Day 6 images at all exposure times, as well as for all 
FluoSpheres (polystyrene positive control). Therefore, those points are not plotted or 
shown.  
As can be seen in Figure 7.3, the Day 3 time point shows less microgel remaining 
as compared to Day 10, despite both of these time points having small error bars. The 
unexplainable low fluorescence at Day 3, followed by an increase at Day 10, was also 
seen in the FluoSphere data (not shown). Therefore, it was concluded that the quantified 
fluorescence was somewhat unreliable, and would not be determined by IVIS analysis. 
 
 
Figure 7.3 Percent of Microgels Remaining in Lungs Over Time by IVIS Fluorescence 
Quantification 
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7.3.1.3 Pulmonary Distribution 
Despite the unresolved issues with IVIS imaging discussed in sections 7.3.1.1 and 
7.3.1.2 , the use of IVIS imaging post mortem on extracted lung samples was still useful 
for visualizing the pulmonary distribution of both polystyrene particles and microgels 
throughout the time points. Figure 7.4 shows the IVIS images of the extracted mouse 
lungs from the polystyrene group at all time points (days 1, 3, 6, 10, 14), using an 
exposure of 0.01 seconds. Figure 7.5 shows the IVIS images of the extracted mouse lungs 
from the microgel group at all time points, using an exposure of 0.5 seconds. 
Observing the images, it may be seen that both polystyrene particles and 
microgels exhibit uniform distribution throughout the upper and lower airways.  Some 
allowance for directed delivery into one lobe over another may be attributed to the 
method of delivery, which would be a result of a delivery point past the carina (first 
bifurcation). The absence of fluorescence in one lung of the polystyrene group indicates 
an error in delivery method, which likely resulted from intubation into the esophagus 
rather than the trachea. None of these outliers were discounted from analysis, however, in 
order to account for the probability of mis-delivery into the esophagus for all time points. 
One final interesting trend, seen in the day 14 image of the microgel group 
(Figure 7.5), is that day 14 lungs are generally free of any fluorescent trace, save for one 
out of eight samples. This is of special significance when recalling that the microgels 
undergo hydrolytic degradation around day 11. It was postulated that the hydrolytic 
degradation would serve as a fail-safe mechanism to promote clearance of the microgels 
from the lungs, thereby preventing long-term accumulation from multiple and frequent 
doses. This data, though not conclusive, is enough to warrant further study of the exact 
clearance mechanism. 
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Figure 7.4 IVIS Images of Extracted Lungs from Mice Dosed with 1μm Fluorescent 
Polystyrene Particles 
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Figure 7.5 IVIS Images of Extracted Lungs from Mice Dosed with AF633 Microgels 
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7.3.2 Fluorescence Quantification from Tissue Homogenates 
In addition to IVIS imaging, the same lung samples from each group were 
homogenized and analyzed for total levels of fluorescence at each time point. These 
samples were compared as a percentage of the initial dose of 0.1 mg (both microgels and 
polystyrene particles). Standard curves were made using untreated homogenized lung 
tissue for background autofluorescence. 
Figure 7.6 displays both the dot plots (which shows the entire distribution of each 
data set) and average percent of particles remaining for each time point, for microgels 
(top) and FluoSpheres fluorescent polystyrene particles (bottom). Figure 7.7 displays the 
average of the data set for both microgels and polystyrene microparticles graphed 
together for comparison, as a percentage of the initial dose.  
The FluoSpheres polystyrene microparticles are cleared very rapidly from the 
lungs, as was seen in Chapter 6 in vitro data. By day 1, approximately 70% of 
FluoSpheres have already been cleared from the lungs, and continues to decrease over 
day 3 and day 6, when somewhat of a baseline level of 15% remaining has been reached. 
The initial rapid clearance over day 1 is likely primarily due to macrophage clearance, as 
has been observed in the literature [4,5]. The slower, secondary clearance mechanism is 
likely due to mucociliary clearance. Furthermore, the data from the polystyrene 
microparticles, as a positive control, agrees with that seen in the literature for polymer 
particles in general [3,4], validating the method of assay. 
In contrast to the polystyrene particles, the microgels exhibit significantly less 
clearance over the first day, with over 85% of microgels still remaining in the lungs at 
day 1. This again correlates very well with in vitro macrophage uptake data seen in 
Chapter 6. Again, like the FluoSpheres, levels of microgel remaining in the lungs 
continues to decrease over day 3 and day 6, down to approximately 45% remaining at day 
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6. In context, this is very significant in that the amount of microgels remaining at day 6 is 
greater than the amount of FluoSpheres remaining at day 1.  
However, the data at day 14 is greatly deviates from the trend seen in the other 
time points in that the fluorescent signal has actually increased to greater than the initial 
dose (~135%). When viewing the dot plot for that data set (Figure 7.6), the entire data set 
displays a marked increase in fluorescence, so it is not due to averaging with an included 
extreme outlier. Furthermore, this data does not agree with the IVIS images seen for 
microgels at day 14 (Figure 7.5). Several possible explanations exist, though none of 
which have been validated conclusively as of yet. It is possible that the microgel samples 
weighed out for dosing to the day 14 set of mice were weighed out incorrectly, at least 
twice as much as for other groups. The IVIS data does not support this, however, and it 
cannot be determined now, after the fact. This would also mean that the data from other 
time points must also be discounted from analysis. Another explanation is sample 
contamination during homogenization, which again, cannot be determined after the fact. 
Lastly, it may be possible that the Alexa Fluor 633, when conjugated to an intact 
microgel, exhibits some level of fluorescent signal quenching. However, due to the 
trypsin degradation step in the assay, it must mean that the fluorescent signal is quenched 
in trypsin-degraded microgels, as well, or that hydrolytically degraded microgels can 
somehow boost the fluorescent signal. This theory is not supported by any previous data, 
however, but should be tested in vitro at the very least. 
Despite the anomalous data from day 14, this data set hints towards a significant 
difference in microgel clearance as compared to polystyrene microparticle clearance. 
This study should be repeated in the future, with some minor changes in method to 
prevent any of the possible errors explained here. 
 
 182 
 
Figure 7.6 Percent of Microgels and Polystyrene Microparticles Remaining in Lungs 
over Time by Fluorescence Quantification from Tissue Homogenates 
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Figure 7.7 Comparison of Percent of Particles Remaining in Lungs over Time by 
Fluorescence Quantification from Tissue Homogenates 
 
7.4 CONCLUSIONS 
In this chapter, the in vivo performance of the microgels was studied in 
comparison to fluorescent polystyrene microparticles in terms of pulmonary distribution 
and clearance patterns over a two week time period. In the realization of this study, a new 
method of intratracheal intubation and aerosol delivery was developed and modified from 
previously published methods [8] in order to minimize incidence of trauma or tracheal 
perforation. The pulmonary distribution of microgels and polystyrene particles was 
monitored via IVIS fluorescent images of extracted mouse lungs post mortem, indicating 
successful delivery to the deep lung. Unfortunately, quantification of particles remaining 
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using the IVIS analysis software was ultimately unreliable and unsuccessful. However, 
the clearance pattern of the particles was successfully quantified by measuring 
fluorescence from lung tissue homogenate. The clearance of fluorescent polystyrene 
particles measured was well in agreement with that published in the literature [4], 
showing approximately 70% of particles cleared from the lungs within the first day. In 
contrast, only about 15% of microgels were cleared from lungs at this same time point, 
and at day 6, 40% of microgels were still remaining in lungs in comparison to only 15% 
of polystyrene particles. Microgel data at day 14 could not be explained, however, but 
hinted towards significant differences in clearance mechanisms between microgels and 
polystyrene microparticles. Collectively, this data presents clues in understanding how to 
affect the particle clearance patterns from the lungs, and should be repeated in the future. 
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Chapter 8: Conclusions and Future Directions 
 
8.1  RESEARCH SUMMARY 
The objective of this dissertation work was to develop an enzyme-responsive 
platform drug delivery system for the delivery of biologic drugs through the pulmonary 
route. In the design of this system, the fragile nature of these biologic drugs was 
considered throughout the development of a hydrogel microparticle, or microgel, 
manufacturing process. The enzyme-responsiveness of the system was made easily 
adaptable through the incorporation of peptide sequences, although as a proof of concept, 
the trypsin-responsive pentapeptide CGRGGC was used throughout this work. These 
enzyme-responsive hydrogel microparticles were then evaluated in vitro, and preliminary 
in vivo studies were performed. 
In Chapter 1, the concept of a disease-responsive hydrogel microparticle for 
pulmonary delivery was introduced, as well as the many design challenges that are 
currently limiting the potential of polymer particle-based pulmonary vehicles for 
controlled drug release. Chief among them is that the ideal sizes for uniform and deep 
lung distribution are also the sizes which are most observed to be rapidly cleared by 
alveolar macrophages. The rationale for utilizing enzyme-responsive systems was also 
discussed, as well as the need for developing new carriers for the emerging class of 
biologic drugs. 
Chapter 4 extensively discussed the various biomaterials that were studied for 
incorporation into the microgel system. This chapter also included background material 
on the Michael addition reaction between sulfhydryl and acrylate groups, as well as the 
modification of polymers to incorporate these reactive groups. Work on peptide 
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bioconjugation chemistry was also covered in this chapter. Finally, optimal hydrogel 
ingredients, ratios, and reaction buffers were determined in this chapter. The final 
composition to move forward with was a 60% combined weight by volume hydrogel 
consisting of a four-arm poly(ethylene) glycol acrylate cross-linked with the CGRGGC 
peptide in 0.3 molar triethanolamine buffer. 
In the next chapter, Chapter 5, the newly developed PEG-CGRGGC hydrogel 
material was scaled down to microparticle scale through the trial of various particle 
synthesis methods. Various particle synthesis methods included mesh molding, grinding, 
cryomilling, emulsions, and more. The method that best preserved the desired material 
properties was an emulsion method. This chapter then details the development and 
optimization of the Michael Addition During water-in-oil Emulsion, or MADE, process 
to produce the microgels. 
Chapter 6 covers the extensive in vitro characterization of these PEG-CGRGGC 
microgels. These studies included hydrogel swelling and hydrolytic degradation studies, 
as well as enzyme-mediated degradation studies. Microgels were confirmed to undergo 
rapid trypsin-mediated degradation. In swelling studies, the microgels were shown to 
swell over the course of 10 days, and begin undergoing hydrolytic degradation thereafter. 
The density and aerodynamic diameter of the microgels was also determined to be within 
the appropriate range of inhalation and deep lung delivery. 
A number of biologic drug candidates were successfully encapsulated within the 
microgels, including proteins, DNA, siRNA, and nanoparticles of different sizes. The 
release of these encapsulated model drugs was also studied in the presence or absence of 
enzyme. The microgels exhibited a rapid release of drug upon enzyme exposure, while 
also displaying efficient retention of the drug without enzyme. In diffusion/hydrolysis-
driven release studies, proteins were shown to slowly diffuse out over the course of 11 
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days before undergoing rapid hydrolysis. Nanoparticles, however, were efficiently 
retained until the point of hydrolytic degradation, around day 12. 
The microgels were also evaluated for cellular interactions in vitro in this same 
chapter, and were found to exhibit no significant cytotoxicity with multiple cell lines. Of 
special interest was the interaction of microgels with RAW 264.7 macrophages in 
comparison to polystyrene particles. It was found that the microgels principally avoided 
uptake by macrophages over short (2 hours) and long (24 hours) time points, whereas 
polystyrene particles were rapidly taken up within both time courses. This avoidance of 
macrophage uptake implicated that the microgels may have improved residence time in 
the lungs, which may in turn improve its performance as a controlled release system for 
pulmonary delivery over other polymer particles. 
Given the promising in vitro performance of microgels, the pulmonary 
distribution and clearance of microgels were then studied with preliminary in vivo 
experiments using BALB/c mice, discussed in Chapter 7. Overall, the microgels 
exhibited on par performance in terms of pulmonary distribution to the lower airways as 
compared with 1 μm polystyrene particles, as confirmed by IVIS (In Vivo Imaging 
System) studies. The clearance of the microgels over the course of two weeks was also 
studied and quantified in comparison to the same polystyrene particles. Similar to the in 
vitro data, the polystyrene particles were rapidly cleared (~70%) within the first day, 
whereas only about 20% of microgels were cleared in the same time span. Following the 
study out to day 10, only ~15% of polystyrene particles remain in the pulmonary space, 
whereas just under 50% of microgels are still remaining. Although this study needs to be 
repeated with some modification, it provided compelling evidence for the improved 
retention and performance of the microgels as a pulmonary controlled release vehicle. 
 189 
However, as mentioned, further study should be done, as will be described in the next 
section. 
 
8.2  FUTURE WORK 
8.2.1 Repeated Pulmonary Distribution, Clearance, and Toxicity 
As described in Chapter 7, promising preliminary data was presented that 
provided evidence for modified clearance patterns of microgels over other polymer 
particles. This study should be further repeated, and complementing data should be 
gathered both from IVIS studies, as well as homogenate-based fluorescent quantification. 
In addition to only the lung distribution being studied, full biodistribution and biokinetic 
studies should also be performed. Biokinetic analysis during microgel clearance should 
elucidate the primary mechanisms of microgel clearance as macrophage clearance, 
mucociliary clearance, or a combination of both. Along with biodistribution and 
biokinetics, the systemic toxicity and immunological response should be evaluated using 
cytokine-based assays and pulmonary edema. It may also be prudent to repeat studies in a 
rat model instead of a mouse model, as is commonly reported. 
 
8.2.2 In Vivo Disease-Triggered Drug Release 
One major theme of this work was the concept of disease-triggered drug release 
using enzyme-specific peptide sequences. Although the enzyme-triggered drug release 
was extensively characterized in vitro in Chapter 6, this concept was not tested in vivo. 
In order to test this system in vivo, a disease-model with up regulated enzyme expression 
in the lungs should be used for comparison of drug release with healthy control groups. 
Some viable candidates for disease models that are currently being considered include an 
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ovalbumin-based airway allergy model, in which levels of matrix metalloproteinase-9 
(MMP-9) are expressed by mast cells in the pulmonary epithelial space [1,2], and 
bleomycin-induced pulmonary fibrosis model, in which levels of matrix 
metalloproteinase-2 (MMP-2) are over expressed in the airways[3-6]. Peptide sequences 
for both of these enzymes have already been well studied and incorporated into similar 
Michael addition hydrogels [7,8], one of which has already been successfully 
incorporated into the system described in this work (data not shown). 
 
8.3 CONCLUSIONS 
The development of enzymatically-degradable hydrogel microparticles, as well as 
the development of methods to synthesize them, has provided the opportunity to make a 
significant impact on controlled release pulmonary drug delivery systems for biologic 
drugs. The Michael addition chemistry used here is especially suitable for biologic drugs, 
which may be denatured by traditional manufacturing methods, and is easily 
accomplished using cysteine-containing peptide sequences to cross-link commercially 
available biopolymers, without the need for bioconjugation or modification. This polymer 
chemistry was successfully scaled into microparticle synthesis via the newly developed 
MADE microgel synthesis method. Microgels synthesized using this method 
reproducibly exhibit enzyme-mediated degradation and release of encapsulated protein, 
DNA, and nanoparticles, and efficient retention without enzyme. Both in vitro and in vivo 
experiments provide evidence for modified retention and clearance of these microgels in 
the pulmonary space, with significant implications for design of future pulmonary 
controlled delivery systems. Collectively, the work in this dissertation has followed the 
conception, development, and evaluation of disease-triggered hydrogel microparticles for 
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pulmonary delivery, supporting the future realization of non-invasive, dynamic and 
disease-responsive delivery systems for the emerging class of biologic drugs. 
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Appendix A: Detailed Protocol and Visual Instructions for Mouse 
Endotracheal Intubation and Intrapulmonary Aerosol Delivery of 
Particles using a Penn-Century MicroSprayer Device 
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Appendix B: Pulmonary Procedure Record and Monitoring Worksheet 
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Glossary 
 
ABBREVIATIONS AND ACRONYMS 
1H NMR proton nuclear magnetic resonance 
Acr  acrylate 
BRENDA Braunschweig Enzyme Database 
CGKGGC cysteine-glycine-lysine-glycine-glycine-cysteine 
CGRGGC cysteine-glycine-arginine-glycine-glycine-cysteine 
CPCHIVtat cationic polymer possessing a cleavage site for HIV-1 protease 
Da  Dalton 
DDS  drug delivery system 
DI H2O de-ionized water 
DNA  deoxyribonucleic acid 
DOX  doxorubicin 
ECM  extracellular matrix 
EDC  1-Ethyl-3-[3-dimethylaminopropyl]carbodimide Hydrochloride 
EPR  enhanced permeation and retention 
ExPASy Expert Protein Analysis System 
FBS  fetal bovine serum 
FDA  Food and Drug Administration 
HEK  human embryonic kidney 
HLB  hydrophilic-lipophilic balance  
kDa  kilo Dalton 
KGHGKK lysine-glycine-histidine-glycine-lysine-lysine 
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MADE Michael addition during emulsion 
MMP  matrix metalloproteinase 
MW  molecular weight 
NHS  N-hydroxysuccinimide 
NMR  nuclear magnetic resonance 
PBS  phosphate buffered saline 
PDB  Protein Data Bank 
PEG  poly(ethylene glycol) 
PEG-4-Acr four arm poly(ethylene glycol) acrylate 
PEG-DA poly(ethylene glycol) diacrylate 
PVA  poly(vinyl alcohol) 
QVRAHGK glutamine-valine-arginine-alanine-histidine-glycine-lysine 
RCF  relative centrifugal force 
S-FIL  step and flash imprint lithography 
SEM  scanning electron microscopy 
siRNA  short interfering ribonucleic acid 
sPLA2  secretory phospholipase A2 
Sulfo-NHS N-hydroxysulfosuccinimide 
TEA  triethanolamine 
UniPROBE Universal PBM Resource for Oligonucleotide Binding Evaluation 
UV  ultraviolet 
w/v  weight by volume, percent 
 207 
 
Bibliography 
 
Ahsan, F., Rivas, I. P., Khan, M. A., & Torres Suarez, A. I. (2002). Targeting to 
macrophages: role of physicochemical properties of particulate carriers--
liposomes and microspheres--on the phagocytosis by macrophages. Journal of 
Controlled Release, 79(1-3), 29–40. 
Aimetti, A. A., Machen, A. J., & Anseth, K. S. (2009). Poly(ethylene glycol) hydrogels 
formed by thiol-ene photopolymerization for enzyme-responsive protein delivery. 
Biomaterials, 30(30), 6048–6054. doi:10.1016/j.biomaterials.2009.07.043 
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., 
Jayaraman, M., et al. (2010). Targeted delivery of RNAi therapeutics with 
endogenous and exogenous ligand-based mechanisms. Molecular Therapy, 18(7), 
1357–1364. doi:10.1038/mt.2010.85 
Andresen, T. L., Jensen, S. S., Kaasgaard, T., & Jørgensen, K. (2005). Triggered 
activation and release of liposomal prodrugs and drugs in cancer tissue by 
secretory phospholipase A2. Current Drug Delivery, 2(4), 353–362. 
Annabi, N., Nichol, J. W., Zhong, X., Ji, C., Koshy, S., Khademhosseini, A., & 
Dehghani, F. (2010). Controlling the porosity and microarchitecture of hydrogels 
for tissue engineering. Tissue engineering Part B, Reviews, 16(4), 371–383. 
doi:10.1089/ten.TEB.2009.0639 
Armstrong, J. K., Wenby, R. B., Meiselman, H. J., & Fisher, T. C. (2004). The 
Hydrodynamic Radii of Macromolecules and Their Effect on Red Blood Cell 
 208 
Aggregation. Biophysical Journal, 87(6), 4259–4270. 
doi:10.1529/biophysj.104.047746 
Arrighi, I., Mark, S., Alvisi, M., Rechenberg, von, B., Hubbell, J. A., & Schense, J. C. 
(2009). Bone healing induced by local delivery of an engineered parathyroid 
hormone prodrug. Biomaterials, 30(9), 1763–1771. 
doi:10.1016/j.biomaterials.2008.12.023 
Asai, D., Kuramoto, M., Shoji, Y., Kang, J.-H., Kodama, K. B., Kawamura, K., Mori, T., 
et al. (2010). Specific transgene expression in HIV-infected cells using protease-
cleavable transcription regulator. Journal of Controlled Release, 141(1), 52–61. 
doi:10.1016/j.jconrel.2009.08.025 
Asai, D., Tsuchiya, A., Kang, J.-H., Kawamura, K., Oishi, J., Mori, T., Niidome, T., et al. 
(2009). Inflammatory cell-specific transgene expression system responding to 
Ikappa-B kinase beta activation. The journal of gene medicine, 11(7), 624–632. 
doi:10.1002/jgm.1342 
Athanasiou, K. A., Agrawal, C. M., Barber, F. A., & Burkhart, S. S. (1998). Orthopaedic 
applications for PLA-PGA biodegradable polymers. Arthroscopy : the journal of 
arthroscopic & related surgery : official publication of the Arthroscopy 
Association of North America and the International Arthroscopy Association, 
14(7), 726–737. 
Baeza, A., Izquierdo-Barba, I., & Vallet-Regí, M. (2010). Biotinylation of silicon-doped 
hydroxyapatite: a new approach to protein fixation for bone tissue regeneration. 
Acta biomaterialia, 6(3), 743–749. doi:10.1016/j.actbio.2009.09.004 
Balendiran, G. K., Dabur, R., & Fraser, D. (2004). The role of glutathione in cancer. Cell 
biochemistry and function, 22(6), 343–352. doi:10.1002/cbf.1149 
 209 
Baram, D., Vaday, G., Salamon, P., Drucker, I., Hershkoviz, R., & Mekori, Y. (2001). 
Human mast cells release metalloproteinase-9 on contact with activated T cells: 
juxtacrine regulation by TNF-{alpha}. The Journal of Immunology, 167, 4008–
4016. 
Barnes, P. J. (2008). Immunology of asthma and chronic obstructive pulmonary disease. 
Nature Reviews Immunology, 8(3), 183–192. doi:10.1038/nri2254 
Bawa, P., Pillay, V., Choonara, Y. E., & Toit, du, L. C. (2009). Stimuli-responsive 
polymers and their applications in drug delivery. Biomedical materials (Bristol, 
England), 4(2), 022001. doi:10.1088/1748-6041/4/2/022001 
Bayer, C. L., Konuk, A. A., & Peppas, N. A. (2010). Development of a protein sensing 
device utilizing interactions between polyaniline and a polymer acid dopant. 
Biomedical microdevices, 12(3), 435–442. doi:10.1007/s10544-010-9400-y 
Benoit, D. S. W., & Anseth, K. S. (2005). Heparin functionalized PEG gels that modulate 
protein adsorption for hMSC adhesion and differentiation. Acta biomaterialia, 
1(4), 461–470. doi:10.1016/j.actbio.2005.03.002 
Benoit, D. S. W., Durney, A. R., & Anseth, K. S. (2007). The effect of heparin-
functionalized PEG hydrogels on three-dimensional human mesenchymal stem 
cell osteogenic differentiation. Biomaterials, 28(1), 66–77. 
doi:10.1016/j.biomaterials.2006.08.033 
Benoit, D. S. W., Henry, S. M., Shubin, A. D., Hoffman, A. S., & Stayton, P. S. (2010). 
pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian 
cancer cells to doxorubicin via knockdown of polo-like kinase 1. Molecular 
Pharmaceutics, 7(2), 442–455. doi:10.1021/mp9002255 
 210 
Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., 
Shindyalov, I. N., et al. (2000). The Protein Data Bank. Nucleic acids research, 
28(1), 235–242. 
Bermejo, M., Gonzalez-Alvarez, I., Alvarez, M. G., Casabo, V. G., Price, J., & Amidon, 
G. L. (2009). Computer Aided Learning in Biopharmacy (pp. 2923–2926). 
Presented at the INTED2009 Proceedings, Valencia, Spain: IATED. 
Beyerle, A., Braun, A., Merkel, O., Koch, F., Kissel, T., & Stoeger, T. (2011). 
Comparative in vivo study of poly(ethylene imine)/siRNA complexes for 
pulmonary delivery in mice. Journal of Controlled Release, 151(1), 51–56. 
doi:10.1016/j.jconrel.2010.12.017 
Bhavsar, M. D., & Amiji, M. M. (2008). Development of novel biodegradable polymeric 
nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the 
gastrointestinal tract. AAPS PharmSciTech, 9(1), 288–294. doi:10.1208/s12249-
007-9021-9 
Biondi, M., Ungaro, F., Quaglia, F., & Netti, P. A. (2008). Controlled drug delivery in 
tissue engineering. Advanced Drug Delivery Reviews, 60(2), 229–242. 
doi:10.1016/j.addr.2007.08.038 
Bivas-Benita, M., Zwier, R., Junginger, H. E., & Borchard, G. (2005). Non-invasive 
pulmonary aerosol delivery in mice by the endotracheal route. European Journal 
of Pharmaceutics and Biopharmaceutics, 61(3), 214–218. 
doi:10.1016/j.ejpb.2005.04.009 
Boontheekul, T., & Mooney, D. J. (2003). Protein-based signaling systems in tissue 
engineering. Current opinion in biotechnology, 14(5), 559–565. 
Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B., 
& Behr, J. P. (1995). A versatile vector for gene and oligonucleotide transfer into 
 211 
cells in culture and in vivo: polyethylenimine. Proceedings of the National 
Academy of Sciences of the United States of America, 92(16), 7297–7301. 
Brunner, A., Mäder, K., & Göpferich, A. (1999). pH and osmotic pressure inside 
biodegradable microspheres during erosion. Pharmaceutical Research, 16(6), 
847–853. 
Byrne, M. E., Hilt, J. Z., & Peppas, N. A. (2008). Recognitive biomimetic networks with 
moiety imprinting for intelligent drug delivery. Journal of Biomedical Materials 
Research Part A, 84(1), 137–147. doi:10.1002/jbm.a.31443 
Byrne, M. E., Park, K., & Peppas, N. A. (2002). Molecular imprinting within hydrogels. 
Advanced Drug Delivery Reviews, 54(1), 149–161. 
Caldorera-Moore, M., & Peppas, N. A. (2009). Micro- and nanotechnologies for 
intelligent and responsive biomaterial-based medical systems. Advanced Drug 
Delivery Reviews, 61(15), 1391–1401. doi:10.1016/j.addr.2009.09.002 
Caldorera-Moore, M., Guimard, N., Shi, L., & Roy, K. (2010). Designer nanoparticles: 
incorporating size, shape and triggered release into nanoscale drug carriers. 
Expert Opinion on Drug Delivery, 7(4), 479–495. 
doi:10.1517/17425240903579971 
Cao, Y., & Langer, R. (2008). A review of Judah Folkman's remarkable achievements in 
biomedicine. Proceedings of the National Academy of Sciences of the United 
States of America, 105(36), 13203. 
Champion, J. A., Walker, A., & Mitragotri, S. (2008). Role of Particle Size in 
Phagocytosis of Polymeric Microspheres. Pharmaceutical Research, 25(8), 1815–
1821. doi:10.1007/s11095-008-9562-y 
Chang, A., Scheer, M., Grote, A., Schomburg, I., & Schomburg, D. (2009). BRENDA, 
AMENDA and FRENDA the enzyme information system: new content and tools 
 212 
in 2009. Nucleic acids research, 37(Database issue), D588–92. 
doi:10.1093/nar/gkn820 
Chen, P., Mwakwari, S., & Oyelere, A. (2008). Gold nanoparticles: From nanomedicine 
to nanosensing. Nanotechnology, Science and Applications, 1, 45–66. 
Chen, Y.-S., Alany, R. G., Young, S. A., Green, C. R., & Rupenthal, I. D. (2011). In vitro 
release characteristics and cellular uptake of poly(D,L-lactic-co-glycolic acid) 
nanoparticles for topical delivery of antisense oligodeoxynucleotides. Drug 
delivery, 18(7), 493–501. doi:10.3109/10717544.2011.589088 
Chintala, S. K., Miller, R. R., & McDevitt, C. A. (1995). Role of heparan sulfate in the 
terminal differentiation of growth plate chondrocytes. Archives of biochemistry 
and biophysics, 316(1), 227–234. doi:10.1006/abbi.1995.1032 
Chiu, L. L. Y., & Radisic, M. (2010). Scaffolds with covalently immobilized VEGF and 
Angiopoietin-1 for vascularization of engineered tissues. Biomaterials, 31(2), 
226–241. doi:10.1016/j.biomaterials.2009.09.039 
Clapper, J. D., Pearce, M. E., Guymon, C. A., & Salem, A. K. (2008). Biotinylated 
biodegradable nanotemplated hydrogel networks for cell interactive applications. 
Biomacromolecules, 9(4), 1188–1194. doi:10.1021/bm701176j 
Conference, E. S. F. B. C., Franklyn Williams, D., & Society for Biomaterials, E. (1987). 
Definitions in biomaterials: proceedings of a consensus conference of the 
European Society for Biomaterials, Chester, England, March 3-5, 1986, 72. 
Corbel, M., Caulet-Maugendre, S., Germain, N., Molet, S., Lagente, V., & Boichot, E. 
(2001). Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix 
metalloproteinase inhibitor batimastat. The Journal of pathology, 193(4), 538–
545. doi:10.1002/path.826 
 213 
Cukierman, E., & Khan, D. R. (2010). The benefits and challenges associated with the 
use of drug delivery systems in cancer therapy. Biochemical pharmacology, 
80(5), 762–770. doi:10.1016/j.bcp.2010.04.020 
Darcan-Nicolaisen, Y., Meinicke, H., Fels, G., Hegend, O., Haberland, A., Kühl, A., 
Loddenkemper, C., et al. (2009). Small interfering RNA against transcription 
factor STAT6 inhibits allergic airway inflammation and hyperreactivity in mice. 
Journal of immunology (Baltimore, Md : 1950), 182(12), 7501–7508. 
doi:10.4049/jimmunol.0713433 
Debbage, P., & Jaschke, W. (2008). Molecular imaging with nanoparticles: giant roles for 
dwarf actors. Histochemistry and cell biology, 130(5), 845–875. 
doi:10.1007/s00418-008-0511-y 
Del Vecchio, S., Zannetti, A., Fonti, R., Pace, L., & Salvatore, M. (2007). Nuclear 
imaging in cancer theranostics. The quarterly journal of nuclear medicine and 
molecular imaging : official publication of the Italian Association of Nuclear 
Medicine (AIMN) [and] the International Association of Radiopharmacology 
(IAR), [and] Section of the Society of Radiopharmaceutica, 51(2), 152–163. 
Dias, R. S., Innerlohinger, J., Glatter, O., Miguel, M. G., & Lindman, B. (2005). 
Coil−Globule Transition of DNA Molecules Induced by Cationic Surfactants:  A 
Dynamic Light Scattering Study. The Journal of Physical Chemistry B, 109(20), 
10458–10463. doi:10.1021/jp0444464 
Drinnan, C. T., Zhang, G., Alexander, M. A., Pulido, A. S., & Suggs, L. J. (2010). 
Multimodal release of transforming growth factor-β1 and the BB isoform of 
platelet derived growth factor from PEGylated fibrin gels. Journal of Controlled 
Release, 147(2), 180–186. doi:10.1016/j.jconrel.2010.03.026
 214 
Edwards, D. A., & Dunbar, C. (2002). Bioengineering of therapeutic aerosols. Annual 
Review of Biomedical Engineering, 4, 93–107. 
doi:10.1146/annurev.bioeng.4.100101.132311 
Ehrbar, M., Metters, A., Zammaretti, P., Hubbell, J. A., & Zisch, A. H. (2005). 
Endothelial cell proliferation and progenitor maturation by fibrin-bound VEGF 
variants with differential susceptibilities to local cellular activity. Journal of 
Controlled Release, 101(1-3), 93–109. doi:10.1016/j.jconrel.2004.07.018 
Ehrbar, M., Rizzi, S. C., Schoenmakers, R. G., Miguel, B. S., Hubbell, J. A., Weber, F. 
E., & Lutolf, M. P. (2007). Biomolecular hydrogels formed and degraded via site-
specific enzymatic reactions. Biomacromolecules, 8(10), 3000–3007. 
doi:10.1021/bm070228f 
Ehrbar, M., Zeisberger, S. M., Raeber, G. P., Hubbell, J. A., Schnell, C., & Zisch, A. H. 
(2008). The role of actively released fibrin-conjugated VEGF for VEGF receptor 
2 gene activation and the enhancement of angiogenesis. Biomaterials, 29(11), 
1720–1729. doi:10.1016/j.biomaterials.2007.12.002 
El-Sherbiny, I. M., McGill, S., & Smyth, H. D. C. (2010). Swellable microparticles as 
carriers for sustained pulmonary drug delivery. Journal of Pharmaceutical 
Sciences, 99(5), 2343–2356. doi:10.1002/jps.22003 
Elbert, D. L. (2011). Liquid-liquid two-phase systems for the production of porous 
hydrogels and hydrogel microspheres for biomedical applications: A tutorial 
review. Acta biomaterialia, 7(1), 31–56. doi:10.1016/j.actbio.2010.07.028 
Elbert, D. L., Pratt, A. B., Lutolf, M. P., Halstenberg, S., & Hubbell, J. A. (2001). Protein 
delivery from materials formed by self-selective conjugate addition reactions. 
Journal of Controlled Release, 76(1-2), 11–25. 
 215 
Elias, D. R., Cheng, Z., & Tsourkas, A. (2010). An Intein-Mediated Site-Specific Click 
Conjugation Strategy for Improved Tumor Targeting of Nanoparticle Systems. 
Small. doi:10.1002/smll.201001095 
Eliason, J. F. (2001). Pegylated cytokines: potential application in immunotherapy of 
cancer. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene 
therapy, 15(11), 705–711. 
Eliaz, R. E., & Szoka, F. C. (2001). Liposome-encapsulated doxorubicin targeted to 
CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer research, 
61(6), 2592–2601. 
Faassen, A. E., Mooradian, D. L., Tranquillo, R. T., Dickinson, R. B., Letourneau, P. C., 
Oegema, T. R., & McCarthy, J. B. (1993). Cell surface CD44-related chondroitin 
sulfate proteoglycan is required for transforming growth factor-beta-stimulated 
mouse melanoma cell motility and invasive behavior on type I collagen. Journal 
of cell science, 105 ( Pt 2), 501–511. 
Faassen, A. E., Schrager, J. A., Klein, D. J., Oegema, T. R., Couchman, J. R., & 
McCarthy, J. B. (1992). A cell surface chondroitin sulfate proteoglycan, 
immunologically related to CD44, is involved in type I collagen-mediated 
melanoma cell motility and invasion. The Journal of cell biology, 116(2), 521–
531. 
Fakhari, A., Baoum, A., Siahaan, T. J., Le, K. B., & Berkland, C. (2010). Controlling 
ligand surface density optimizes nanoparticle binding to ICAM-1. Journal of 
Pharmaceutical Sciences. doi:10.1002/jps.22342 
Fass, L. (2008). Imaging and cancer: a review. Molecular Oncology, 2(2), 115–152. 
Ferrari, M. (2005). Cancer nanotechnology: opportunities and challenges. Nature 
Reviews Cancer, 5(3), 161–171. 
 216 
Fisher, J. P., Mikos, A. G., & D Bronzino, J. (2007). Tissue Engineering ‎. 
Fisher, O. Z., & Peppas, N. A. (2009). Polybasic Nanomatrices Prepared by UV-Initiated 
Photopolymerization. Macromolecules, 42(9), 3391–3398. 
doi:10.1021/ma801966r 
Fisher, O. Z., Khademhosseini, A., Langer, R., & Peppas, N. A. (2010). Bioinspired 
materials for controlling stem cell fate. Accounts of Chemical Research, 43(3), 
419–428. doi:10.1021/ar900226q 
Fong, W.-K., Hanley, T., & Boyd, B. J. (2009). Stimuli responsive liquid crystals provide 
“on-demand” drug delivery in vitro and in vivo. Journal of Controlled Release, 
135(3), 218–226. doi:10.1016/j.jconrel.2009.01.009 
Fu, K., Pack, D. W., Klibanov, A. M., & Langer, R. (2000). Visual evidence of acidic 
environment within degrading poly(lactic-co-glycolic acid) (PLGA) 
microspheres. Pharmaceutical Research, 17(1), 100–106. 
Gaffney, J., Matou-Nasri, S., Grau-Olivares, M., & Slevin, M. (2010). Therapeutic 
applications of hyaluronan. Molecular bioSystems, 6(3), 437–443. 
doi:10.1039/b910552m 
Gallardo, D., Skalsky, B., & Kleinebudde, P. (2008). Controlled release solid dosage 
forms using combinations of (meth)acrylate copolymers. Pharmaceutical 
development and technology, 13(5), 413–423. doi:10.1080/10837450802202098  
Ganta, S., Devalapally, H., Shahiwala, A., & Amiji, M. (2008). A review of stimuli-
responsive nanocarriers for drug and gene delivery. Journal of Controlled 
Release, 126(3), 187–204. doi:10.1016/j.jconrel.2007.12.017 
Gao, W., Chan, J., & Farokhzad, O. C. (2010). pH-responsive Nanoparticles for Drug 
Delivery. Molecular Pharmaceutics. doi:10.1021/mp100253e 
 217 
Gao, Z. G., Lee, D. H., Kim, D. I., & Bae, Y. H. (2005). Doxorubicin loaded pH-sensitive 
micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice. 
Journal of drug targeting, 13(7), 391–397. doi:10.1080/10611860500376741  
Garcia-Contreras, L., Fiegel, J., Telko, M. J., Elbert, K., Hawi, A., Thomas, M., 
VerBerkmoes, J., et al. (2007). Inhaled large porous particles of capreomycin for 
treatment of tuberculosis in a guinea pig model. Antimicrobial agents and 
chemotherapy, 51(8), 2830–2836. doi:10.1128/AAC.01164-06 
Gasteiger, E., Gattiker, A., Hoogland, C., Ivanyi, I., Appel, R. D., & Bairoch, A. (2003). 
ExPASy: The proteomics server for in-depth protein knowledge and analysis. 
Nucleic acids research, 31(13), 3784–3788. 
Gavenis, K., Schneider, U., Groll, J., & Schmidt-Rohlfing, B. (2010). BMP-7-loaded 
PGLA microspheres as a new delivery system for the cultivation of human 
chondrocytes in a collagen type I gel: the common nude mouse model. The 
International journal of artificial organs, 33(1), 45–53. 
Geiser, M., & Kreyling, W. G. (2010). Deposition and biokinetics of inhaled 
nanoparticles. Particle and fibre toxicology, 7, 2. doi:10.1186/1743-8977-7-2 
George, M., & Abraham, T. (2006). Polyionic hydrocolloids for the intestinal delivery of 
protein drugs: Alginate and chitosan—a review. Journal of Controlled Release. 
Gertz, M. A. (2008). New targets and treatments in multiple myeloma: Src family kinases 
as central regulators of disease progression. Leukemia & lymphoma, 49(12), 
2240–2245. doi:10.1080/10428190802475311 
Ghosn, B., Kasturi, S. P., & Roy, K. (2008). Enhancing polysaccharide-mediated delivery 
of nucleic acids through functionalization with secondary and tertiary amines. 
Current Topics in Medicinal Chemistry, 8(4), 331–340. 
 218 
Gilham, I., & Rowland, T. (2001). Predictive medicine: Potential benefits from the 
integration of diagnostics and pharmaceuticals. Journal of Medical Marketing. 
Glangchai, L. C., Caldorera-Moore, M., Shi, L., & Roy, K. (2008). Nanoimprint 
lithography based fabrication of shape-specific, enzymatically-triggered smart 
nanoparticles. Journal of Controlled Release, 125(3), 263–272. 
doi:10.1016/j.jconrel.2007.10.021 
Gobin, A. S., & West, J. L. (2002). Cell migration through defined, synthetic ECM 
analogs. The FASEB Journal: Official Publication of the Federation of American 
Societies for Experimental Biology, 16(7), 751–753. doi:10.1096/fj.01-0759fje 
Gobin, A. S., & West, J. L. (2003). Val-ala-pro-gly, an elastin-derived non-integrin 
ligand: Smooth muscle cell adhesion and specificity. Journal of Biomedical 
Materials Research. 
Gombotz, W. R., & Pettit, D. K. (1995). Biodegradable polymers for protein and peptide 
drug delivery. Bioconjugate Chemistry, 6(4), 332–351. 
Göpferich, A. (1996). Mechanisms of polymer degradation and erosion. Biomaterials, 
17(2), 103–114. 
Grant, J., Blicker, M., Piquette-Miller, M., & Allen, C. (2005). Hybrid films from blends 
of chitosan and egg phosphatidylcholine for localized delivery of …. Journal of 
Pharmaceutical Sciences. 
Grier, D. G. (2003). A revolution in optical manipulation. Nature, 424(6950), 810–816. 
doi:10.1038/nature01935 
Griset, A. P., Walpole, J., Liu, R., Gaffey, A., Colson, Y. L., & Grinstaff, M. W. (2009). 
Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an 
acid-responsive polymeric drug delivery system. Journal of the American 
Chemical Society, 131(7), 2469–2471. doi:10.1021/ja807416t 
 219 
Grove, T. Z., Osuji, C. O., Forster, J. D., Dufresne, E. R., & Regan, L. (2010). Stimuli-
Responsive Smart Gels Realized via Modular Protein Design. Journal of the 
American Chemical Society, 132(40), 14024–14026. doi:10.1021/ja106619w 
Guo, X., Park, H., Young, S., Kretlow, J. D., van den Beucken, J. J., Baggett, L. S., 
Tabata, Y., et al. (2010). Repair of osteochondral defects with biodegradable 
hydrogel composites encapsulating marrow mesenchymal stem cells in a rabbit 
model. Acta biomaterialia, 6(1), 39–47. doi:10.1016/j.actbio.2009.07.041 
Hadinoto, K., Phanapavudhikul, P., Kewu, Z., & Tan, R. B. H. (2007a). Dry powder 
aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers 
of nanoparticulate drugs: effects of phospholipids. International Journal of 
Pharmaceutics, 333(1-2), 187–198. doi:10.1016/j.ijpharm.2006.10.009 
Hadinoto, K., Zhu, K., & Tan, R. B. H. (2007b). Drug release study of large hollow 
nanoparticulate aggregates carrier particles for pulmonary delivery. International 
Journal of Pharmaceutics, 341(1-2), 195–206. doi:10.1016/j.ijpharm.2007.03.035 
Hahn, S. K., Kim, J. S., & Shimobouji, T. (2007). Injectable hyaluronic acid 
microhydrogels for controlled release formulation of erythropoietin. Journal of 
Biomedical Materials Research Part A, 80(4), 916–924. doi:10.1002/jbm.a.30997 
Haller, M. F., & Saltzman, W. M. (1998). Nerve growth factor delivery systems. Journal 
of Controlled Release, 53(1-3), 1–6. 
Harris, T. J., Maltzahn, von, G., Lord, M. E., Park, J.-H., Agrawal, A., Min, D.-H., Sailor, 
M. J., et al. (2008). Protease-triggered unveiling of bioactive nanoparticles. Small, 
4(9), 1307–1312. doi:10.1002/smll.200701319 
Hatakeyama, H., Akita, H., Kogure, K., Oishi, M., Nagasaki, Y., Kihira, Y., Ueno, M., et 
al. (2007). Development of a novel systemic gene delivery system for cancer 
 220 
therapy with a tumor-specific cleavable PEG-lipid. Gene Therapy, 14(1), 68–77. 
doi:10.1038/sj.gt.3302843 
Hayashi, T., Stetler-Stevenson, W. G., Fleming, M. V., Fishback, N., Koss, M. N., Liotta, 
L. A., Ferrans, V. J., et al. (1996). Immunohistochemical study of 
metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse 
alveolar damage and idiopathic pulmonary fibrosis. The American journal of 
pathology, 149(4), 1241–1256. 
He, C., Kim, S. W., & Lee, D. S. (2008). In situ gelling stimuli-sensitive block 
copolymer hydrogels for drug delivery. Journal of Controlled Release, 127(3), 
189–207. doi:10.1016/j.jconrel.2008.01.005 
Heller, J. (1985). Controlled drug release from poly(ortho esters). Annals of the New York 
Academy of Sciences, 446, 51–66. 
Helm, C.-L. E., Fleury, M. E., Zisch, A. H., Boschetti, F., & Swartz, M. A. (2005). 
Synergy between interstitial flow and VEGF directs capillary morphogenesis in 
vitro through a gradient amplification mechanism. Proceedings of the National 
Academy of Sciences of the United States of America, 102(44), 15779–15784. 
doi:10.1073/pnas.0503681102 
Helm, C.-L. E., Zisch, A., & Swartz, M. A. (2007). Engineered blood and lymphatic 
capillaries in 3-D VEGF-fibrin-collagen matrices with interstitial flow. 
Biotechnology and bioengineering, 96(1), 167–176. doi:10.1002/bit.21185 
Hern, D., & Hubbell, J. A. (1998). Incorporation of adhesion peptides into nonadhesive 
hydrogels useful for tissue resurfacing. Journal of Biomedical Materials 
Research. 
Hirose, K., Marui, A., Arai, Y., Kushibiki, T., Kimura, Y., Sakaguchi, H., Yuang, H., et 
al. (2008). Novel approach with intratracheal administration of microgelatin 
 221 
hydrogel microspheres incorporating basic fibroblast growth factor for rescue of 
rats with monocrotaline-induced pulmonary hypertension. The Journal of thoracic 
and cardiovascular surgery, 136(5), 1250–1256. doi:10.1016/j.jtcvs.2008.05.038 
Ho, Y.-P., & Leong, K. W. (2010). Quantum dot-based theranostics. Nanoscale, 2(1), 
60–68. doi:10.1039/b9nr00178f 
Huang, X., El-Sayed, I. H., Qian, W., & El-Sayed, M. A. (2007). Cancer cells assemble 
and align gold nanorods conjugated to antibodies to produce highly enhanced, 
sharp, and polarized surface Raman spectra: a potential cancer diagnostic marker. 
Nano Letters, 7(6), 1591–1597. doi:10.1021/nl070472c 
Huynh, D. P., Nguyen, M. K., Pi, B. S., Kim, M. S., Chae, S. Y., Lee, K. C., Kim, B. S., 
et al. (2008). Functionalized injectable hydrogels for controlled insulin delivery. 
Biomaterials, 29(16), 2527–2534. doi:10.1016/j.biomaterials.2008.02.016 
Ikada, Y., & Tabata, Y. (1998). Protein release from gelatin matrices. Advanced Drug 
Delivery Reviews, 31(3), 287–301. 
Inoue, A., Takahashi, K. A., Arai, Y., Tonomura, H., Sakao, K., Saito, M., Fujioka, M., et 
al. (2006). The therapeutic effects of basic fibroblast growth factor contained in 
gelatin hydrogel microspheres on experimental osteoarthritis in the rabbit knee. 
Arthritis and rheumatism, 54(1), 264–270. doi:10.1002/art.21561 
Jain, J. P., Modi, S., Domb, A. J., & Kumar, N. (2005). Role of polyanhydrides as 
localized drug carriers. Journal of Controlled Release, 103(3), 541–563. 
doi:10.1016/j.jconrel.2004.12.021 
Janib, S. M., Moses, A. S., & MacKay, J. A. (2010). Imaging and drug delivery using 
theranostic nanoparticles. Advanced Drug Delivery Reviews. 
doi:10.1016/j.addr.2010.08.004 
 222 
Ji, Y., Xu, G. P., Zhang, Z. P., Xia, J. J., Yan, J. L., & Pan, S. H. (2010). BMP-2/PLGA 
delayed-release microspheres composite graft, selection of bone particulate 
diameters, and prevention of aseptic inflammation for bone tissue engineering. 
Annals of biomedical engineering, 38(3), 632–639. doi:10.1007/s10439-009-
9888-6 
Jia, X., & Kiick, K. L. (2009). Hybrid multicomponent hydrogels for tissue engineering. 
Macromolecular Bioscience, 9(2), 140–156. doi:10.1002/mabi.200800284 
Jiang, X., Dai, H., Leong, K. W., Goh, S.-H., Mao, H.-Q., & Yang, Y.-Y. (2006). 
Chitosan-g-PEG/DNA complexes deliver gene to the rat liver via intrabiliary and 
intraportal infusions. The journal of gene medicine, 8(4), 477–487. 
doi:10.1002/jgm.868 
Johns, R. E., El-Sayed, M. E. H., Bulmus, V., Cuschieri, J., Maier, R., Hoffman, A. S., & 
Stayton, P. S. (2008). Mechanistic analysis of macrophage response to IRAK-1 
gene knockdown by a smart polymer-antisense oligonucleotide therapeutic. 
Journal of Biomaterials Science, Polymer Edition, 19(10), 1333–1346. 
doi:10.1163/156856208786052326 
Kaasgaard, T., Andresen, T. L., Jensen, S. S., Holte, R. O., Jensen, L. T., & Jørgensen, K. 
(2009). Liposomes containing alkylated methotrexate analogues for 
phospholipase A(2) mediated tumor targeted drug delivery. Chemistry and 
physics of lipids, 157(2), 94–103. doi:10.1016/j.chemphyslip.2008.11.005 
Kadiyala, I., Loo, Y., Roy, K., Rice, J., & Leong, K. W. (2010). Transport of chitosan-
DNA nanoparticles in human intestinal M-cell model versus normal intestinal 
enterocytes. European Journal of Pharmaceutical Sciences, 39(1-3), 103–109. 
doi:10.1016/j.ejps.2009.11.002 
 223 
Kasturi, S. P., Sachaphibulkij, K., & Roy, K. (2005). Covalent conjugation of 
polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA 
vaccines. Biomaterials, 26(32), 6375–6385. 
doi:10.1016/j.biomaterials.2005.03.043 
Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Hua, T., Nakaya, H. I., 
Ravindran, R., et al. (2011). Programming the magnitude and persistence of 
antibody responses with innate immunity. Nature, 470(7335), 543–547. 
doi:10.1038/nature09737 
Katas, H., & Alpar, H. O. (2006). Development and characterisation of chitosan 
nanoparticles for siRNA delivery. Journal of Controlled Release, 115(2), 216–
225. doi:10.1016/j.jconrel.2006.07.021 
Kempen, D. H. R., Lu, L., Hefferan, T. E., Creemers, L. B., Maran, A., Classic, K. L., 
Dhert, W. J. A., et al. (2008). Retention of in vitro and in vivo BMP-2 
bioactivities in sustained delivery vehicles for bone tissue engineering. 
Biomaterials, 29(22), 3245–3252. doi:10.1016/j.biomaterials.2008.04.031 
Khare, A. R., & Peppas, N. A. (1993). Release behavior of bioactive agents from pH-
sensitive hydrogels. Journal of Biomaterials Science, Polymer Edition, 4(3), 275–
289. 
Khare, A. R., & Peppas, N. A. (1995). Swelling/deswelling of anionic copolymer gels. 
Biomaterials, 16(7), 559–567. 
Kiick, K. L. (2008). Peptide- and protein-mediated assembly of heparinized hydrogels. 
Soft Matter, 4, 29–37. doi:10.1039/b711319f 
Kim, B.-S., Park, S. W., & Hammond, P. T. (2008). Hydrogen-bonding layer-by-layer-
assembled biodegradable polymeric micelles as drug delivery vehicles from 
surfaces. ACS nano, 2(2), 386–392. doi:10.1021/nn700408z 
 224 
Kim, M.-S., Choi, Y.-J., Noh, I., & Tae, G. (2007). Synthesis and characterization of in 
situ chitosan-based hydrogel via grafting of carboxyethyl acrylate. Journal of 
Biomedical Materials Research Part A, 83(3), 674–682. doi:10.1002/jbm.a.31278 
Kim, S., Chung, E. H., Gilbert, M., & Healy, K. E. (2005). Synthetic MMP-13 
degradable ECMs based on poly(N-isopropylacrylamide-co-acrylic acid) semi-
interpenetrating polymer networks. I. Degradation and cell migration. Journal of 
Biomedical Materials Research Part A, 75(1), 73–88. doi:10.1002/jbm.a.30375 
Kim, Y.-K., Kwon, J.-T., Choi, J. Y., Jiang, H.-L., Arote, R., Jere, D., Je, Y. H., et al. 
(2010). Suppression of tumor growth in xenograft model mice by programmed 
cell death 4 gene delivery using folate-PEG-baculovirus. Cancer Gene Therapy, 
17(11), 751–760. doi:10.1038/cgt.2010.28 
Klein, T. J., Malda, J., Sah, R. L., & Hutmacher, D. W. (2009). Tissue engineering of 
articular cartilage with biomimetic zones. Tissue engineering Part B, Reviews, 
15(2), 143–157. doi:10.1089/ten.TEB.2008.0563 
Ko, J., Park, K., Kim, Y.-S., Kim, M. S., Han, J. K., Kim, K., Park, R.-W., et al. (2007). 
Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-
amino ester) block copolymer micelles for cancer therapy. Journal of Controlled 
Release, 123(2), 109–115. doi:10.1016/j.jconrel.2007.07.012 
Kreyling, W. G., Semmler-Behnke, M., Takenaka, S., & Möller, W. (2012). Differences 
in the Biokinetics of Inhaled Nano- versus Micrometer-Sized Particles. Accounts 
of Chemical Research. doi:10.1021/ar300043r 
Kumar, M., Behera, A. K., Lockey, R. F., Zhang, J., Bhullar, G., La Cruz, De, C. P., 
Chen, L.-C., et al. (2002). Intranasal gene transfer by chitosan-DNA nanospheres 
protects BALB/c mice against acute respiratory syncytial virus infection. Human 
gene therapy, 13(12), 1415–1425. doi:10.1089/10430340260185058 
 225 
Lai, S. K., Wang, Y.-Y., & Hanes, J. (2009). Mucus-penetrating nanoparticles for drug 
and gene delivery to mucosal tissues. Advanced Drug Delivery Reviews, 61(2), 
158–171. doi:10.1016/j.addr.2008.11.002 
Langer, R., & Peppas, N. (2003). Advances in biomaterials, drug delivery, and 
bionanotechnology. AIChE Journal, 49(12), 2990–3006. 
Langer, R., & Vacanti, J. P. (1993). Tissue engineering. Science, 260(5110), 920–926. 
Lee, D., Zhang, W., Shirley, S., Kong, X., & Hellermann, G. (2007). Thiolated 
Chitosan/DNA Nanocomplexes Exhibit Enhanced and Sustained Gene Delivery. 
Pharmaceutical Research. 
Lee, E. S., Shin, H. J., Na, K., & Bae, Y. H. (2003). Poly(L-histidine)-PEG block 
copolymer micelles and pH-induced destabilization. Journal of Controlled 
Release, 90(3), 363–374. 
Lee, J., Oh, Y. J., Lee, S. K., & Lee, K. Y. (2010). Facile control of porous structures of 
polymer microspheres using an osmotic agent for pulmonary delivery. Journal of 
Controlled Release, 146(1), 61–67. doi:10.1016/j.jconrel.2010.05.026 
Lee, M., Li, W., Siu, R. K., Whang, J., Zhang, X., Soo, C., Ting, K., et al. (2009). 
Biomimetic apatite-coated alginate/chitosan microparticles as osteogenic protein 
carriers. Biomaterials, 30(30), 6094–6101. 
doi:10.1016/j.biomaterials.2009.07.046 
Leslie-Barbick, J. E., Moon, J. J., & West, J. L. (2009). Covalently-immobilized vascular 
endothelial growth factor promotes endothelial cell tubulogenesis in poly(ethylene 
glycol) diacrylate hydrogels. Journal of Biomaterials Science, Polymer Edition, 
20(12), 1763–1779. doi:10.1163/156856208X386381 
Li, B., Yoshii, T., Hafeman, A. E., Nyman, J. S., Wenke, J. C., & Guelcher, S. A. 
(2009a). The effects of rhBMP-2 released from biodegradable 
 226 
polyurethane/microsphere composite scaffolds on new bone formation in rat 
femora. Biomaterials, 30(35), 6768–6779. doi:10.1016/j.biomaterials.2009.08.038 
Li, L., Okada, H., Takemura, G., Esaki, M., Kobayashi, H., Kanamori, H., Kawamura, I., 
et al. (2009b). Sustained release of erythropoietin using biodegradable gelatin 
hydrogel microspheres persistently improves lower leg ischemia. Journal of the 
American College of Cardiology, 53(25), 2378–2388. 
doi:10.1016/j.jacc.2009.02.056 
Li, X., Ding, L., Xu, Y., Wang, Y., & Ping, Q. (2009c). Targeted delivery of doxorubicin 
using stealth liposomes modified with transferrin. International Journal of 
Pharmaceutics, 373(1-2), 116–123. doi:10.1016/j.ijpharm.2009.01.023 
Lin, C.-C., & Anseth, K. S. (2009). PEG hydrogels for the controlled release of 
biomolecules in regenerative medicine. Pharmaceutical Research, 26(3), 631–
643. doi:10.1007/s11095-008-9801-2 
Liu, F., & Basit, A. W. (2010). A paradigm shift in enteric coating: achieving rapid 
release in the proximal small intestine of man. Journal of Controlled Release, 
147(2), 242–245. doi:10.1016/j.jconrel.2010.07.105 
Liu, X., Howard, K. A., Dong, M., Andersen, M. Ø., Rahbek, U. L., Johnsen, M. G., 
Hansen, O. C., et al. (2007). The influence of polymeric properties on 
chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials, 28(6), 
1280–1288. doi:10.1016/j.biomaterials.2006.11.004 
Liu, Y., & Daum, P. (2000). The effect of refractive index on size distributions and light 
scattering coefficients derived from optical particle counters. Journal of Aerosol 
Science, 31(8), 945–957. 
Losi, P., Briganti, E., Magera, A., Spiller, D., Ristori, C., Battolla, B., Balderi, M., et al. 
(2010). Tissue response to poly(ether)urethane-polydimethylsiloxane-fibrin 
 227 
composite scaffolds for controlled delivery of pro-angiogenic growth factors. 
Biomaterials, 31(20), 5336–5344. doi:10.1016/j.biomaterials.2010.03.033 
Löwik, D. W. P. M., Leunissen, E. H. P., van den Heuvel, M., Hansen, M. B., & van 
Hest, J. C. M. (2010). Stimulus responsive peptide based materials. Chemical 
Society reviews, 39(9), 3394–3412. doi:10.1039/b914342b 
Lucke, A., Kiermaier, J., & Göpferich, A. (2002). Peptide acylation by poly(alpha-
hydroxy esters). Pharmaceutical Research, 19(2), 175–181. 
Lustig, S., & Peppas, N. (1988). Solute diffusion in swollen membranes. IX. Scaling laws 
for solute diffusion in gels. Journal of Applied Polymer Science, 36(4), 735–747. 
Lutolf, M. P., Lauer-Fields, J. L., Schmoekel, H. G., Metters, A. T., Weber, F. E., Fields, 
G. B., & Hubbell, J. A. (2003a). Synthetic matrix metalloproteinase-sensitive 
hydrogels for the conduction of tissue regeneration: engineering cell-invasion 
characteristics. Proceedings of the National Academy of Sciences of the United 
States of America, 100(9), 5413–5418. doi:10.1073/pnas.0737381100 
Lutolf, M. P., Weber, F. E., Schmoekel, H. G., Schense, J. C., Kohler, T., Müller, R., & 
Hubbell, J. A. (2003b). Repair of bone defects using synthetic mimetics of 
collagenous extracellular matrices. Nature Biotechnology, 21(5), 513–518. 
doi:10.1038/nbt818 
Lutolf, M., & Hubbell, J. A. (2003). Synthesis and physicochemical characterization of 
end-linked poly(ethylene glycol)-co-peptide hydrogels formed by Michael-type 
addition. Biomacromolecules, 4(3), 713–722. 
Lutolf, M., Tirelli, N., Cerritelli, S., Cavalli, L., & Hubbell, J. A. (2001). Systematic 
modulation of Michael-type reactivity of thiols through the use of charged amino 
acids. Bioconjugate Chemistry, 12(6), 1051–1056. 
 228 
Makino, K., Yamamoto, N., Higuchi, K., Harada, N., Ohshima, H., & Terada, H. (2003). 
Phagocytic uptake of polystyrene microspheres by alveolar macrophages: effects 
of the size and surface properties of the microspheres. Colloids and surfaces B, 
Biointerfaces, 27(1), 33–39. 
Mann, B. K., Gobin, A. S., Tsai, A. T., Schmedlen, R. H., & West, J. L. (2001). Smooth 
muscle cell growth in photopolymerized hydrogels with cell adhesive and 
proteolytically degradable domains: synthetic ECM analogs for tissue 
engineering. Biomaterials, 22(22), 3045–3051. 
Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., & Katayama, D. S. (2010). 
Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 27(4), 
544–575. doi:10.1007/s11095-009-0045-6 
Manning, M. C., Patel, K., & Borchardt, R. T. (1989). Stability of protein 
pharmaceuticals. Pharmaceutical Research, 6(11), 903–918. 
Mao, H., & Roy, K. (2001). Chitosan-DNA nanoparticles as gene carriers - synthesis 
characterization and transfection efficiency. Journal of Controlled Release, 23. 
Mapili, G., Lu, Y., Chen, S., & Roy, K. (2005). Laser-layered microfabrication of 
spatially patterned functionalized tissue-engineering scaffolds. Journal of 
Biomedical Materials Research Part B, Applied Biomaterials, 75(2), 414–424. 
doi:10.1002/jbm.b.30325 
Mather, B., Viswanathan, K., Miller, K., & Long, T. (2006). Michael addition reactions 
in macromolecular design for emerging technologies. Progress In Polymer 
Science, 31(5), 487–531. 
Maxwell, D. J., Hicks, B. C., Parsons, S., & Sakiyama-Elbert, S. E. (2005). Development 
of rationally designed affinity-based drug delivery systems. Acta biomaterialia, 
1(1), 101–113. doi:10.1016/j.actbio.2004.09.002 
 229 
McGonigle, J. S., Tae, G., Stayton, P. S., Hoffman, A. S., & Scatena, M. (2008). 
Heparin-regulated delivery of osteoprotegerin promotes vascularization of 
implanted hydrogels. Journal of Biomaterials Science, Polymer Edition, 19(8), 
1021–1034. doi:10.1163/156856208784909381 
Meng, F., Hennink, W., & Zhong, Z. (2009). Reduction-sensitive polymers and 
bioconjugates for biomedical applications. Biomaterials. 
Metters, A., & Hubbell, J. A. (2005). Network formation and degradation behavior of 
hydrogels formed by Michael-type addition reactions. Biomacromolecules, 6(1), 
290–301. doi:10.1021/bm049607o 
Miyata, T., Asami, N., & Uragami, T. (1999). A reversibly antigen-responsive hydrogel. 
Nature, 399(6738), 766–769. doi:10.1038/21619 
Miyata, T., Jige, M., Nakaminami, T., & Uragami, T. (2006). Tumor marker-responsive 
behavior of gels prepared by biomolecular imprinting. Proceedings of the 
National Academy of Sciences of the United States of America, 103(5), 1190–
1193. doi:10.1073/pnas.0506786103 
Miyata, T., Uragami, T., & Nakamae, K. (2002). Biomolecule-sensitive hydrogels. 
Advanced Drug Delivery Reviews, 54(1), 79–98. 
Mohamed, F., & van der Walle, C. F. (2008). Engineering biodegradable polyester 
particles with specific drug targeting and drug release properties. Journal of 
Pharmaceutical Sciences, 97(1), 71–87. doi:10.1002/jps.21082 
Molineux, G. (2002). Pegylation: engineering improved pharmaceuticals for enhanced 
therapy. Cancer treatment reviews, 28 Suppl A, 13–16. 
Molineux, G. (2003). Pegylation: engineering improved biopharmaceuticals for 
oncology. Pharmacotherapy, 23(8 Pt 2), 3S–8S. 
 230 
Moss, J. A., Stokols, S., Hixon, M. S., Ashley, F. T., Chang, J. Y., & Janda, K. D. (2006). 
Solid-phase synthesis and kinetic characterization of fluorogenic enzyme-
degradable hydrogel cross-linkers. Biomacromolecules, 7(4), 1011–1016. 
doi:10.1021/bm051001s 
Moustoifa, E.-F., Alouini, M.-A., Salaün, A., Berthelot, T., Bartegi, A., Albenque-Rubio, 
S., & Déléris, G. (2010). Novel cyclopeptides for the design of MMP directed 
delivery devices: a novel smart delivery paradigm. Pharmaceutical Research, 
27(8), 1713–1721. doi:10.1007/s11095-010-0164-0 
Moya, M. L., Cheng, M.-H., Huang, J.-J., Francis-Sedlak, M. E., Kao, S.-W., Opara, E. 
C., & Brey, E. M. (2010a). The effect of FGF-1 loaded alginate microbeads on 
neovascularization and adipogenesis in a vascular pedicle model of adipose tissue 
engineering. Biomaterials, 31(10), 2816–2826. 
doi:10.1016/j.biomaterials.2009.12.053 
Moya, M. L., Garfinkel, M. R., Liu, X., Lucas, S., Opara, E. C., Greisler, H. P., & Brey, 
E. M. (2010b). Fibroblast growth factor-1 (FGF-1) loaded microbeads enhance 
local capillary neovascularization. The Journal of surgical research, 160(2), 208–
212. doi:10.1016/j.jss.2009.06.003 
Mudhakir, D., & Harashima, H. (2009). Learning from the viral journey: how to enter 
cells and how to overcome intracellular barriers to reach the nucleus. The AAPS 
Journal, 11(1), 65–77. doi:10.1208/s12248-009-9080-9 
Murthy, N., Campbell, J., Fausto, N., Hoffman, A. S., & Stayton, P. S. (2003). 
Bioinspired pH-responsive polymers for the intracellular delivery of biomolecular 
drugs. Bioconjugate Chemistry, 14(2), 412–419. doi:10.1021/bc020056d 
Nagai, N., Kumasaka, N., Kawashima, T., Kaji, H., Nishizawa, M., & Abe, T. (2010). 
Preparation and characterization of collagen microspheres for sustained release of 
 231 
VEGF. Journal of materials science Materials in medicine, 21(6), 1891–1898. 
doi:10.1007/s10856-010-4054-0 
Naidu, B. N., Sorenson, M. E., Connolly, T. P., & Ueda, Y. (2003). Michael addition of 
amines and thiols to dehydroalanine amides: a remarkable rate acceleration in 
water. The Journal of organic chemistry, 68(26), 10098–10102. 
doi:10.1021/jo034762z 
Neut, D., Kluin, O. S., Crielaard, B. J., van der Mei, H. C., Busscher, H. J., & Grijpma, 
D. W. (2009). A biodegradable antibiotic delivery system based on poly-
(trimethylene carbonate) for the treatment of osteomyelitis. Acta orthopaedica, 
80(5), 514–519. doi:10.3109/17453670903350040 
Newburger, D. E., & Bulyk, M. L. (2009). UniPROBE: an online database of protein 
binding microarray data on protein-DNA interactions. Nucleic acids research, 
37(Database issue), D77–82. doi:10.1093/nar/gkn660 
Nie, T., Baldwin, A., Yamaguchi, N., & Kiick, K. L. (2007). Production of heparin-
functionalized hydrogels for the development of responsive and controlled growth 
factor delivery systems. Journal of Controlled Release, 122(3), 287–296. 
doi:10.1016/j.jconrel.2007.04.019 
Nomi, M., Atala, A., Coppi, P. D., & Soker, S. (2002). Principals of neovascularization 
for tissue engineering. Molecular aspects of medicine, 23(6), 463–483. 
Oana, H., Tsumoto, K., Yoshikawa, Y., & Yoshikawa, K. (2002). Folding transition of 
large DNA completely inhibits the action of a restriction endonuclease as revealed 
by single-chain observation. FEBS letters, 530(1-3), 143–146. 
Okuma, T., Terasaki, Y., Kaikita, K., Kobayashi, H., Kuziel, W. A., Kawasuji, M., & 
Takeya, M. (2004). C-C chemokine receptor 2 (CCR2) deficiency improves 
bleomycin-induced pulmonary fibrosis by attenuation of both macrophage 
 232 
infiltration and production of macrophage-derived matrix metalloproteinases. The 
Journal of pathology, 204(5), 594–604. doi:10.1002/path.1667 
Onaca, O., Enea, R., Hughes, D. W., & Meier, W. (2009). Stimuli-responsive 
polymersomes as nanocarriers for drug and gene delivery. Macromolecular 
Bioscience, 9(2), 129–139. doi:10.1002/mabi.200800248 
Ozeki, M., & Tabata, Y. (2006). Interaction of hepatocyte growth factor with gelatin as 
the carrier material. Journal of Biomaterials Science, Polymer Edition, 17(1-2), 
163–175. 
Park, J. W., Kirpotin, D. B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U. B., Marks, J. 
D., et al. (2001). Tumor targeting using anti-her2 immunoliposomes. Journal of 
Controlled Release, 74(1-3), 95–113. 
Parks, S. K., Chiche, J., & Pouysségur, J. (2010). pH control mechanisms of tumor 
survival and growth. Journal of cellular physiology. doi:10.1002/jcp.22400 
Patel, B., Gupta, V., & Ahsan, F. (2012). PEG–PLGA based large porous particles for 
pulmonary delivery of a highly soluble drug, low molecular weight heparin. 
Journal of Controlled Release, 162(2), 310–320. 
doi:10.1016/j.jconrel.2012.07.003 
Patterson, J., & Hubbell, J. A. (2010). Enhanced proteolytic degradation of molecularly 
engineered PEG hydrogels in response to MMP-1 and MMP-2. Biomaterials, 
31(30), 7836–7845. doi:10.1016/j.biomaterials.2010.06.061 
Patterson, J., & Hubbell, J. A. (2011). SPARC-derived protease substrates to enhance the 
plasmin sensitivity of molecularly engineered PEG hydrogels. Biomaterials, 
32(5), 1301–1310. doi:10.1016/j.biomaterials.2010.10.016 
 233 
Pavet, V., Portal, M. M., Moulin, J. C., Herbrecht, R., & Gronemeyer, H. (2010). 
Towards novel paradigms for cancer therapy. Oncogene. 
doi:10.1038/onc.2010.460 
Pedersen, P. J., Adolph, S. K., Subramanian, A. K., Arouri, A., Andresen, T. L., 
Mouritsen, O. G., Madsen, R., et al. (2010). Liposomal formulation of retinoids 
designed for enzyme triggered release. Journal of medicinal chemistry, 53(9), 
3782–3792. doi:10.1021/jm100190c 
Peppas, N. A., Bures, P., Leobandung, W., & Ichikawa, H. (2000). Hydrogels in 
pharmaceutical formulations. European Journal of Pharmaceutics and 
Biopharmaceutics, 50(1), 27–46. 
Peppas, N. A., Keys, K. B., Torres-Lugo, M., & Lowman, A. M. (1999). Poly(ethylene 
glycol)-containing hydrogels in drug delivery. Journal of Controlled Release, 
62(1-2), 81–87. 
Pfister, L. A., Papaloïzos, M., Merkle, H. P., & Gander, B. (2007). Nerve conduits and 
growth factor delivery in peripheral nerve repair. Journal of the peripheral 
nervous system : JPNS, 12(2), 65–82. doi:10.1111/j.1529-8027.2007.00125.x 
Picard, F. J., & Bergeron, M. G. (2002). Rapid molecular theranostics in infectious 
diseases. Drug Discovery Today, 7(21), 1092–1101. 
Pieper, J. S., Hafmans, T., van Wachem, P. B., van Luyn, M. J. A., Brouwer, L. A., 
Veerkamp, J. H., & van Kuppevelt, T. H. (2002). Loading of collagen-heparan 
sulfate matrices with bFGF promotes angiogenesis and tissue generation in rats. 
Journal of Biomedical Materials Research, 62(2), 185–194. 
doi:10.1002/jbm.10267 
 234 
Pilcer, G., & Amighi, K. (2010). Formulation strategy and use of excipients in pulmonary 
drug delivery. International Journal of Pharmaceutics, 392(1-2), 1–19. 
doi:10.1016/j.ijpharm.2010.03.017 
Podual, K., Doyle, F. J., & Peppas, N. A. (2000a). Dynamic behavior of glucose oxidase-
containing microparticles of poly(ethylene glycol)-grafted cationic hydrogels in 
an environment of changing pH. Biomaterials, 21(14), 1439–1450. 
Podual, K., Doyle, F. J., & Peppas, N. A. (2000b). Glucose-sensitivity of glucose 
oxidase-containing cationic copolymer hydrogels having poly(ethylene glycol) 
grafts. Journal of Controlled Release, 67(1), 9–17. 
Portney, N., & Ozkan, M. (2006). Nano-oncology: drug delivery, imaging, and sensing. 
Analytical and Bioanalytical Chemistry, 384(3), 620–630. 
Pouton, C. W., Wagstaff, K. M., Roth, D. M., Moseley, G. W., & Jans, D. A. (2007). 
Targeted delivery to the nucleus. Advanced Drug Delivery Reviews, 59(8), 698–
717. doi:10.1016/j.addr.2007.06.010 
Pusztai, A., Grant, G., Bardocz, S., Baintner, K., Gelencsér, E., & Ewen, S. W. (1997). 
Both free and complexed trypsin inhibitors stimulate pancreatic secretion and 
change duodenal enzyme levels. The American journal of physiology, 272(2 Pt 1), 
G340–50. 
Putnam, D., Gentry, C. A., Pack, D. W., & Langer, R. (2001). Polymer-based gene 
delivery with low cytotoxicity by a unique balance of side-chain termini. 
Proceedings of the National Academy of Sciences of the United States of America, 
98(3), 1200–1205. doi:10.1073/pnas.031577698 
Qiu, Y., & Park, K. (2001). Environment-sensitive hydrogels for drug delivery. Advanced 
Drug Delivery Reviews, 53(3), 321–339. 
 235 
Rekha, M. R., & Sharma, C. P. (2009). Synthesis and evaluation of lauryl succinyl 
chitosan particles towards oral insulin delivery and absorption. Journal of 
Controlled Release, 135(2), 144–151. doi:10.1016/j.jconrel.2009.01.011 
Rezler, E. M., Khan, D. R., Lauer-Fields, J., Cudic, M., Baronas-Lowell, D., & Fields, G. 
B. (2007). Targeted drug delivery utilizing protein-like molecular architecture. 
Journal of the American Chemical Society, 129(16), 4961–4972. 
doi:10.1021/ja066929m 
Roberts, M. J., Bentley, M. D., & Harris, J. M. (2002). Chemistry for peptide and protein 
PEGylation. Advanced Drug Delivery Reviews, 54(4), 459–476. 
Robinson, S. N., & Talmadge, J. E. (2002). Sustained release of growth factors. In vivo 
(Athens, Greece), 16(6), 535–540. 
Roy, K., Mao, H., & Huang, S. (1999). Oral gene delivery with chitosan-DNA 
nanoparticles generates immunologic protection in a murine model of peanut 
allergy. Nature Medicine, 5(4), 5. 
Rytting, E., Nguyen, J., Wang, X., & Kissel, T. (2008). Biodegradable polymeric 
nanocarriers for pulmonary drug delivery. Expert Opinion on Drug Delivery, 5(6), 
629–639. doi:10.1517/17425247.5.6.629 
Sahoo, S. K., Ma, W., & Labhasetwar, V. (2004). Efficacy of transferrin-conjugated 
paclitaxel-loaded nanoparticles in a murine model of prostate cancer. 
International Journal of Cancer, 112(2), 335–340. doi:10.1002/ijc.20405 
Sakiyama-Elbert, S. E., & Hubbell, J. A. (2000). Controlled release of nerve growth 
factor from a heparin-containing fibrin-based cell ingrowth matrix. Journal of 
Controlled Release, 69(1), 149–158. 
Saltzman, W. M., & Baldwin, S. (1998). Materials for protein delivery in tissue 
engineering. Advanced Drug Delivery Reviews, 33(1-2), 71–86. 
 236 
Saltzman, W. M., & Olbricht, W. L. (2002). Building drug delivery into tissue 
engineering. Nature Reviews Drug discovery, 1(3), 177–186. 
Sano, A., Hojo, T., Maeda, M., & Fujioka, K. (1998). Protein release from collagen 
matrices. Advanced Drug Delivery Reviews, 31(3), 247–266. 
Sarfati, G., Dvir, T., Elkabetz, M., Apte, R. N., & Cohen, S. (2010). Targeting of 
polymeric nanoparticles to lung metastases by surface-attachment of YIGSR 
peptide from laminin. Biomaterials. doi:10.1016/j.biomaterials.2010.09.014 
Sasaki, N., Minami, T., Yamada, K., Yamada, H., Inoue, Y., Kobayashi, M., & Tabata, 
Y. (2008). In vivo effects of intra-articular injection of gelatin hydrogen 
microspheres containing basic fibroblast growth factor on experimentally induced 
defects in third metacarpal bones of horses. American journal of veterinary 
research, 69(12), 1555–1559. doi:10.2460/ajvr.69.12.1555 
Satav, S. S., Bhat, S., & Thayumanavan, S. (2010). Feedback regulated drug delivery 
vehicles: carbon dioxide responsive cationic hydrogels for antidote release. 
Biomacromolecules, 11(7), 1735–1740. doi:10.1021/bm1005454 
Sato, H. (2002). Enzymatic procedure for site-specific pegylation of proteins. Advanced 
Drug Delivery Reviews, 54(4), 487–504. 
Sawant, R. M., Hurley, J. P., Salmaso, S., Kale, A., Tolcheva, E., Levchenko, T. S., & 
Torchilin, V. P. (2006). “SMART” drug delivery systems: double-targeted pH-
responsive pharmaceutical nanocarriers. Bioconjugate Chemistry, 17(4), 943–949. 
doi:10.1021/bc060080h 
Sánchez, A., Tobío, M., González, L., Fabra, A., & Alonso, M. J. (2003). Biodegradable 
micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. 
European Journal of Pharmaceutical Sciences, 18(3-4), 221–229. 
 237 
Schipper, N., Olsson, S., Hoogstraate, J., deBoer, A., Vårum, K., & Artursson, P. (1997). 
Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of 
absorption enhancement. Pharmaceutical Research, 14(7), 923–929. 
Schipper, N., Vårum, K., & Artursson, P. (1996). Chitosans as absorption enhancers for 
poorly absorbable drugs. 1: Influence of molecular weight and degree of 
acetylation on drug transport across human intestinal epithelial (Caco-2) cells. 
Pharmaceutical Research, 13(11), 1686–1692. 
Schipper, N., Vårum, K., Stenberg, P., Ocklind, G., Lennernäs, H., & Artursson, P. 
(1999). Chitosans as absorption enhancers of poorly absorbable drugs 3: Influence 
of mucus on absorption enhancement. European Journal of Pharmaceutical 
Sciences, 8(4), 335–343. 
Scott, E. A., Nichols, M. D., Kuntz-Willits, R., & Elbert, D. L. (2010). Modular scaffolds 
assembled around living cells using poly(ethylene glycol) microspheres with 
macroporation via a non-cytotoxic porogen. Acta biomaterialia, 6(1), 29–38. 
doi:10.1016/j.actbio.2009.07.009 
Seeherman, H. J., Archambault, J. M., Rodeo, S. A., Turner, A. S., Zekas, L., D'Augusta, 
D., Li, X. J., et al. (2008). rhBMP-12 accelerates healing of rotator cuff repairs in 
a sheep model. The Journal of bone and joint surgery American volume, 90(10), 
2206–2219. doi:10.2106/JBJS.G.00742 
Seeherman, H. J., Li, X. J., Bouxsein, M. L., & Wozney, J. M. (2010). rhBMP-2 induces 
transient bone resorption followed by bone formation in a nonhuman primate 
core-defect model. The Journal of bone and joint surgery American volume, 
92(2), 411–426. doi:10.2106/JBJS.H.01732 
 238 
Seeherman, H., & Wozney, J. M. (2005). Delivery of bone morphogenetic proteins for 
orthopedic tissue regeneration. Cytokine & growth factor reviews, 16(3), 329–
345. doi:10.1016/j.cytogfr.2005.05.001 
Seeherman, H., Li, R., Bouxsein, M., Kim, H., Li, X. J., Smith-Adaline, E. A., Aiolova, 
M., et al. (2006). rhBMP-2/calcium phosphate matrix accelerates osteotomy-site 
healing in a nonhuman primate model at multiple treatment times and 
concentrations. The Journal of bone and joint surgery American volume, 88(1), 
144–160. doi:10.2106/JBJS.D.02453 
Segura, T., Anderson, B. C., Chung, P. H., Webber, R. E., Shull, K. R., & Shea, L. D. 
(2005). Crosslinked hyaluronic acid hydrogels: a strategy to functionalize and 
pattern. Biomaterials, 26(4), 359–371. doi:10.1016/j.biomaterials.2004.02.067 
Seliktar, D., Zisch, A. H., Lutolf, M. P., Wrana, J. L., & Hubbell, J. A. (2004). MMP-2 
sensitive, VEGF-bearing bioactive hydrogels for promotion of vascular healing. 
Journal of Biomedical Materials Research Part A, 68(4), 704–716. 
doi:10.1002/jbm.a.20091 
Shaikh, R. P., Pillay, V., Choonara, Y. E., Toit, du, L. C., Ndesendo, V. M. K., Bawa, P., 
& Cooppan, S. (2010). A review of multi-responsive membranous systems for 
rate-modulated drug delivery. AAPS PharmSciTech, 11(1), 441–459. 
doi:10.1208/s12249-010-9403-2 
Shen, Y., Tang, H., Radosz, M., Van Kirk, E., & Murdoch, W. J. (2008). pH-responsive 
nanoparticles for cancer drug delivery. Methods in molecular biology (Clifton, 
NJ), 437, 183–216. doi:10.1007/978-1-59745-210-6_10 
Shim, J., & Nho, Y. (2003). Preparation of poly (acrylic acid)-chitosan hydrogels by 
gamma irradiation and in vitro drug release. Journal of Applied Polymer Science. 
 239 
Sierra, D. H. (1993). Fibrin sealant adhesive systems: a review of their chemistry, 
material properties and clinical applications. Journal of biomaterials applications, 
7(4), 309–352. 
Simpson, J. L., Scott, R. J., Boyle, M. J., & Gibson, P. G. (2005). Differential proteolytic 
enzyme activity in eosinophilic and neutrophilic asthma. American Journal of 
Respiratory and Critical Care Medicine, 172(5), 559–565. 
doi:10.1164/rccm.200503-369OC 
Singh, A., Nie, H., Ghosn, B., Qin, H., Kwak, L. W., & Roy, K. (2008). Efficient 
modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-
targeted siRNA and DNA vaccine to antigen-presenting cells. Molecular Therapy, 
16(12), 2011–2021. doi:10.1038/mt.2008.206 
Singh, A., Suri, S., & Roy, K. (2009). In-situ crosslinking hydrogels for combinatorial 
delivery of chemokines and siRNA-DNA carrying microparticles to dendritic 
cells. Biomaterials, 30(28), 5187–5200. doi:10.1016/j.biomaterials.2009.06.001 
Solsona, I. A., Smith, R. B., Livingstone, C., & Davis, J. (2006). Metabolic mimics: thiol 
responsive drug release. Journal of colloid and interface science, 302(2), 698–
701. doi:10.1016/j.jcis.2006.06.042 
Son, Y.-J., & McConville, J. T. (2008). Advancements in dry powder delivery to the 
lung. Drug Development and Industrial Pharmacy, 34(9), 948–959. 
doi:10.1080/03639040802235902 
Spicer, P. P., & Mikos, A. G. (2010). Fibrin glue as a drug delivery system. Journal of 
Controlled Release, 148(1), 49–55. doi:10.1016/j.jconrel.2010.06.025 
Steinbüchel, A., & Matsumura, S. (2003). Biopolymers: Miscellaneous biopolymers and 
biodegradation of synthetic polymers ‎. 
 240 
Sumer, B., & Gao, J. (2008). Theranostic nanomedicine for cancer. Nanomedicine 
(London, England), 3(2), 137–140. doi:10.2217/17435889.3.2.137 
Sung, J. C., Pulliam, B. L., & Edwards, D. A. (2007). Nanoparticles for drug delivery to 
the lungs. Trends in Biotechnology, 25(12), 563–570. 
doi:10.1016/j.tibtech.2007.09.005 
Suri, S., & Schmidt, C. E. (2009). Photopatterned collagen-hyaluronic acid 
interpenetrating polymer network hydrogels. Acta biomaterialia, 5(7), 2385–
2397. doi:10.1016/j.actbio.2009.05.004 
Suri, S., & Schmidt, C. E. (2010). Cell-laden hydrogel constructs of hyaluronic acid, 
collagen, and laminin for neural tissue engineering. Tissue engineering Part A, 
16(5), 1703–1716. doi:10.1089/ten.tea.2009.0381 
Suzuki, Y., Tanihara, M., Nishimura, Y., Suzuki, K., Kakimaru, Y., & Shimizu, Y. 
(1998). A new drug delivery system with controlled release of antibiotic only in 
the presence of infection. Journal of Biomedical Materials Research, 42(1), 112–
116. 
Ta, H., Dass, C., & Dunstan, D. (2008). Injectable chitosan hydrogels for localised cancer 
therapy. Journal of Controlled Release. 
Tabata, Y. (2003). Tissue regeneration based on growth factor release. Tissue 
engineering, 9 Suppl 1, S5–15. doi:10.1089/10763270360696941 
Tae, G., Scatena, M., Stayton, P. S., & Hoffman, A. S. (2006). PEG-cross-linked heparin 
is an affinity hydrogel for sustained release of vascular endothelial growth factor. 
Journal of Biomaterials Science, Polymer Edition, 17(1-2), 187–197. 
Taqvi, S., Dixit, L., & Roy, K. (2006). Biomaterial-based notch signaling for the 
differentiation of hematopoietic stem cells into T cells. Journal of Biomedical 
Materials Research Part A, 79(3), 689–697. doi:10.1002/jbm.a.30916 
 241 
Tauro, J. R., & Gemeinhart, R. A. (2005a). Extracellular protease activation of 
chemotherapeutics from hydrogel matrices: a new paradigm for local 
chemotherapy. Molecular Pharmaceutics, 2(5), 435–438. 
doi:10.1021/mp050028n 
Tauro, J. R., & Gemeinhart, R. A. (2005b). Matrix metalloprotease triggered delivery of 
cancer chemotherapeutics from hydrogel matrixes. Bioconjugate Chemistry, 
16(5), 1133–1139. doi:10.1021/bc0501303 
Tauro, J. R., Lee, B.-S., Lateef, S. S., & Gemeinhart, R. A. (2008). Matrix 
metalloprotease selective peptide substrates cleavage within hydrogel matrices for 
cancer chemotherapy activation. Peptides, 29(11), 1965–1973. 
doi:10.1016/j.peptides.2008.06.021 
Thissen, H., Chang, K.-Y., Tebb, T. A., Tsai, W.-B., Glattauer, V., Ramshaw, J. A. M., & 
Werkmeister, J. A. (2006). Synthetic biodegradable microparticles for articular 
cartilage tissue engineering. Journal of Biomedical Materials Research Part A, 
77(3), 590–598. doi:10.1002/jbm.a.30612 
Thompson, A. D., Betz, M. W., Yoon, D. M., & Fisher, J. P. (2009). Osteogenic 
differentiation of bone marrow stromal cells induced by coculture with 
chondrocytes encapsulated in three-dimensional matrices. Tissue engineering Part 
A, 15(5), 1181–1190. doi:10.1089/ten.tea.2007.0275 
Thornton, P. D., & Heise, A. (2010). Highly specific dual enzyme-mediated payload 
release from peptide-coated silica particles. Journal of the American Chemical 
Society, 132(6), 2024–2028. doi:10.1021/ja9094439 
Thyagarajapuram, N., Olsen, D., & Middaugh, C. R. (2007). The structure, stability, and 
complex behavior of recombinant human gelatins. Journal of Pharmaceutical 
Sciences, 96(12), 3363–3378. doi:10.1002/jps.21022 
 242 
Tokatlian, T., Shrum, C. T., Kadoya, W. M., & Segura, T. (2010). Protease degradable 
tethers for controlled and cell-mediated release of nanoparticles in 2- and 3-
dimensions. Biomaterials, 31(31), 8072–8080. 
doi:10.1016/j.biomaterials.2010.07.030 
Tong, L., Wei, Q., Wei, A., & Cheng, J.-X. (2009). Gold nanorods as contrast agents for 
biological imaging: optical properties, surface conjugation and photothermal 
effects. Photochemistry and Photobiology, 85(1), 21–32. doi:10.1111/j.1751-
1097.2008.00507.x 
A Truskey, G., Yuan PhD, F., Yuan, F., & F Katz, D. (2004). Transport phenomena in 
biological systems ‎. 
Tsapis, N., Bennett, D., Jackson, B., Weitz, D. A., & Edwards, D. A. (2002). Trojan 
particles: large porous carriers of nanoparticles for drug delivery. Proceedings of 
the National Academy of Sciences of the United States of America, 99(19), 
12001–12005. doi:10.1073/pnas.182233999 
Tønnesen, H. H., & Karlsen, J. (2002). Alginate in drug delivery systems. Drug 
Development and Industrial Pharmacy, 28(6), 621–630. doi:10.1081/DDC-
120003853  
Uebersax, L., Merkle, H. P., & Meinel, L. (2009). Biopolymer-based growth factor 
delivery for tissue repair: from natural concepts to engineered systems. Tissue 
engineering Part B, Reviews, 15(3), 263–289. doi:10.1089/ten.TEB.2008.0668 
Urech, L., Bittermann, A. G., Hubbell, J. A., & Hall, H. (2005). Mechanical properties, 
proteolytic degradability and biological modifications affect angiogenic process 
extension into native and modified fibrin matrices in vitro. Biomaterials, 26(12), 
1369–1379. doi:10.1016/j.biomaterials.2004.04.045 
van Blitterswijk, C.A., & Thomsen, P. (2008). Tissue engineering. 
 243 
van de Weert, M., Hennink, W. E., & Jiskoot, W. (2000). Protein instability in 
poly(lactic-co-glycolic acid) microparticles. Pharmaceutical Research, 17(10), 
1159–1167. 
van de Wetering, P., Metters, A. T., Schoenmakers, R. G., & Hubbell, J. A. (2005). 
Poly(ethylene glycol) hydrogels formed by conjugate addition with controllable 
swelling, degradation, and release of pharmaceutically active proteins. Journal of 
Controlled Release, 102(3), 619–627. doi:10.1016/j.jconrel.2004.10.029 
Vartak, D. G., & Gemeinhart, R. A. (2007). Matrix metalloproteases: underutilized 
targets for drug delivery. Journal of drug targeting, 15(1), 1–20. 
doi:10.1080/10611860600968967  
Vauthier, C., Schmidt, C., & Couvreur, P. (1999). Measurement of the density of 
polymeric nanoparticulate drug carriers by isopycnic centrifugation. Journal of 
nanoparticle research : an interdisciplinary forum for nanoscale science and 
technology. 
Velasco, D., Elvira, C., & San Román, J. (2008). New stimuli-responsive polymers 
derived from morpholine and pyrrolidine. Journal of materials science Materials 
in medicine, 19(4), 1453–1458. doi:10.1007/s10856-007-3315-z 
Verestiuc, L., Nastasescu, O., Barbu, E., Sarvaiya, I., Green, K. L., & Tsibouklis, J. 
(2006). Functionalized chitosan/NIPAM (HEMA) hybrid polymer networks as 
inserts for ocular drug delivery: Synthesis,in vitro assessment, andin vivo 
evaluation. Journal of Biomedical Materials Research Part A, 77A(4), 726–735. 
doi:10.1002/(ISSN)1552-4965 
Veronese, F. M., & Pasut, G. (2005). PEGylation, successful approach to drug delivery. 
Drug Discovery Today, 10(21), 1451–1458. doi:10.1016/S1359-6446(05)03575-0 
 244 
Wacker, B. K., Alford, S. K., Scott, E. A., Thakur, Das, M., Longmore, G. D., & Elbert, 
D. L. (2008). Endothelial cell migration on RGD-peptide-containing PEG 
hydrogels in the presence of sphingosine 1-phosphate. Biophysical Journal, 94(1), 
273–285. doi:10.1529/biophysj.107.109074 
Wanakule, P., & Roy, K. (2012). Disease-responsive drug delivery: the next generation 
of smart delivery devices. Current drug metabolism, 13(1), 42–49. 
Wanakule, P., Liu, G. W., Fleury, A. T., & Roy, K. (2012). Nano-inside-micro: Disease-
responsive microgels with encapsulated nanoparticles for intracellular drug 
delivery to the deep lung. Journal of Controlled Release, 162(2), 429–437. 
doi:10.1016/j.jconrel.2012.07.026 
Wang, C.-K., Ho, M.-L., Wang, G.-J., Chang, J.-K., Chen, C.-H., Fu, Y.-C., & Fu, H.-H. 
(2009). Controlled-release of rhBMP-2 carriers in the regeneration of 
osteonecrotic bone. Biomaterials, 30(25), 4178–4186. 
doi:10.1016/j.biomaterials.2009.04.029 
Wang, J. (2008). In vivo glucose monitoring: towards “Sense and Act” feedback-loop 
individualized medical systems. Talanta, 75(3), 636–641. 
doi:10.1016/j.talanta.2007.10.023 
Wang, W. (1999). Instability, stabilization, and formulation of liquid protein 
pharmaceuticals. International Journal of Pharmaceutics, 185(2), 129–188. 
Wee, S., & Gombotz, W. (1998). Protein release from alginate matrices. Advanced Drug 
Delivery Reviews, 31(3), 267–285. 
Wijaya, A., Schaffer, S. B., Pallares, I. G., & Hamad-Schifferli, K. (2009). Selective 
release of multiple DNA oligonucleotides from gold nanorods. ACS nano, 3(1), 
80–86. doi:10.1021/nn800702n 
 245 
Wong, C., Stylianopoulos, T., Cui, J., Martin, J., Chauhan, V. P., Jiang, W., Popović, Z., 
et al. (2011). Multistage nanoparticle delivery system for deep penetration into 
tumor tissue. Proceedings of the National Academy of Sciences of the United 
States of America, 108(6), 2426–2431. doi:10.1073/pnas.1018382108 
Wood, M. D., MacEwan, M. R., French, A. R., Moore, A. M., Hunter, D. A., Mackinnon, 
S. E., Moran, D. W., et al. (2010). Fibrin matrices with affinity-based delivery 
systems and neurotrophic factors promote functional nerve regeneration. 
Biotechnology and bioengineering, 106(6), 970–979. doi:10.1002/bit.22766 
Wood, M. D., Moore, A. M., Hunter, D. A., Tuffaha, S., Borschel, G. H., Mackinnon, S. 
E., & Sakiyama-Elbert, S. E. (2009). Affinity-based release of glial-derived 
neurotrophic factor from fibrin matrices enhances sciatic nerve regeneration. Acta 
biomaterialia, 5(4), 959–968. doi:10.1016/j.actbio.2008.11.008 
Woodruff, M. A., Rath, S. N., Susanto, E., Haupt, L. M., Hutmacher, D. W., Nurcombe, 
V., & Cool, S. M. (2007). Sustained release and osteogenic potential of heparan 
sulfate-doped fibrin glue scaffolds within a rat cranial model. Journal of 
molecular histology, 38(5), 425–433. doi:10.1007/s10735-007-9137-y 
Wu, Y., MacKay, J. A., McDaniel, J. R., Chilkoti, A., & Clark, R. L. (2009). Fabrication 
of elastin-like polypeptide nanoparticles for drug delivery by electrospraying. 
Biomacromolecules, 10(1), 19–24. doi:10.1021/bm801033f 
Wygrecka, M., Markart, P., Ruppert, C., Petri, K., Preissner, K. T., Seeger, W., & 
Guenther, A. (2007). Cellular origin of pro-coagulant and (anti)-fibrinolytic 
factors in bleomycin-injured lungs. The European respiratory journal : official 
journal of the European Society for Clinical Respiratory Physiology, 29(6), 1105–
1114. doi:10.1183/09031936.00097306 
 246 
Xiong, M., Forrest, M., Karls, A., & Kwon, G. (2007). Biotin-Triggered Release of Poly 
(ethylene glycol)− Avidin from Biotinylated Polyethylenimine …. Bioconjugate 
Chemistry. 
Xu, X., Yee, W.-C., Hwang, P. Y. K., Yu, H., Wan, A. C. A., Gao, S., Boon, K.-L., et al. 
(2003). Peripheral nerve regeneration with sustained release of 
poly(phosphoester) microencapsulated nerve growth factor within nerve guide 
conduits. Biomaterials, 24(13), 2405–2412. 
Yaguchi, T., Fukuda, Y., Ishizaki, M., & Yamanaka, N. (1998). Immunohistochemical 
and gelatin zymography studies for matrix metalloproteinases in bleomycin-
induced pulmonary fibrosis. Pathology international, 48(12), 954–963. 
Yamamoto, M., Takahashi, Y., & Tabata, Y. (2006). Enhanced bone regeneration at a 
segmental bone defect by controlled release of bone morphogenetic protein-2 
from a biodegradable hydrogel. Tissue engineering, 12(5), 1305–1311. 
doi:10.1089/ten.2006.12.1305 
Yang, B.-B., Lum, P. K., Hayashi, M. M., & Roskos, L. K. (2004). Polyethylene glycol 
modification of filgrastim results in decreased renal clearance of the protein in 
rats. Journal of Pharmaceutical Sciences, 93(5), 1367–1373. 
doi:10.1002/jps.20024 
Yap, T. A., Carden, C. P., & Kaye, S. B. (2009). Beyond chemotherapy: targeted 
therapies in ovarian cancer. Nature Reviews Cancer, 9(3), 167–181. 
doi:10.1038/nrc2583 
You, J.-O., & Auguste, D. T. (2008). Feedback-regulated paclitaxel delivery based on 
poly(N,N-dimethylaminoethyl methacrylate-co-2-hydroxyethyl methacrylate) 
nanoparticles. Biomaterials, 29(12), 1950–1957. 
doi:10.1016/j.biomaterials.2007.12.041 
 247 
Young, S., Wong, M., Tabata, Y., & Mikos, A. G. (2005). Gelatin as a delivery vehicle 
for the controlled release of bioactive molecules. Journal of Controlled Release, 
109(1-3), 256–274. doi:10.1016/j.jconrel.2005.09.023 
Zhang, G., Drinnan, C. T., Geuss, L. R., & Suggs, L. J. (2010). Vascular differentiation 
of bone marrow stem cells is directed by a tunable three-dimensional matrix. Acta 
biomaterialia, 6(9), 3395–3403. doi:10.1016/j.actbio.2010.03.019 
Zhang, L., Furst, E. M., & Kiick, K. L. (2006). Manipulation of hydrogel assembly and 
growth factor delivery via the use of peptide-polysaccharide interactions. Journal 
of Controlled Release, 114(2), 130–142. doi:10.1016/j.jconrel.2006.06.005 
Zisch, A. H., Lutolf, M. P., & Hubbell, J. A. (2003a). Biopolymeric delivery matrices for 
angiogenic growth factors. Cardiovascular pathology : the official journal of the 
Society for Cardiovascular Pathology, 12(6), 295–310. 
Zisch, A. H., Lutolf, M. P., Ehrbar, M., Raeber, G. P., Rizzi, S. C., Davies, N., Schmökel, 
H., et al. (2003b). Cell-demanded release of VEGF from synthetic, biointeractive 
cell ingrowth matrices for vascularized tissue growth. The FASEB Journal: 
Official Publication of the Federation of American Societies for Experimental 
Biology, 17(15), 2260–2262. doi:10.1096/fj.02-1041fje 
 
 
 248 
 
Vita 
 
Prinda Wanakule was born in Austin, Texas in May of 1985 to Nisai and Paulla 
Wanakule. She attended Palm Harbor University High School, where she was enrolled in 
the Center for Wellness and Medical Professions program, and worked part time as a 
Nurse Helper/Nursing Assistant in the Emergency Room of Mease Countryside Hospital. 
In August 2003, Prinda began attending the University of Florida in Gainesville, FL on a 
full scholarship from the Florida Bright Futures Scholarship Program, and additional 
scholarships from the Environmental Protection Agency, National Science Foundation 
Particle Engineering Research Center, Engineering Dean’s Scholarship, and the 
University Scholars Program. While at the University of Florida, Prinda conducted nearly 
four years of undergraduate research in the Department of Environmental Engineering 
Sciences (Dr. Chang-Yu Wu) and the Department of Mechanical & Aerospace 
Engineering (Dr. Malisa Sarntinoranont), and ultimately received a Bachelor of Science 
degree in Agricultural and Biological Engineering with a minor in Biomechanics. She 
was also heavily involved in the College of Engineering student organizations, serving as 
President of the Society of Women Engineers and Vice President of Programs for the 
Benton Engineering Council. In recognition of her academics, research, and service, she 
was the recipient of the Class of 2007 Gator Engineering 4-Year Scholar award. 
Following graduation in May 2007, Prinda began pursuing her Ph.D. in 
Biomedical Engineering at the University of Texas at Austin as a National Science 
Foundation Graduate Research Fellow, with additional support from the University in the 
form of THRUST, Bruton, Heuer and Women in Engineering Program Fellowships, as 
 249 
well as the Society of Women Engineers Jill S. Tietjen Scholarship. Working in Dr. 
Krishnendu Roy’s Laboratory for Cellular and Macromolecular Engineering, Prinda’s 
graduate studies focused on enzyme-responsive biomaterials, hydrogels, and disease-
responsive drug delivery systems. Towards the end of her graduate career, Prinda held 
five peer reviewed journal publications, one book chapter in press, a patent application, 
and over 25 conference proceedings related to her research, as well as her work in 
engineering education-related topics. In 2011, Prinda was recognized by the Society of 
Women Engineers as the Outstanding Graduate Collegiate Member for her leadership 
and dedication in promoting engineering education and research. That same year, she was 
also recognized as one of the leading young women scientists in the nation, and invited to 
meet First Lady Michelle Obama at the White House in Washington, D.C. 
Prinda is currently continuing research in disease-responsive drug delivery and 
biomaterials, while continuing to engage in the improvement and promotion of education 
in science, technology, and engineering. 
 
 
 
Permanent email: prinda.wanakule@gmail.com or prinda@utexas.edu  
This dissertation was typed by Prinda Wanakule. 
 
 
